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Ribonuclease P (RNase P) is a divalent metal ion-dependent endonuclease 
that catalyzes cleavage of the 5’ leader of precursor transfer RNA (pre-tRNA), an 
essential tRNA processing step in all domains of life. Bacterial RNase P is a 
potential antibacterial target because it is essential for cell survival and varies in 
composition from its eukaryotic counterparts. Bacterial RNase P contains a catalytic 
RNA (P RNA) with one protein subunit while eukaryotic nuclear RNase P has 
multiple protein subunits with a catalytic RNA core and the human mitochondrial 
RNase P (mtRNase P) consists solely of protein subunits.  
In this dissertation research, first a novel fluorescence polarization (FP) assay 
was developed to facilitate rapid and real-time measurements of RNase P activity. 
This new FP assay was optimized for high-throughput screening to search for new 
inhibitors of bacterial RNase P in small molecule (2,880 compounds) and natural 
product extracts (22,720 samples) libraries. A new RNase P inhibitor was identified 
from the screen. Second, to test the biochemical role and metal ion binding function 
of a carbonyl oxygen (oxygen-4, O4) in the universally conserved bulged uridine 
(U51) of P RNA, RNase P with single atom modifications of 4-thiouridine, 4-
deoxyuridine, 3-methyluridine and an abasic site were prepared and analyzed. 
Binding data demonstrate that the O4 of U51 enhances pre-tRNA affinity in a 




enhances pre-tRNA cleavage by interacting with a magnesium ion stabilizing an 
active enzyme-substrate conformation. Third, a library of human mitochondiral pre-
tRNAs and high purity human mtRNase P was prepared for studying the substrate 
specificity of human mtRNase P. Single-turnover cleavage data demonstrate that the 
MRPP3 subunit of human mtRNase P is catalytically active alone in vitro and that 
the MRPP1∙MRPP2 subcomplex increases the cleavage rate and cleavage site 
fidelity. Overall, the work presented in this dissertation has provided a new real-time 
and high-throughput methodology to assay RNase P activity in vitro, enhanced our 
understanding of how bacterial RNase P recognizes inhibitors and metal ions, and 
laid the foundation for elucidating substrate recognition by the newly identified 




CHAPTER 1  
INTRODUCTION: MOLECULAR RECOGNITION BY RNASE P1 
 Introduction 
Transfer RNA (tRNA) is a central adapter molecule during ribosome-dependent 
protein synthesis [1]. Biosynthesis of mature functional tRNA requires extensive 
processing steps, such as the removal of 5’ and 3’ end sequences from polycistronic 
precursor transcript, 3’ CCA addition, splicing, editing, and base modifications [1] 
(Figure 1-1). The early steps for processing immature precursor tRNA (pre-tRNA) 
include the removal of extraneous sequences at the 5’ and 3’ termini by 
ribonucleases [2]. The 5’ end maturation of tRNA is catalyzed by ribonuclease P 
(RNase P), a divalent metal ion-dependent endonuclease responsible for cleavage 
of the 5’ end leader from pre-tRNA [3-6]. In all three domains of life, RNase P 
catalyzes endonucleolytic hydrolysis of the phosphodiester bond between the N(-1) 
and N(1) bases, generating a 5’ monophosphate group (5’ p) and a 3’ hydroxyl 
group (3’ OH) in tRNA body and 5’ leader products, respectively (Figure 1-2) [4, 5, 
7]. RNase P also processes various non-tRNA substrates in cells [8] and is 
implicated in regulating mRNA degradation and gene expression [9, 10].  
 
                                            
1 Contents in Chapter 1 are in preparation for an invited review article entitled “Molecular recognition 






Figure 1-1: A simplified tRNA maturation pathway. RNase P is ubiquitously responsible for 
catalyzing the 5’ end maturation of tRNA. 3’ end processing has two major pathways by 
either an endonuclease such as RNase Z (3’ endo pathway) or by multiple exonucleases (3’ 
exo pathway), which typically depends on whether the 3’CCA is encoded in the sequence 
[2]. N: the discriminator nucleotide. Some tRNAs are also transcribed with intron sequences 








Figure 1-2: RNase P catalyzes 5’ end maturation of tRNA. (A) Cartoon presentation of 
RNase P catalyzed hydrolysis of a phosphodiester bond in a pre-tRNA to generating tRNA 
with a mature 5’ end and a 5’ leader [7]. (B) RNase P is a divalent metal ion-dependent 
endonuclease that catalyzes the hydrolysis of a specific phosphodiester bond and generates 








Figure 1-3: Evolution of RNase P enzymes. (A) RNase P is conserved in all three kingdoms 
of life. Ribonucleoprotein (RNP) RNase P consists of one RNA and variable numbers of 
protein subunits [2, 11]. (B) Eukaryal RNase P evolved from ribonucleoprotein complexes to 
protein-only isoforms [12]. (C) Venn diagrams illustrating the composition and homology 
among RNase P proteins and a cartoon drawing of a minimum consensus secondary 







In most organisms, RNase P is a ribonucleoprotein (RNP) complex consisting 
of a single catalytic RNA subunit (P RNA) and variable numbers of protein subunits 
(1 in Bacteria, 4-5 in Archaea and 9-10 in Eukarya nuclei) [14-19] (Figure 1-3). In 
recent studies, examples of exclusively protein-based RNase P have been identified 
in eukaryal organisms, such as human mitochondria [20] and plants [21, 22]. These 
findings present RNase P as an excellent model system to compare RNA- and 
protein-based catalysis [23, 24]. Similar to the ribosome, another indispensable RNP 
and RNA-based catalyst, bacterial RNase P is also essential for bacterial cell 
survival and considered as a potential antibacterial drug target [25].  
Over the past four decades, much progress has been made in understanding 
the composition, structure and function of RNP RNase P (see reviews by [4, 6, 13, 
19, 26, 27]) which has led to the use of RNase P as a tool for regulating gene 
expression in cells [28]. However, we still lack a comprehensive understanding on a 
molecular basis of how RNase P RNA synergistically interacts with protein subunits 
and essential metal ions to recognize substrates and perform catalysis [6, 19]. 
Furthermore, specific and potent inhibitors for bacterial RNase P remain to be 
discovered as potential novel anti-infection agents [29, 30]. In addition, newly 
identified protein-only RNase P awaits systematic characterization [20-22, 31]. Here 
I describe the current picture of the evolutionary spread and diverse scaffolds of 
RNase P enzymes with a focus on bacterial and human mitochondrial RNase P. I 
also discuss recent advances in elucidating the kinetic mechanism and identification 




and protein-based RNase Ps. Lastly, I will conclude with a summary of the 
objectives of this dissertation research. 
1.2 RNase P Enzymes: Essential yet Diverse 
RNase P is conserved in all organisms examed, with one exception in a small 
host-dependent archaeon, Nanoachaeum equitans, in which leader-less tRNAs are 
transcribed [32, 33]. The 5’ end processing of tRNA catalyzed by RNase P is 
indispensable in all free-living organisms [2]. RNase P also processes various non-
tRNA substrates in vivo (see summaries in [8, 34]). Most RNP RNase Ps have a 
single RNA subunit that folds into similar types of secondary structure, but share 
relatively low sequence homology [4, 6, 35]. The number of RNase P protein 
subunits has increased substantially from 1 in Bacteria, 4-5 in Archaea and 9-10 in 
Eukarya to the complete depletion of the RNA subunit in land plants. This makes 
RNase P one of the most diverse and essential enzymes characterized to date [12, 
24] (Figure 1-3). 
1.2.1 Ribonucleoprotein (RNP) RNase P 
1.2.1.1 RNase P RNA2 
The first RNase P holoenzyme was identified in E. coli from two essential 
genes: rnpA, which encodes the protein subunit (~120 amino acids), and rnpB, 
which encodes the RNase P RNA (~400 nucleotides) [36-40]. Bacterial RNase P 
RNA is a true enzyme in vitro that catalyzes multiple turnover reactions under high 
                                            
2 Much of RNase P RNA sequence and secondary structure data were compiled in The “RNase P 
Database” (http://www.mbio.ncsu.edu/rnasep/seqs&structures.html) by James W. Brown at North 




ionic strength conditions [41-44]. RNase P RNA may therefore be considered a relic 
of the “RNA world” [6].  
Phylogenetic analysis classified RNase P RNA (P RNA) into two major types of 
secondary structures [13, 35, 45, 46] (Figure 1-5), the type-A (for ancestral type) 
presents in most bacteria, and the type-B (for Bacillus type) found only in low-GC 
Gram-positive bacteria [47, 48]. In addition, type-C P RNA related to type-B but 
lacking P13 and P14 stems has been found in a member of green non-sulfur 
bacteria [47, 48].  
A consensus sequence of bacterial P RNA contains five Conserved Regions 
(CR-I to CR-V) (Figure 1-3) that contain 13 universally conserved nucleotides in all P 
RNAs and 50 other nucleotides that are highly conserved in bacteria [49-51]. This 
minimum P RNA has catalytic activity in vitro [50]. RNase P RNA has two 
independent folding domains: the specificity-domain (S-domain), which contains CR-
II and III, and the catalytic-domain (C-domain), which contains CR-I, IV and V 
(Figure 1-4) [52, 53]. Functions of these two domains in bacterial P RNA have been 
investigated using numerous biochemical studies such as footprinting, cross-linking, 
affinity cleavage, nucleotide analog interference mapping and structural studies [54-
62]. The C-domain alone is catalytically active and in the presence of the protein 
subunit catalyzes cleavage of pre-tRNA that is 100- to 500-fold more slowely than 
intact P RNA, indicating that the C-domain contains the catalytic site [63-65]. 
However, the C-domain∙protein complex binds pre-tRNA substrate at least 100-fold 
weaker than the intact holoenzyme [64]. The S-domain increases substrate binding 




Type-A P RNAs in Archaea generally lack P8 and P13/14 stems. Less complex 
P RNA structures are found in archaea Methanococcus and Archaeoglobus fulgidus, 
(type-M, lacking P8, P16, P6 pseudoknot and the CCA recognition loop in P15) [66] 
and Thermoproteaceae (type-T, lacking most of the S-domain) [67]. Bioinformatic 
analysis of P RNA structure and sequence suggest that archaeal P RNA evolved 
from an early segregated lineage [68].  
The eukaryal P RNAs (nuclear and organellar) surveyed to date have diverse 
secondary structures [35, 51]. The P13, P14 and L15 structural elements are 
missing in eukaryal nuclear P RNA [69]. In organelles, secondary structures of 
Reclinomonas americana (a small protozoan) mitochondrial and Porphyra purpurea 
(a non-green algae) chloroplast P RNA are similar to their bacterial ancestors [35]. 
However, S. cerevisiae mitochondrial P RNA only requires a considerably reduced 
sequence containing CR-I, CR-IV and CR-V (Figure 1-3) and one large protein 
subunit, RPM2, which shares no sequence homology with any known RNP proteins 
[70-72]. Certain archaeal and eukaryal P RNAs are capable of catalyzing the 
cleavage of their respective substrates under single-turnover conditions and extreme 
ionic strength and MgCl2 concentrations with a slower cleavage rate than their 
bacterial counterparts [73, 74].  
1.2.1.2 Bacterial RNase P 
Bacterial RNase P is the simplest (one RNA and one protein) and most 
extensively characterized RNP holoenzyme. Bacterial P RNA alone efficiently 
catalyzes cleavage of the 5’ leader from pre-tRNA under high ionic strength and 




vivo [75]. RNase P protein is suggested to affect the folding of P RNA moderately 
[76] and decrease the concentration of monovalent and divalent cations required for 
catalysis [77, 78]. It enhances reactivity under physiological conditions and directly 
contacts the pre-tRNA 5’ leader to increase substrate affinity [76, 79-82]. In solution, 
bacterial RNase P holoenzyme forms a dimer in the absence of substrate [83, 84].  
Crystal structures of S-domains and/or full length type-A and type B P RNA are 
available for Thermotoga maritima (type-A, PDB IDs: 1U9S [85] and 2A2E [86]), 
Bacillus subtilis (type-B, PDB ID: 1NBS [87]) and Bacillus stearothermophilus (type-
B, PDB IDs: 2A64 [88]) (Figure 1-4). A crystal structure of T. maritima RNase P 
holoenzyme in complex with a yeast tRNAPhe and soaked with 5’ leader has also 
been solved recently, providing many molecular details about the holoenzyme (PDB 
IDs: 3Q1R and 3Q1Q [89]) (Figure 1-4 and Figure 1-5). In this ternary complex, CR-
II and CRIII regions in the S-domain form base stacking contacts with the D- and 
TψC-loop of tRNA. CR-I, CR-IV and CR-V regions in the C-domain adopt a non-
helical module that forms an A-minor interaction with the acceptor-stem of tRNA, 
base pairs with 3’ RCCA motif of tRNA, binds to the protein subunit, and contains 
the putative active site near helix P4 (Figure 1-4 and Figure 1-5) [89]. Catalytic metal 
ions are proposed near helix P4 and the 5’ end of tRNA (Figure 1-5) [89]. The overall 
structure of this ternary complex agrees well with models built using free P RNA 
structures and/or solution probing and photoaffinity cross-linking data [76, 86, 90]. 
However, these models vary in positioning of the putative active site [76, 86, 90]. 
Higher resolution structures of RNase P ternary complex are still needed for refining 






Figure 1-4: Crystal structure of T. maritima RNase P ternary complex. (A) A cartoon 
representation of T. maritima RNase P holoenzyme in complex with tRNA and a 5-nt leader 
(4.2 Å resolution, PDB code: 3Q1R [89]). The helix P4 is red, tRNA is pink, P protein is blue 
helices P2/3 are green, P15/16/17 are dark blue and P7-P12 are purple. Metal ions near the 
active site of P RNA are cyan spheres and a metal ion with 3’ CCA of tRNA is a pink sphere. 
(B) An expanded view displaying the two metal ions (M1, M2, cyan spheres) near the P4 
helix (U52 is yellow, G51 is orange and A50 is red) as well as the 5’ leader interacting with 
the P protein and U294 and G295 (light green) in J18/2 of P RNA [89]. U294, G295, U52, 
G51 and A50 correspond to A318, G319, U51, G50 and A49 in B. subtilis P RNA. F17, F21, 
K51, R52, K56, R89 and K90 correspond to F16, F20, K52, K53, N56, R85 and K86 in B. 








Figure 1-5: Bacterial P RNA secondary structure and molecular interactions. Tertiary 
interactions are shown in connected gray box (dashed lines). (A) Secondary structure 
adopted from T. maritima RNase P ternary complex [89]. Color-coded arrowheads indicate 
interaction sites in P RNA with P protein (blue), tRNA (red), 5’ leader (orange) and 3’RCCA 
motif (green). The boxed nucleotides are conserved: universally conserved are in solid pink 
block, 100% conserved in bacterial are in pink box and >80% conserved in bacterial are in 
green box (B) Secondary structure adapted from B. stearothermophilus crystal structure 
(PDB IDs: 2A64 [88]). Metal ion binding sites from studies of E. coli (phosphorothioate 
modifications), B. stearothermophilus (anomalous X-ray scattering analysis of heavy metal 
soak), and B. subtilis (phosphothioate and NMR and XAS) RNase P are indicated [91-96]. 
 
Structures of bacterial RNase P proteins (~14 kDa) from Bacillus subtilis (PDB 
ID: 1A6F [33]), Staphylococcus aureus (type-B RNase P, NMR structure, PDB ID: 
1D6T[97]), and T. maritima (PDB ID: 1NZ0 [98]) have also been determined 
individually [81, 97, 98]. These proteins share low sequence homology but adopt a 
similar structure which comprises of a central cleft formed by one α-helix and four β-
sheets, a negatively charged loop and a left-handed βαβ cross-over connection that 
contains the most conserved region, termed RNR motif (RNRXKRXXR). 
Biochemical data suggest that the RNR motif interacts with both pre-tRNA and P 
RNA and stabilizes a conformational change that occur during the B. subtilis RNase 
P catalytic cycle [99]. The protein subunits of E. coli (type-A) and B. subtilis (type-B) 
RNase P are interchangeable in vivo [100], although the P RNA affinity is altered 
[101]. The rnpA gene encoding P protein in B. subtilis [102] and E. coli [103] can 
also be replaced by rnpA gene from other bacterial species in vivo, but the  growth 
rate is slower [103]. On the other hand, archaeal and eukaryotic protein subunits 
Rpp21 and Rpp29 cannot rescue the rnpA gene deletion, which is consistent with 





1.2.1.3 Archaeal and Eukaryal RNP RNase P 
RNP RNase P in Archaea and Eukarya has increased complexity in protein 
subunits (Figure 1-3). Archaeal RNase P contains at least four protein subunits, 
Rpp21, Rpp29, Rpp30 and Pop5 (by nomenclature of human RNase P protein 
subunits), which share sequence homology with yeast and human RNase P proteins 
[10]. An additional protein L7Ae, a ribosomal protein and homolog of human RNase 
P protein Rpp38, co-purifies with RNase P activity in Methanococcus maripaludis 
(Mma) and increases the catalytic efficiency (kcat/KM) of pre-tRNA cleavage by 360-
fold [104].  
Low-level single-turnover activity is detected from type-A archaeal RNase P 
RNA alone from certain species such as methanobacteria, thermococci and 
halobacteria under high ionic strength and Mg2+ concentration conditions [73].  The 
poor catalytic activity of archaea P RNA is suggested to result from low substrate 
affinity (KM > 40 µM) [73]. The weak substrate affinity may due to loss of certain 
secondary structural elements (P18, P13/14) that form long-range tetraloop 
interactions and juxtapose the S- and C-domain observed in bacterial P RNA [8]. 
The bulges in P10/11 of bacterial S-domain that are proposed in substrate 
recognition are also missing in archaeal and eukaryal P RNAs. This lack of tertiary 
structure stabilization by P18 and P13/14 may be compensated by protein subunits 
that bind to and stabilize P RNA structure [105]. Footprinting data using recombinant 
proteins suggest that the protein pairs, Rpp21-Rpp29 and Pop5-Rpp30, contact the 
S-domain and C-domian of Pyrococcus furiosus P RNA, respectively [106, 107]. In 




substrate affinity and Pop5-Rpp30 increases the rate of cleavage [108, 109]. These 
proteins also play a role in cleavage site-selection in small model substrates [110]. 
Three-dimensional structures of some archaeal proteins have been determined: 
Rpp30 (PDB ID: 1V77 [111]), Pop5 (PDB ID: 2AV5 [112]), Rpp29 (PDB IDs: 1PC0 
[113], 1OQK [114], 1V76 [115], and 1TS9 [116]), Rpp21 (PDB IDs: 1X0T [117] and 
2K3R [118]) and Rpp38 (PDB ID: 2CZW [119]). In the future, structures of archaeal 
RNase P holoenzyme and/or ternary complex will provide great insights into the 
molecular recognition and catalytic mechanism of this multi-unit enzyme, in 
comparison with the bacterial enzyme [19].  
Eukaryal nuclear RNP RNase P contains one RNA and nine to ten proteins (4-
5 are archaeal homologs) and shares at least eight protein subunits with its sibling, 
RNase MRP (mitochondrial RNA processing ribonuclease) [120-125]. RNase MRP 
is mainly localized in the nucleus [126, 127] and processes precursor ribosomal 
RNA (pre-rRNA) [128-130]. Human RNase MRP has been implicated in diseases 
[131, 132]. Compared to their bacterial and archaeal counterparts, eukaryal RNase 
P enzymes are not as well characterized structurally and biochemically. A crystal 
structure of two yeast RNase P/MRP proteins, Pop6 and Pop7, in complex with the 
P3 domain of P RNA has been determined [133]. The P3 domain in eukaryal P RNA 
typically contains a distinct large internal loop not present in bacterial and archaeal P 
RNAs [35] (Figure 1-3). Two-hybrid analysis and UV-crosslinking studies have 
partially revealed the structural organization of the yeast RNase P holoenzyme [134, 
135]. A recent low resolution modular architecture defined by electron microscopy 




RNase MRP are different, which may explain their different substrate specificity 
[136].  
1.2.2 RNase P without RNA 
An RNase P enzyme lacking an RNA subunit has long been proposed in plants 
and human mitochondria from the different density, insensitivity to nuclease 
treatment and reactivity with pro-Rp phosphorothioate modified pre-tRNA substrate 
[137-140]. Furthermore, RNase P RNA genes have not been identified in most land 
plants, and some algae and protists groups [12, 124], indicating either the absence 
of this gene or a sequence that diverges greatly.  RNase P activity independent of 
an RNA subunit was first demonstrated in human mitochondrial RNase P from a 
complex of three recombinant proteins, MRPP1 (TRMT10C), MRPP2 (SDR5C1) and 
MRPP3 (or “proteinaceous RNase P, PRORP) [141]. Subsequently, a single protein 
that has RNase P activity has been identified and characterized from Arabidopsis 
thaliana (PRORP1 in mitochondria and chloroplast, PRORP2 and 3 in nucleus) [142, 
143] and Trypanosoma brucei (PRORP1 in nucleus and PRORP2 in mitochondria) 
[31]. PRORP, MRPP1 and MRPP2 proteins do not show significant sequence 
homology to any previously identified RNase P protein components. Remarkably, T. 
brucei PRORP1 is able to substitute the large multi-subunit yeast nuclear RNase P 
in vivo albeit with a slower growth rate [31]. In small green algae, Ostreococcus 
tauri, mitochondrial and chloroplast genomes each encode a distinct RNase P RNA 
gene, and the nuclear genome encodes a bacterial P protein-like protein and a 
PRORP analog, but cellular locations and in vitro functions of these components 




wide range of eukaryal branches suggest that PRORP may have originated from the 
root of the eukaryal tree [31]. 
The crystal structure of A. thaliana PRORP1 revealed three distinct domains in 
this protein-only RNase P [23] (Figure 1-6). The C-terminal metallonuclease domain 
is linked to the N-terminal pentatricopeptide repeat domain (PPR) domain by a 
structural-zinc domain. The metallonuclease domain is structurally homologous to 
the Nedd4-BP1, YacP nucleases (NYN) which has structural homology to FLAP 
nucleases [145]. PRORP1 cleavage activity is also dependent on divalent metal ions 
such as Mg2+ and Mn2+ [23, 146]. The metal-bound structure of PRORP1 reveals an 
active site with conserved aspartate residues that can bind two manganese ions 
[23]. Therefore, a two metal ion, general acid/base mechanism is proposed [23] 
(Figure 1-8). The PPR domain has multiple helical repeats that enhance pre-tRNA 
affinity and is important for cleavage activity [23]. PPR domains are also found in a 
large number of RNA-binding proteins involved in mitochondrial and chloroplast 






Figure 1-6: Crystal structures of protein-only RNase P proteins and/or analogs. (A) A. 
thaliana PRORP1 structure with two Mn2+ ions (PDB ID: 4G24 [23]) showing the 
metallonuclease (blue, Mn2+ in orange sphere), Zinc-domain (yellow, Zn2+ as blue sphere) 
and PPR-domain (dark pink). (B) A close-up of Mn2+-bound PRORP1 active site. (C) Crystal 
structure of C-terminal methyltransferase domain (MTase domain, PDB ID: 4FMW) of 
human TRMT10A, a homolog of MRPP1, showing a homodimer with bound S-adenosyl-L-
homocysteine (SAH, gray molecule) and K+ ion (purple sphere). (D) Close-up of the SAH 
binding site in TRMT10A. (E) Crystal structure of MRPP2 (PDB ID: 1U7T [151]) with a 





MRRP3 (PRORP), which shares 29% amino acid sequence similarity with A. 
thaliana PRORP1, is the metallonuclease subunit in human mitochondrial RNase P 
(mtRNase P). However, MRPP3 requires two other proteins, a tRNA 
methyltransferase (MRPP1) and a short-chain fatty acid dehydrogenase (MRPP2) to 
cleave mitochondrial pre-tRNA substrates [141]. All three human MRPP proteins are 
encoded in the nucleus and imported into the mitochondria [141]. MRPP1 
(TRMT10C) belongs to the TM10 family of S-adenosyl-methionine (SAM) dependent 
tRNA m1Guanosine methyltransferases [152, 153]. MRPP2 activates MRPP1 in 
catalyzing the N1 methylation of both guanosine and adenosine at position 9 (m1R9) 
in mt-tRNA [152]. A crystal structure of the MTase domain (C-terminal) of human 
TMRT10A (or TM10A), a MRPP1 analog, has been solved (Figure 1-6D, PDB ID: 
4FMW [154]). The C-terminal region of MRPP1 likely adopts a similar MTase fold 
based on sequence homology [153]. MRPP2 (SDR5C1) is a NAD+-dependent 
dehydrogenase that catalyzes β-oxidation of various short-chain steroid and fatty 
acid substrates [155, 156]. MRPP2 forms a homotetramer in solution and in crystal 
structures (PDB ID: 1U7Z [151], Figure 1-6F). Upon binding to β-amyloid (Aβ), 
MRPP2 has a deformed NAD binding site, which may provide a link to Alzheimer’s 
disease (PDB ID 1SO8 [157]). Additional structural and biochemical studies are 
needed to elucidate the molecular details of the roles of each mtRNase P subunits in 
catalysis and substrate recognition. 
In HeLa cells, a knockdown of each mtRNase P subunits by siRNA causes 
accumulation of mitochondrial precursor RNAs and subsequence defects in protein 




noncoding RNAs transcribed from the light strand of mtDNA [159]. Interestingly, 
MRPP1 and 2 localize to nascent RNA transcripts and co-localize with a newly 
identified mitochondrial RNA-binding protein, the G-rich sequence factor 1 (GRSF1), 
to form the so-called “mitochondrial RNA granules” [160]. According to the 
“punctuation mechanism” for human mitochondrial genome, mt-tRNA processing by 
mtRNase P is an important first step in mitochondrial mRNA biogenesis [161-163]. 
Our understanding of the cellular location, biological function and structure of human 
mtRNase P has just begun.   
1.2.3 RNase P as a Drug Target  
Bacterial RNase P is one of two known RNA-based catalysts that behave as 
classic enzymes, catalyzing multiple turnovers and remaining unchanged following 
catalysis [164]. The other example is the ribosome, a large ribonucleoprotein 
complex of which the ribosomal RNA is both catalytic and the prime target of 
numerous antibiotics, including aminoglycosides and macrolides [165]. As an 
essential RNA-based enzyme, bacterial RNase P fulfills several criteria as a novel 
broad-spectrum antimicrobial drug target [25, 166-168]. RNase P is essential for 
bacterial cell viability so the disruption of its function by inhibitors will affect bacterial 
cell growth [75, 169, 170]. Furthermore, the conserved structural features in the 
bacterial form of this enzyme suggest the possibility of developing compounds that 
inhibit a broad range of bacterial RNase Ps [25]. Additionally, substantial differences 
in composition between the bacterial and eukaryal RNase P indicate that it should 




limit toxicity [3, 171, 172]. However, clinically useful inhibitors targeting RNase P 
have not been reported (for a comprehensive discussion see [30]). 
A few bacterial RNase P inhibitors, including small synthetic molecules and 
known antibiotics, have been reported (Figure 1-7). Several synthetic compounds 
such as bis-benzimidazoles (IC50 = 5 – 21 μM) [173-175], porphines and porphyrins 
(Ki = 1 – 4 μM) [175] inhibit E. coli RNase P by binding to the pre-tRNA substrates. 
Recently, a small molecule (RNP A1000, Figure 1-6C) has been suggested to 
interact with the protein component of Staphylococcus aureus RNase P and alter 
cellular mRNA turnover and pathogenesis [176]. This compound has not yet been 






Figure 1-7: Bacterial RNase P inhibitors. (A) Synthetic compounds that inhibit E. coli RNase 
P by binding to pre-tRNA substrate [173-175]. (B) A small molecule inhibitor suggested to 
affect the protein subunit of S. aureus RNase P [176]. (C) Neomycin B and neomycin B-
amino acid conjugates that inhibit E. coli RNase P [177-179].  
 
Aminoglycosides (mainly neomycin B and kanamycin B) and neomycin B-
amino acid conjugates, inhibit E. coli RNase P with IC50 values from 0.1 to 6 μM 




of about 125 nM for E. coli RNase P [178].  Inhibition of E. coli RNase P by 
aminoglycosides is competitive with Mg2+ and decreases at high pH [177, 178]. 
Neomycin B also suppresses Pb2+-induced cleavage by P RNA [177]. Thus, 
aminoglycosides are proposed to inhibit RNase P by displacing Mg2+ ions bound to 
P RNA [177, 180]. Possible interaction of NeoR6 with metal ions near L15 region of 
bacterial P RNA has been proposed based on the loss of inhibition against an 
archaeal type-M RNase P that lacks L15 loop [179]. However, mutations and 
deletions in the proposed metal binding site in the L15 loop in E. coli P RNA do not 
significantly affect inhibition by NeoR6 conjugates [179], leaving the mode of 
inhibition unclear. Computational calculations suggest that the NeoR6 conjugates 
could compete with both pre-tRNA and P protein on binding to P4 and P15 helices 
and displace Mg2+ ions near the P4 helix and the P15 loop [181], but biochemical 
studies directly testing these hypothesis have not been reported to date.  
Discovery of more potent and specific inhibitors and analysis of the mechanism 
of inhibition will allow the evaluation of feasibility of targeting RNase P for novel 
antimicrobial agents [25]. In addition, the development of compounds that can 
specifically bind to the RNase P RNA and/or protein subunits will serve as useful 
chemical biology tools for probing structure and function of this essential enzyme. 
Traditional radiochemical assays for RNase P are discontinuous, labor-intensive and 
less suitable for a high-throughput screening format. Therefore, I have developed a 
real-time fluorescence polarization assay to facilitate measurement of the cleavage 
activity of B. subtilis RNase P and performed high-throughput screens to search for 




1.3 Catalytic Mechanism 
1.3.1 Catalysis and Role of Divalent Metal Ions 
RNase P catalytic activity is absolutely dependent on divalent metal ions [41, 
44]. RNase P catalyzed pre-tRNA cleavage is activated by Mg2+, Ca2+, Mn2+ and 
Zn2+ in vitro [182-184], and likely utilizes Mg2+ as a cofactor in vivo [42-44]. A large 
number of Mg2+ ions (>150) associate with RNase P RNA [42-44, 185] and at least 
three specific Mg2+ ions are involved in catalysis as suggested by Hill analysis [44, 
186]. The interaction of these metal ions with RNase P can be through inner-sphere 
or outer-sphere contacts. An inner-sphere metal ion directly coordinates a functional 
group in the P RNA while the interaction with an outer-sphere metal ion is water-
mediated [187]. Specific Mg2+ ions could be catalytic or co-catalytic metal ions that 
coordinate functional groups in P RNA and/or pre-tRNA substrate to enhance 
substrate affinity, stabilize conformational change, activate the nucleophile and 
stabilize the transition state [188].  
 
 
Scheme 1-1: A minimum kinetic mechanism for B. subtilis RNase P. This kinetic mechanism 
shows pre-tRNA substrate (S) association to RNase P (E), a metal ion stabilized 
conformational change (ES to ES*), cleavage and product release (L: 5’ leader, and P: tRNA) 
[189, 190].  
 
Our lab has developed a minimum kinetic mechanism for the B. subtilis 
holoenzyme using transient kinetic methods, which suggests that at least two 
classes of inner-sphere metal ions are required to achieve catalysis by B. subtilis 




in RNase P, the RNase P-pre-tRNA complex (ES) can be formed in cobalt hexamine 
(Cohex, Co(NH3)63+), a Mg(H2O)62+ mimic. Cobalt hexamine does not catalyze 
phosphodiester cleavage so divalent metal ions can be mixed with ESCohex to 
activate active ES* conformation and/or catalysis. Under these conditions, at least 
one high affinity metal ion (𝐾1 2⁄ , 𝑀𝑔2+
∆𝑐𝑚𝑓
 ~ 60 µM) stabilizes a conformational change 
that occurs after pre-tRNA binding to RNase P (ES to ES*) and that increases 
substrate affinity [191, 192]. Another class of lower affinity metal ion (𝐾1 2⁄ , 𝑀𝑔2+
𝑐𝑙𝑒𝑎𝑣𝑎𝑔𝑒
 ~ 20 
mM) activates cleavage. The conformational change step is coupled to the 
interaction between the P protein and the 5’ leader of pre-tRNA and is rate-limiting 
for cleavage at high pH. Single molecule fluorescence resonance energy transfer 
(smFRET) experiments also show that in Co(NH3)63+ the majority of the RNase P-
pre-tRNA complex is in the ES conformation (80-90%). Addition of calcium ions 
increases the population of ES*, indicating that the metal ions stabilize the active 
ES* conformation (Koutmou, Walter and Fierke, manuscript in preparation). 
However, the binding sites for these functionally important Mg2+ ions in pre-tRNA 
and/or bacterial RNase P holoenzyme remain unclear. 
The newly identified protein-only RNase P enzymes provide a model system to 
compare catalytic strategies used by ancient (RNA) and modern (protein) enzymes. 
It was speculated that protein enzymes evolved to increase catalytic efficiency [193, 
194]. However, the efficiencies of pre-tRNA cleavage catalyzed by A. thaliana 
PRORP1, 2 and 3 are substantially slower (kcat/KM ~1 x105 M-1s-1 at 37˚C) [22, 24, 
195, 196] than the bacterial RNase P holoenzyme (~4 x106 M-1s-1) [164] and the 




x 108 M-1s-1) at 37˚C [197]. P RNA is proposed to use a metal-bound hydroxide as 
the catalytic nucleophile and one or more metal ions for transition state stabilization 
[198], while PRORP1 may adopt a two-metal-ion general acid/base mechanism, as 
proposed from the recent crystal structure studies [23] (Figure 1-8). In addition, the 
pro-Rp non-bridging oxygen at the scissile bond is proposed to coordinate an inner-
sphere metal ion for bacterial RNase P [199-202], while the phosphorothioate 
substitution experiments suggest that a metal ion in PRORP1 interacts with pro-Sp 
oxygen at the cleavage site of pre-tRNA [23, 137, 203] (Figure 1-8). Catalytic 




Figure 1-8: Comparison of proposed catalytic mechanisms for RNP and protein-only RNase 
P. (A) Model proposed from the crystal structure of T. maritima RNase P complex [89]. A 
magnesium-bound hydroxide is the nucleophile for RNA-based RNase P catalysis [204]. (B) 
A two-metal-ion general acid/base model is proposed as the mechanism for PRORP1 [23]. 
1.3.2 Identification of Metal Binding Sites in RNP RNase P 
Identification of specific metal ion binding sites in RNase P RNA is complicated 
by the large number of nonspecific structural metal ions and the difficulties in 




studies [188]. Several specific metal ion ligands important for cleavage activity have 
been implicated by studies using atomic mutagenesis and functional group 
substitutions in both pre-tRNA and RNase P RNA (Figure 1-5 and Figure 1-9). 
Phosphorothioate substitution of the pro-Rp nonbridging oxygen in the scissile 
phosphodiester bond decreases cleavage rate of P RNA by 103- to 104-fold which 
can be partially rescued by addition of thiophilic metal ions (Mn2+ and Cd2+) 
suggesting an inner-sphere coordination of a metal ion with this oxygen [199-202, 
205]. Sulfur substitution of the pro-Sp oxygen and the 3’ bridging oxygen at the 
cleavage site lead to a slow miscleavage at -1 position catalyzed by P RNA, which 
suggests possible roles of these oxygen atoms in catalysis [206]. In the N(-1) 
nucleotide, 2’-deoxy substitution for the 2’-OH group decreases reaction rate 200- to 
3000-fold and decreases Mg2+ affinity by 104-fold (cooperativity from 3 to 2) for P 
RNA. In addition, 2’-NH2 substitution at 2’ position leads to miscleavage at low pH 
and 103-fold lower cleavage rate at high pH [205]. The reduced activity by 2’-NH2 
and 2’-H modifications can be increased by about 100-fold by Mn2+ ions [205]. 
Therefore, this 2’-OH group is suggested to interact with a metal ion though a water 
molecule [207] 
In P RNA, helix P4 is the most highly conserved region, harboring 6 of the 13 
universally conserved nucleotides [6] (Figure 1-5 and Figure 1-9). Nucleotide analog 
interference mapping (NAIM) results suggest that the P1-P4 multihelix junction 
coordinates one or more Mg2+ ions important for activity of E. coli RNase P [91] 
(Figure 1-55B). In E. coli and B. subtilis RNase P P RNA, phosphorothioate 




bonds of A49 and G50 (B. subtilis numbering corresponding to A67 and G68 in E. 
coli) reduce the single-turnover cleavage rate by 100- to 104-fold without affecting 
global structure and substrate affinity [92, 93, 185]. Some of these sulfur 
substitutions can be rescued by Mn2+ and/or Cd2+, suggesting inner-sphere 
coordination with metal ions is important for catalysis. When Mn2+ is used to rescue 
the catalytic activity of E. coli P RNA with pro-Rp and pro-Sp sulfur substitutions in 
A49, two different affinities of Mn2+ ions are observed, suggesting two distinct metal 
ions bind to the nonbridging oxygens [92, 93]. An N7-deaza-2’deoxyadenosine 
substitution of either A48 or A47 in combination with the pro-Sp sulfur substitution of 
A49 in E. coli P RNA further decrease cleavage rate but the N7-deaza modification 






Figure 1-9: Models for inner-sphere metal ion binding sites in the helix P4 of baterial P RNA. 
(A) Sequence of B. subtilis RNase P helix P4.  (B) Overlay of the NMR model of B. subtilis 
P4 helix [95] (yellow, and G378, G379 in cyan) with the T. maritima RNase P ternary 
structure [89] (red and orange spheres showing metal ions and G378, G379 in magenta, 
U51 is in green). (C) Overlay of helix P4 structure in T. maritime RNase P ternary complex 
[89] (dark pink with U51 colored in orange and metal ions are pink spheres) and B. 
stearothermophilus P RNA [88]. (D) Metal coordination in the NMR model [95]. (E) 
Transition state model proposed from T. maritima RNase P ternary complex crystal structure 
[89].  
 
X-ray absorption and NMR spectroscopic studies on a P4 helix stem-loop 
mimic propose a model in which nucleobases corresponding to G378 and G379 
coordinate an inner-sphere Mg2+ ion (Figure 1-9) [94, 95]. Anomalous X-ray 




soaked in heavy metal ions (such as Os3+, Pb2+, Sm3+, Gd3+, or Yb3+) also indicate a 
number of possible metal ion binding sites near helix P4 (M4, M5, M6 in Figure 
1-5B) [96]. In the recent T. maritima RNase P•tRNA ternary complex, two metal ions 
(Sm3+, and Eu3+ soak, 4.2 Å resolution) are observed adjacent to the backbone 
phosphate of A49 and G50 and the carbonyl oxygen at position 4 (O4) in the base of 
U51 [89] (M1, M2 in Figure 1-9C). This observation is in accordance with previous 
phosphorothioate substitution data that the pro-Rp oxygen at A49 and G50 
backbone phosphodiester bonds directly coordinates a metal ion important for 
catalysis. However, there is little biochemical evidence of the proposed inner-sphere 
coordination of the M1 metal with O4 in U51, a universally conserved nucleotide that 
is often identified as a bulge by solution probing [208] and in free P RNA structures 
[86, 88] (Figure 1-9). In contrast, in the T. maritima RNase P ternary complex crystal 
structure, this U is flipped to an inward position [89] (Figure 1-9C). 
In E. coli P RNA, site-directed mutations that delete or reposition the bulged 
uridine in helix P4 decrease cleavage of normal substrate by up to 70-fold (U to C), 
and decrease the substrate affinity of P RNA by 50- and 100-fold (U to G and double 
U bulge, respectively) [209]. Tb3+-catalyzed cleavage of P RNA suggest that none of 
these mutations affect the global folding of P RNA [209]. The 4-thiouridine 
modification of this nucleotide cross-links to the +5 nucleotide in the acceptor-stem 
of pre-tRNA substrate [210], which might suggest that this uridine is not located next 
to the cleavage site in an active conformation. Mutation of this uridine in the T. 
maritima RNase P to cytosine affects the catalytic efficiency (kcat/KM) of holoenzyme 




to 200- to 1700-fold decrease in activity (kcat/KM) [211]. These biochemical studies 
suggest that the positioning and identity of this uridine play an important role in 
RNase P catalysis but did not provide direct evidence for an inner-sphere interaction 
with a catalytic metal ion. Therefore, in Chapter 3, I applied nucleotide analog 
substitutions in combination with transient kinetics to directly probe the divalent 
metal ion binding and biochemical functions of this universally conserved uridine in 
B. subtilis RNase P.  
1.4 Substrate Recognition 
RNase P is a versatile enzyme that can catalyze the cleavage of various 
substrates in vivo and in vitro (see summaries in [34, 212]).  Bacterial RNase P can 
process pre-4.5S RNA [213], pre-tmRNA [214], mRNAs [215-217], and riboswitches 
[218, 219]. The catalytic efficiency (kcat/KM) for certain non-tRNA substrates, such as 
pre-4.5S RNA, is comparable to that of pre-tRNA but with a higher KM. Eukaryal 
RNP RNase P cleaves unstructured RNAs [220] and non-coding RNAs [221, 222] in 
a manner that is independent of structure or sequence. These broad substrate pools 
highlight the importance of RNase P function in cells. The primary and most studied 
RNase P substrate is pre-tRNA. Therefore I will focus the following discussion on 
substrate recognition of pre-tRNA substrates and pre-tRNA-derived model 
substrates. 
1.4.1 Structural Features of tRNA 
Most tRNAs from all kingdoms have a consensus “canonical” cloverleaf 




which deviate from the canonical tRNA in primary sequence, secondary structure 
and likely tertiary structure [223]. Mammalian tRNA can be divided into four different 
groups [110]. One type is similar to canonical tRNA where the majority of 
nucleotides in the D-loop and TψC-loop engaged in tertiary interactions (Figure 
1-10) are conserved, such as human mt-tRNALeu(UUR) (Figure 1-12L). The majority of 
mammalian mt-tRNAs have lost the conserved tertiary interactions between the D- 
and TψC-loop, such as in human mt-tRNATyr (Figure 1-12M). In an extreme case, 
mammalian mt-tRNASer(AGY) lacks the entire D- or T-domain (Figure 1-12N). These 
“bizarre” tRNAs raise the question whether the human mtRNase P proteins are 




Figure 1-10: Secondary and tertiary structures of canonical tRNA. (A) and (B) Secondary 
structure of B. subtilis tRNAAsp. (C) A crystal structure of an unmodified E. coli tRNAPhe (PDB 
ID: 3L0U, [225]) 
 
1.4.2 Sequence-specific Interactions by Bacterial RNase P 
Both P protein and P RNA contribute to the recognition of pre-tRNA substrates 




pre-tRNA relative to tRNA [164]. The affinity and cleavage rate of pre-tRNA by 
holoenzyme also depends on the leader length from 2- to 5-nt [79, 226]. This trend is 
not observed in P RNA alone [79, 226], suggesting that the bacterial P protein 
enhances the substrate affinity and cleavage activity of RNase P by interacting with 
the 5’ leader. This interaction with 5’ leader also results in uniformed binding affinity 
of various pre-tRNA substrates by combining low affinity tRNA body with high affinity 
leader sequences [227]. Cross-linking and fluorescence resonance energy transfer 
(FRET) experiments first demonstrated a direct interaction between the 5’ leader 
and P protein [80, 226]. The observed leader position in the T. maritima RNase P 
complex structure is consistent with these biochemical data [89].   
Sequence-specific interactions between bacterial RNase P have been 
identified in both 5’ sequence flanking the tRNA genes and the 3’ RCCA motif [61, 
62, 228, 229], Figure 1-10). These interactions enhance pre-tRNA affinity and 
cleavage. The 3’ RCCA motif of tRNA forms Watson-Crick base pairs with a UGG 
sequence in the P15 loop (L15) [230]. The 3’ RCCA interaction motif is missing in 
archaeal type-M P RNA and eukaryal P RNA, consistent with the lack of encoded 3’ 
CCA motif in pre-tRNA genes in these organisms [2]. 
In the 5’ leader, biochemical studies identified a sequence preference for uracil 
at position N(-1) in pre-tRNA in both E. coli and B. subtilis and suggest a base 
pairing interaction between this nucleotide and an adenine in J5/15 of P RNA [62, 
231]. Statistical analyses of the sequences of pre-tRNA genes for these species also 
reveal an enrichment of U at this position [232]. For B. subtilis RNase P, mutations 




position forming a trans-Waston-Crick-sugar-edge interaction with G319 in B. subtilis 
P RNA (Lim, Chen and Fierke, unpublished data) [233]. This A preference is 
consistent with a statistically significant enhancement of A content at the N(-2) 
position in B. subtilis pre-tRNA genes [232]. A nucleotide preference of adenine at 
the N(-4) position is suggested from a combination of hydrogen bonding and steric 
interactions with F20 and Y34 residues in B. subtilis  P protein [232].  In B. subtilis 
this sequence selectivity is magnified at physiologically relevant divalent metal ion 
concentrations (~1-3 mM). The base identity at the N(-3) position of B. subtilis pre-
tRNA also affects pre-tRNA affinity and is proposed to be located near P RNA/P 
protein interface and interact with both subunits [233]. These proposal of N(-1) to N(-
4) interactions are consistent with the leader position observed in the crystal 
structure of T. maritima RNase P ternary complex [89] (Figure 1-4). These sequence 
preferences are also interdependent, varying as the identity of the neighboring base 
changes [232, 233].  
Bioinformatic analyses on pre-tRNA genes from 161 bacterial species suggest 
that 91% of these species have statistically significant enrichments in the 5’ leader 
region [232]. Nucleotides N(-1) to N(-4) have the highest enrichment with an 
increasing number of species showing preferences as the position is closer to the 
RNase P cleavage site. These genomic data also suggest different patterns of 
nucleotide enrichments for different bacterial species [232]. These results together 
suggest that sequence-specific recognition between RNase P and pre-tRNA 5’ 







Figure 1-11: Sequence specific interactions between 5’ and 3’ sequences of pre-tRNA and 
bacterial RNase P. The 3’ RCCA base pairs with UGG motif in the L15 loop. U(-1) contacts 
A256 (B. subtilis numbering, A213 in T. maritima). A(-2) interacts with G318 in B. subtilis 
(U294 in T. maritima).   
1.4.3 Substrate Specificity  
Identification of minimum substrate elements has also provided clues into 
mechanism of substrate recognition. In general, the anticodon-stem-loop domain is 
not needed for recognition by RNase P [234], consistent with the exposure of the 
anti-codon domain observed in the ternary crystal structure [89]. The first model 
substrate of bacterial RNase P contains the 5’ leader sequence, 3’ RCCA, acceptor -
stem and T-stem-loop of E. coli pre-tRNAPhe [234]. A similar stem-loop model 
substrate and even a 3-bp-stem-tetraloop substrate derived from E. coli pre-tRNATyr 
suppressor (pre-tRNATyrsu3+, or pSu3) can be accurately processed by P RNA with 
decreased catalytic efficiency (Figure 1-12A) [235]. The 5’ leader, 3’ RCCA and 
acceptor-T-stem-loop therefore are proposed as three important substrate 
recognition elements [5, 236]. But a D-armless mt-pre-tRNASer(AGY) (Figure 1-12N) is 




deleted T. thermophillus pre-tRNAGly substrates (Figure 1-12H) [237], which may 
indicate that mitochondrial substrate is not ideal for bacterial RNase P.  
 
 
Figure 1-12: Secondary structure of pre-tRNA and pre-tRNA-related model substrates for 
RNase P. The solid arrow indicates canonical RNase P cleavage site and dashed arrow 





In archaeal RNase P, the protein subunits and divalent metal ions affect both 
cleavage fidelity and efficiency [110, 238]. For Pyrococcus furiosus (Pfu) P RNA, 
either in complex with four proteins (Rpp21∙Rpp29 and Pop5∙Rpp30) or additions of 
high Mg2+ reduce miscleavage of pATSerCGGAAA and pMini3bpCG model substrates 
[110] derived from E. coli pre-tRNASer suppressor [239] (Figure 1-12B to D). 
However, a pMini3bpUG substrate (wobble base pair at N(-1) to N73) is not 
detectably cleaved by Pfu P RNA complexed only with Rpp21∙Rpp29 while the 
pATSerUGGAAA and pMini3bpUG model substrates can be cleaved by Pfu P RNA 
alone [110]. But deletion or elongation of the D-domain of a cyanobacterial pre-
tRNAGln substrate lead to a considerable amount of miscleavage at -1 position by E. 
coli RNase P holoenzyme [238], indicating that D-TψC-loop interaction in pre-tRNA 
is also an important factor for bacterial RNase P to recognize non-cognate 
substrates. 
For human nuclear RNase P, a linker sequence of at least one nucleotide 
between the acceptor-stem and TψC-stem in model substrate is needed for catalytic 
activity [240] (Figure 1-12F). Substrate lacking the anticodon domain and most of the 
V-loop is not cleaved by human nRNase P, indicating that this enzyme likely 
recognizes a different tertiary structure features of tRNA [240]. In addition, insertions 
of extra base pairs (2-bp) in either the acceptor-stem (Figure 1-12G) or the T-stem in 
the model substrate resulted in a miscleavage at -2 position by human nuclear 
RNase P but did not affect the fidelity of cleavage by E. coli P RNA [240]. These 
data led to a hypothesis that eukaryal RNase P likely uses a more strict “measuring 




between 5’ leader and 3’ trailer sequences of eukaryal nuclear pre-tRNA may also 
affect processing rate by RNase P [60, 197] (Figure 1-12K). 
Because most plant tRNAs are canonical [241, 242], it is not unexpected that 
A. thaliana PRORPs can cleave a bacterial substrate (T. thermophillus pre-tRNAGly) 
[203]. Notably, A. thaliana PRORP2 is only able to cleave this bacterial substrate at 
28 ˚C instead of 37 ˚C [203], which may suggest that dynamics of either pre-tRNA or 
PRORP1 are important for recognition. A. thaliana PRORP1 can also catalyze 
cleavage of a t-element substrate (Figure 1-12J) [142]. For A. thaliana PRORP1, 
conserved nucleotides in D- and TψC-loop (G18, G19, C56, and C57) are protected 
by PRORP1 in footprinting studies, leading to the hypothesis that the PPR-domain in 
the enzyme contacts this region [146]. Deletion of D- and anticodon- domains or 
mutation of the conserved G18 nucleotide in the A. thaliana pre-tRNACys (Figure 
1-12I) abolishes PRORP1 catalyzed cleavage under multiple-turnover conditions 
[146]. However, deletion or elongation of the D-stem in the cyanobacterial pre-
tRNAGln substrate does not affect cleavage by A. thaliana RNase P extracts under 
single turnover conditions [238]. These data argue that the D-stem-loop contribution 
for PRORP catalyzed reaction is substrate-dependent. 
Although plant PRORPs function as a single protein, human mtRNase P 
require two additional proteins (MRPP1 and 2) that may assist MRPP3 in 
recognizing non-canonical mt-tRNAs. Canonical tRNA species are generally 
cleavable by most RNase P holoenzymes except for partially purified human 
mtRNase P [243]. MRPP1∙MRPP2 subcomplex catalyzes N1 methylation of both G9 




(R9) is normally buried in the tRNA structure making reverse-Hoogsten triple-base 
interactions with the N12-N23 base pair (Figure 1-10) [244-246]. N1 methylation of 
A9 in mt-tRNALys has been demonstrated to switch the primary transcript from an 
extended hairpin to a canonical cloverleaf structure by solution structure probing and 
single molecule FRET experiments [247-249]. Recognition of R9 by MRPP1 may 
provoke a conformational change in mt-tRNA and facilitate cleavage by MRPP3 
[250]. However, experimental data suggest that the methyltransferase activity is not 
essential for activation of MRPP3 cleavage [152]. In addition, human mt-tRNA is a 
hot spot for pathogenic point mutations [251, 252], but the effects of these mutations 
on mt-pre-tRNA processing has not been studied with recombinant human mtRNase 
P proteins.  
Clearly, cleavage activity and recognition mechanism vary for the different 
classes of RNase P enzymes and may also depend on substrate identities and 
experimental conditions. Dissecting the mechanism of substrate recognition by 
different RNase P enzymes is important for designing inhibitors that specifically 
target RNase P in pathogens while leaving human isoforms intact. In the future, 
further mechanistic studies of highly purified eukaryal RNase P enzymes are still 
needed. Molecular details of substrate recognition by the protein-only human 
mtRNase P remain underexplored. Therefore, in Chapter 4, I investigate catalytic 





In summary, recent structure and function studies of RNP RNase P have 
revealed new insights into the molecular basis of the interactions of the P RNA 
subunit interacts with protein subunits, metal ions and substrates. The structure of 
the bacterial RNase P holoenzyme-tRNA complex enabled a direct view of the 
architecture of the enzyme. In addition, the discoveries of protein-only RNase P 
further increased the compositional diversity of this essential enzyme and provided a 
new direction to investigate the evolution of RNase P. Additional high-resolution 
structures of all forms of RNase P and continuing structure and function studies will 
provide a fundamental understanding of this essential enzyme, which may ultimately 
assist in designing therapeutics to either target or utilize RNase P for human health.  
1.6 Objectives of this Research 
The overall objective of this thesis research is to advance our understanding of 
the function of RNase P, an essential divalent metal ion-dependent endonuclease 
and a potential drug target. Specific RNase P inhibitors have not been identified to 
date. Therefore, Chapter 2 describes the development of a novel real-time 
fluorescence polarization assay that is capable of measuring both single- and 
multiple-turnover cleavage activity of B. subtilis RNase P and ligand binding to tRNA. 
This assay is further optimized for high-throughput screening and a new B. subtilis 
RNase P inhibitor is identified. 
In Chapter 3, I utilized the FP assay and a combination of nucleotide 




helix of P RNA and the data suggest that this universally conserved nucleotide forms 
an outer-sphere metal contact and is important for a conformational change step in 
B. subtilis RNase P catalysis. This is the first P RNA site identified that significantly 
alters the conformational change that limits the cleavage rate of RNase P.  
In Chapter 4, I purified all of the three protein subunits of human mtRNase P 
and cloned a library of human mitochondrial pre-tRNA genes to start investigating 
substrate recognition by this new member of the RNase P family. Single-turnover 
cleavage data revealed that, unlike previously published results [141, 152], the 
MRPP3 subunit by itself is catalytically active. However, the MRPP1∙MRPP2 
subunits enhance both cleavage rate and fidelity of mitochondrial pre-tRNA 
substrate. Last, Chapter 5 discusses future directions that can apply the 
methodology and framework described in this work to further investigate the 
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CHAPTER 2  
DEVELOPMENT OF A FLUORESCENCE POLARIZATION ASSAY TO 
MEASURE ACTIVITY AND SCREEN FOR INHIBITORS OF B. SUBTILIS 
RNASE P1 
 Abstract 
Ribonuclease P (RNase P) is an essential endonuclease that catalyzes the 5’ 
end maturation of precursor-tRNA (pre-tRNA). Bacterial RNase P is an attractive 
potential antibacterial target because it is essential for cell survival and has a distinct 
subunit composition from its eukaryal counterparts. To accelerate both structure-
function studies and discovery of inhibitors of RNase P, we developed a real-time 
fluorescence polarization (FP) assay to measure RNase P activity using pre-tRNA 
with fluorophore attached at the 5’ end. This FP assay can also measure binding of 
small molecules to pre-tRNA. Inhibition of B. subtilis RNase P by neomycin B and 
kanamycin B was examined by the FP assay. These compounds bind to the pre-
tRNA substrate with a Kd value that is comparable to the IC50 for inhibition of RNase 
P, suggesting that the mode of inhibition is binding to the substrate. To identify 
inhibitors that function by binding to RNase P, we optimized this FP assay for high-
throughput screening (HTS) of both RNase P inhibition and pre-tRNA binding. Using 
                                            
1 Chapter 2 is adapted from the manuscript in preparation entitled “Fluorescence polarization to 
measure activity and screen for inhibitors of bacterial ribonuclease P” by Xin Liu, Yu Chen, and Carol 




the assay we screened compound libraries that contain over 25,000 samples and 
identified a new in vitro inhibitor of B. subtilis RNase P. The FP methodology and 
inhibitors identified in this work will further our understanding of how RNase P 
recognizes ligands and assist in designing antibacterial compounds that target 
RNase P in future. 
2.2 Background 
RNA exerts numerous important functions in living systems and has become a 
target for novel drug discovery [1-4]. In the pathway for generating mature functional 
transfer RNA (tRNA), ribonuclease P (RNase P) catalyzes cleavage of the 5’ end 
from all precursor tRNAs (pre-tRNAs) [5-7]. Bacterial RNase P also catalyzes 
cleavage of various RNA substrates [8], such as pre-4.5S RNA [9], pre-tmRNA [10],  
mRNAs [11-13], and riboswitches [14, 15]. In most organisms, RNase P is a 
ribonucleoprotein consisting of a single catalytic RNA subunit (P RNA) and variable 
numbers of protein subunits depending on the organism (1 in Bacteria, ≥ 4 in 
Archaea and ≥ 9 in Eukarya nuclei) [16-19]. Recently, examples of solely protein-
based RNase P have been identified or predicted in human mitochondria [20], the 
plant Arabidopsis thaliana [21, 22], and some algae and protists [23, 24]. Bacterial 
RNase P is a potential antibacterial drug target because of the essential role in RNA 
processing and the differential subunit composition from its eukaryal counterparts 
[25]. However, no specific bacterial RNase P inhibitors have been reported to date, 




Several reported inhibitors of E. coli RNase P are known ribosomal antibiotics, 
including puromycin (IC50 ~ 3 mM) [27], aminoglycosides (e.g. neomycin B, IC50 = 60 
μM) [28], and neomycin B derivatives with arginine, lysine and guanidinium moieties 
(IC50 values ranging from 0.1 to 6 μM) [29, 30]. The usefulness of these 
aminoglycoside derivatives in vivo may be limited due to their high positive charges 
that lead to promiscuous binding to nucleic acids. Aminoglycosides are also weak 
non-competitive inhibitors of eukaryal RNase P (Ki = 143 µM for neomycin B to 
Dictyostelium discoideum RNase P). A series of synthetic compounds, such as bis-
benzimidazoles (IC50 = 5 – 21 μM) [31, 32], porphines and porphyrins (Ki = 1 – 4 μM) 
[33] have also been identified as inhibitors of E. coli RNase P. However, the mode of 
inhibition of these compounds is mainly through binding to substrates and therefore 
they are not specific RNase P inhibitors [32, 33]. Spiramycin, a macrolide antibiotic, 
was reported to activate the steady state turnover catalyzed by E. coli RNase P 
holoenzyme and P RNA by 18- and 12- fold respectively [34]. Recently, a small 
molecule has been suggested to bind to the protein component of RNase P (RnpA) 
from Staphylococcus aureus to alter mRNA turnover and pathogenesis [35]. 
Possibly this compound could inhibit bacterial RNase P by interfering with formation 
of P protein-P RNA complex but no biochemical studies has been reported on how it 
could modulate RNase P holoenzyme activity. 
Rational design of inhibitions using an antisense approach and an in silico 
screening, has also been applied to RNase P. Antisense RNAs have been 
developed to target P RNA in the region of P11 and L15 for E. coli and P5.1 for B. 




target RNase P in vivo, the antisense nucleic acids have to be conjugated with 
invasive peptides [39]. To discover inhibitors that function by disrupting interactions 
between the pre-tRNA substrate and the P protein subunit, virtual screening was 
used to dock compounds from the ZINC database [40] to the central cleft of the B. 
subtilis  P protein. The proposed hits await experimental evaluation [26]. To further 
evaluate bacterial RNase P as a viable drug target, more potent and specific 
inhibitors of bacterial RNase P need to be discovered and characterized. 
Conventional methods for measuring RNase P activity and inhibition are mainly 
radiochemical [28]. Pre-tRNAs are labeled with 32P-labeled to monitor cleavage rate 
by following the reactions using denaturing polyacrylamide gel electrophoresis 
(PAGE) and quantification of the extent of cleavage by phosphorimaging. These 
radiochemical assays are discontinuous, labor-intensive and relatively low-
throughput.  
Fluorescence techniques provide an attractive non-radioactive approach to 
measure RNase P activity. Previously, substrate binding and transient kinetics of B. 
subtilis RNase P have been measured using a fluorescein-labeled pre-tRNAAsp or a 
Fl-pre-tRNAAsp paired with or without a tetramethylrodamine-labeled P protein to 
monitor a change in fluorescence intensity or fluorescence resonance energy 
transfer (FRET) [41-43]. In these single-turnover experiments, sensitivity and signal 
dynamic range are sufficient [42]. However, these approaches lack sensitivity for 
measuring steady-state kinetics where the substrate is in excess and the enzyme 




 Here we describe a new fluorescence polarization (FP) assay for B. subtilis 
RNase P activity using a previously reported 5’ fluorescein-labeled pre-tRNAAsp 
substrate (Fl-pre-tRNA [41], Scheme 2-1). This FP assay measures RNase P activity 
in a continuous format and is suitable to high-throughput screening of inhibitors. 
Using this FP assay, I measured inhibition of B. subtilis RNase P by previously 
reported E. coli RNase P inhibitors, neomycin B (NeoB) and kanamycin B (KanB). I 
measured the affinity of pre-tRNA for these inhibitors by FP assay, suggesting that 
inhibition of RNase P is at least partly due to binding to the substrate. The FP assay 
therefore also has a potential application of identifying compounds that interact with 
pre-tRNA. Finally, I used this assay to conduct a pilot high-throughput screen for 
RNase P inhibitors and identified a new in vitro inhibitor of B. subtilis RNase P. 
These results demonstrate that the FP assay facilitates both analysis of pre-tRNA 
processing catalyzed by RNase P and the screening for inhibitors of RNase P. 
2.3 Results 
2.3.1 Fluorescence Polarization to Measure Pre-tRNA Cleavage 
To develop a non-radiochemical assay for measuring RNase P activity in real-
time, and for identification of RNase P we developed a fluorescence polarization 
(FP) method because it is sensitive, ratio-metric, robust and easy to transition to a 
high-throughput mode [44]. In general, FP assays are based on the phenomenon 
that the degree of polarization of a fluorophore reflects the mobility of the fluorophore 
based on molecular mass ([45] and reference therein). To measure the cleavage 




fluorescein labeled pre-tRNAAsp substrate with a 5-nucleotide leader (Fl-pre-tRNA 
[41], Scheme 2-1). In theory, when Fl-pre-tRNA is excited by polarized light, the 
emission light remains largely polarized (higher anisotropy) because the Fl-pre-tRNA 
macromolecule rotates substantially slower than the fluorescence lifetime of 
fluorescein. After RNase P catalyzed cleavage of the Fl-pre-tRNA, emitted light from 
the fluorescein-5-nucleotide leader (Fl-5-nt-leader) product is depolarized (lower 
anisotropy) Because the 5-nt leader rotates more rapidly than the 82-nt Fl-pre-tRNA 
substrate, the anisotropy of the Fl-pre-tRNA and the 5-nt leader product differ by 2 to 
3-fold, providing a wide dynamic range for the cleavage assay (Figure 2-1).  A time-
dependent decrease in FP signal was observed upon mixing B. subtilis RNase P 
holoenzyme with the Fl-pre-tRNA substrate under both single- ([E]/[S]>10) and 
multiple-turnover ([S]/[E]>10) conditions (Figure 2-1). Similar FP reaction curves 
have also been observed for RNase P catalyzed cleavage of 5’ fluorescein labeled 
pre-tRNAAsp with 2, 7, and 10-nucleotide leaders (data not shown). Fluorescence 
polarization/anisotropy measures the ratio of parallel and perpendicular light so the 
assay is ratio-metric and highly accurate (error < 5% even with just a 2-fold dynamic 






Scheme 2-1: A fluorescence polarization cleavage assay for RNase P. A fluorescein dye 
(orange dot) is attached to the 5’ end of a B. subtilis pre-tRNAAsp with a 5-nt leader (Fl-pre-
tRNA). When excited with polarized light, the Fl-pre-tRNA tumbles slower than the lifetime of 
the fluorophore so that the emitted light remains polarized. Upon cleavage of 5’ end leader 
by RNase P, the Fl-5nt-leader strand rotates faster leading to enhanced depolarization of 
the emitted light.   
 
To examine whether the FP change directly reflects cleavage catalyzed by 
RNase P, endpoint gel assays were carried out in parallel to compare the cleavage 
rate constants. These assay results demonstrated that the single-turnover cleavage 
rate constant and the multiple-turnover reaction velocity calculated from the FP 
assay are comparable to the values determined from the gel assay (Table 2-1). 
These data demonstrate that the real-time FP signal accurately measure the 





Figure 2-1: Fluorescence polarization measurements of pre-tRNA cleavage catalyzed by 
RNase P. (A) A single-turnover (STO) reaction time course measured in buffer A (50 mM 
Tris/Mes pH = 5.5, 10 mM MgCl2, 200 mM KCl, 20 mM DTT); with 25 nM Fl-pre-tRNA and 
500 nM B. subtilis RNase P holoenzyme at 37 ˚C. The solid line is a single exponential fit of 
the data with kobs = 0.024, when Equation 2-1 and 2-2 was used to adjust for total 
florescence change the kobs = 0.032 (see Materials and Methods). (B) A multiple-turnover 
(MTO) reaction measured in buffer C (50 mM Tris-HCl pH = 8, 10 mM MgCl2, 100 mM KCl, 
20 mM DTT) with 20 nM Fl-pre-tRNA and 1 nM B. subtilis RNase P holoenzyme and 4 nM P 
protein at 37 ˚C. Total fluorescence does not change for multiple turnover reactions 
compared to substrate alone controls. The steady-state cleavage velocity is measured from 
the initial rate (dashed blue line). 
 
Table 2-1: Comparison of cleavage rates measured by different assays2 
 
Assay methods Single turnover cleavage 
ratea, kobs (s-1) 
Multiple turnover velocityb,  
v0 (nM·s-1) 
FP real-time assay 0.032 ± 0.001 2.2 ± 0.1 
Fluorescence gel assay 0.033 ± 0.006 ― 
32P gel assay ― 1.9 ± 0.1 
a Measured in buffer A (50 mM Tris/Mes pH = 5.5, 10 mM MgCl2, 200 mM KCl, 20 mM 
DTT) with 25 nM Fl-pre-tRNA, 500 nM holoenzyme at 37˚C;  
b Measured in HTS buffer (50 mM Tris-HCl pH = 7.2, 10 mM MgCl2, 100 mM KCl, 20 mM 
DTT, 12 mg/ml yeast tRNAMix, 10 mM spermidine, and 0.01% (v/v) NP-40) by 100nM Fl-
pre-tRNA or 32P-prtRNA substrate, 0.15 nM holoenzyme and 1.5 nM of P protein at 
25˚C. 
 
Furthermore, the steady-state kinetic parameters calculated by the FP assay 
(kcat = 0.18 ± 0.01 s-1, KM = 101 ± 15 nM, kcat/KM =1800 ± 200 mM-1s-1, Figure 2-2) 
are in the same range as previously reported for cleavage of pre-tRNAAsp with a 35-
                                            




nt leader ([46], kcat = 0.83 s-1, KM = 230 nM, kcat/KM =3500 mM-1s-1). The modest 
decrease in activity is likely due to variation in assay conditions, such as the 
substitution of KCl for NH4Cl [46]. Under identical buffer conditions, the initial rate 
from the FP assay is in good agreement with that measured using the radioactive 
assay (Table 2-1).  
 
Figure 2-2: Steady-state kinetics measured by fluorescence polarization assay. Reaction 
condition is the same as described in Figure 2-1 with varying Fl-pre-tRNA concentrations. 
Results are in duplicates and error bars are showing standard deviations. Data were fit to 
Michaelis-Menten equation and kcat = 0.18 ± 0.01 s-1, KM = 101 ± 15 nM, kcat/KM =1800 ± 
200 mM-1s-1. 
 
The term fluorescence polarization (FP) is closely related to fluorescence 
anisotropy (FA) that describes the same phenomenon ([45] and reference therein). 
Both FP and FA have been widely used in literature across biochemical applications 
to calculate percentage of reaction progress and ligand bound [47, 48]. Anisotropy 
has a simple linear additive relationship for calculating fraction of species in solution, 
while the additivity of polarization is not linear [49]. In the present study of RNase P, 
both FP and FA values were recorded and the rate constants calculated from these 
data are the same within error (< 3%). The FP measurements provide a larger 




(Equation 2-8). Therefore, data described in this chapter used FP values for 
analyzing RNase P activity and high-throughput screening.   
The degree of fluorescence polarization is dependent on various factors that 
affect the mobility of the fluorophore, including molecular size, viscosity and 
temperature [45]. Polarization is a ratiometric measurement since it is defined as a 
function of the observed parallel and perpendicular fluorescence light intensity. 
Therefore, polarization of Fl-pre-tRNA is independent of concentration. However, the 
FP signal is dependent on the cation concentration and buffer composition. The FP 
of Fl-pre-tRNA increases with a hyperbolic dependence on the concentration of Mg2+ 
or spermidine (Figure A-1, Appendix A). This cation dependence of FP suggests that 
the mobility of fluorescein in Fl-pre-tRNA decreases at high cation concentrations, 
likely reflecting a more stable pre-tRNA structure under these conditions.  
2.3.2 Neomycin B and Kanamycin B Inhibit B. subtilis RNase P and Bind to 
Pre-tRNA Substrate  
Next we applied the assay to measure inhibition of B. subtilis RNase P by 
aminoglycosides such as neomycin B (NeoB) and kanamycin B (KanB) that have 
been reported previously to inhibit E. coli RNase P[28]. Using the FP assay, we 
measured the dependence of B. subtilis RNase P activity on the concentration of 
NeoB and KanB under a kcat/KM condition (Figure 2-3). Both compounds inhibit B. 
subtilis RNase P cleavage activity. NeoB is slightly more potent (IC50= 23 µM) than 
KanB (IC50= 52 µM). These IC50 values are comparable to those measured inhibition 





Figure 2-3: Neomycin B and kanamycin B inhibit B. subtilis RNase P. Dose-response 
curves of inhibition by neomycin B () and kanamycin B () were measured in buffer B (50 
mM Tris-HCl pH = 7.2, 10 mM MgCl2, 100 mM KCl, 20 mM DTT) with 20 nM Fl-pre-tRNA 
and 0.4 nM RNase P with 4 nM P protein at 37˚C. The concentrations for neomycin B and 
kanamycin B that inhibit activity by 50% (IC50) are 23 ± 3 µM and 52 ± 6 µM, respectively.  
 
Interestingly, titration of NeoB or KanB into the Fl-pre-tRNA alone led to an 
enhancement in FP (Figure 2-4), indicating that these compounds are binding to the 
Fl-pre-tRNA. The total fluorescence intensity remained constant (data not shown). 
The dissociation constants (Kd) were obtained from fitting Equation 2-5 to the FP 
titration curve (Figure 2-4 and Table 2-2). The Kd of NeoB (90 µM) agrees well with 
published value for NeoB binding to a native yeast tRNAPhe (Kd= 90 µM) [50]. 
Unexpectedly, the FP of the fully bound complexes with NeoB and KanB varies 
(Figure 2-4). The significant change in FP upon binding of NeoB (M.W. = 614.6 
g/mol) or KanB (483.3 g/mol) to Fl-pre-tRNA could not be explained by the modest 
increase of the molecular mass of the complex (Equations 2-6 and 2-7). Additionally, 
ΔFP of ~ 30 mP of the fully bound complex with NeoB compound compared to Kan 
B cannot be explained by the small different in mass (ΔM.W. = 131 g/mol). 
Dimerization of the Fl-pre-tRNA could be a possibility for the observed increase in 




NeoB compared to KanB [50] leads to an alteration in the mobility of the attached 
fluorescein in Fl-pre-tRNA. Furthermore, the affinity of NeoB (Kd = 90 μM) and KanB 
(Kd = 217 μM) are similar to the values of IC50 for inhibition of RNase P (IC50= 23 µM 
and = 52 µM, respectively), suggesting that the binding of these compounds to the 
pre-tRNA substrate could contribute to RNase P inhibition. 
 
Figure 2-4: Neomycin B and kanamycin B bind to Fl-pre-tRNA. (A) Binding of NeoB () and 
KanB () to Fl-pre-tRNA measured by FP in Buffer B (50 mM Tris-HCl pH = 7.2, 10 mM 
MgCl2, 100 mM KCl, 20 mM DTT), at 37˚C with 50 nM FI-pre-tRNA. Kd of neomycin B and 
kanamycin B to Fl-pre-tRNA are 90 ± 5 μM and 217 ± 20 μM, respectively. (B) Yeast 
tRNAMix competes with Fl-pre-tRNA for binding neomycin B and kanamycin B with into either 
200 µM NeoB () or 1 mM KanB () and varying concentrations of yeast tRNAMix. Error 
bars are showing standard deviations from five replicates. 
 
Further studies support that NeoB and KanB bind to Fl-pre-tRNA and that the 
binding contributes to the mode of inhibition. Competition of yeast tRNAMix with the 
Fl-pretRNA for binding NeoB or KanB was demonstrated by a decrease in FP 
(Figure 2-4). Yeast tRNAMix increases the Kd,app of NeoB and KanB to Fl-pre-tRNA by 
up to 3-fold (Table 2-2). Yeast tRNAMix also increases the IC50 of NeoB and KanB for 
inhibition of RNase P by 5-fold and > 40-fold, respectively (Table 2-2). Control 
experiments showed that yeast tRNAMix does not affect the cleavage rate of RNase 




(data not shown). Therefore, the decreased inhibition of NeoB and KanB in presence 
of yeast tRNAMix is most likely due to a decreased fraction of inhibitor bound to Fl-
pre-tRNA, consistent with the substrate binding playing a role in observed inhibition 
of RNase P by these compounds. 
Spermidine is also competitive with NeoB inhibition of RNase P. In the 
presence of 100 mM KCl, 5-10 mM Mg2+ and 10 mM spermidine, < 10% inhibition of 
enzyme activity or binding of Fl-pre-tRNA was observed at 1 mM of NeoB. This is 
consistent with previous studies indicating that inhibition of E. coli RNase P by 
aminoglycosides is demolished by high concentrations of NH4Cl (100 mM) and 
spermidine (10 mM) [28, 29]. Spermidine also increased the FP signal for Fl-pre-
tRNA to a level comparable to saturating NeoB (400 µM). This result is consistent 
with the previously observed stabilization of native yeast tRNAPhe by spermidine [50]. 
In addition, the steady-state cleavage activity (kcat/KM conditions) of B. subtilis 
RNase P increases with the spermidine concentration. At 10 mM sperimidine activity 
is enhanced by 2- and 6-fold for holoenzyme and P RNA, respectively (Figure A-2, 
Appendix A). This stimulation effect is comparable to the enhancement of cleavage 
activity on the M1 RNA by spermidine [51]. As observed with E. coli RNase P [28], 
high concentrations of Mg2+ also decrease NeoB inhibition of B. subtilis RNase P 
(Figure A-3, Appendix A). To increase the selectivity of ligand binding to RNase P, 
yeast tRNAMix and spermidine were included in the development of a high-









Table 2-2: Yeast tRNA and spermidine decrease inhibition of B. subtilis RNase P by 
neomycin B and kanamycin B. 
 
 NeoB KanB 
Assay condition IC50 Kd IC50 Kd 
Buffer Ba 23 ± 3 µM 90 ± 5 μM  52 ± 6 µM  217 ± 20 μM 
+ 12 mg/ml Yeast tRNAb > 100 µMd 97 ± 23 μM  > 2 mMd  540 ± 60 μM 
+ 10 mM Spermidinec >> 1 mMe >> 1 mMe n.d.f n.d.f 
a Measured in buffer B (50 mM Tris-HCl pH = 7.2, 10 mM MgCl2, 100 mM KCl, 20 mM 
DTT) and with 20 nM Fl-pre-tRNA, 0.4 nM holoenzyme and 4 nM P protein at 37˚C. 
b and c Same as a but with 50 nM Fl-pre-tRNA. 
d Less than 50% of inhibition or percent bound is observed at this concentration 
measured. 
e <10% inhibition or binding was observed at this this concentration measured. 
f n.d. = not determined. 
2.3.3 Comparison of Theoretical and Experimental FP of Fl-pre-tRNA 
The observation that binding of NeoB and KanB to Fl-pre-tRNA altered the FP 
signal was unexpected because these compounds (0.4-0.6 Da) should not generate 
a noticeable change in FP upon binding to Fl-pre-tRNA (26 kDa) according to the 
Perrin equation [45]. The Perrin equation indicates that a large molecule will have a 
longer rotational correlation time (Equation 2-6) thus higher polarization (Equation 2-
7). The rotational correlation time is usually calculated using the Stoke’s equation 
(Equation 2-6) by adopting a rigid attachment model for of the fluorophore to 
spherical proteins. Using this equation, we calculated the theoretical FP value 
(Equation 2-6 and 2-7). The calculation for FP of Fl-5-nt-leader and the fully bound 
Fl-pre-tRNA·RNase P complex recapitulate the experimental values. However, the 




which is much smaller than predicted theoretical value at ~190 mP. This discrepancy 
suggests that either the 5’ end fluorescein molecule or the Fl-pre-tRNA complex is 
more dynamic than predicted by the model. In contrast, the FP reading of the fully 
bound NeoB·Fl-pre-tRNA complex (~160 mP, marked by  in Figure 2-5) is close to 
the calculated value, consistent with previous observations that NeoB substantially 
stabilizes the secondary and tertiary structure of native yeast tRNAPhe [50].  
 
Figure 2-5: Comparison of theoretical calculation and experimental results on the 
polarization value of fluorescein labeled pre-tRNA in relation to molecular weight. The 
molecular weight of a pre-tRNAAsp with 5-nt leader is calculated from the sequence as 
shown in Figure 2-1. Solid line is the theoretical FP value generated by Equation 2-7. Solid 
symbols indicate experimental FP values measured in Buffer B (50 mM Tris-HCl pH = 7.2, 
10 mM MgCl2, 100 mM KCl, 20 mM DTT) except for Fl-pre-tRNA·RNase P were measured 
in 10 mM CaCl2 and 200 mM KCl. Fl-5-nt-leader (), Fl-pre-tRNA (), Fl-pre-tRNA bound to 
NeoB (), Fl-pre-tRNA·RNase P (). 
2.3.4 High-throughput Screen for Inhibitors of B. subtilis RNase P3  
To optimize the FP assay for high-throughput screening (HTS), a matrix of 
experiments were carried out to choose the conditions for an RNase P-catalyzed 
                                            
3 The compound pinpointing and cherry-picking for the high-throughput screen were carried out by 
Steven Swaney from the Center for Chemical Genomics (CCG) at the University of Michigan. Xin Liu 
performed the HTS experiments. Paul Kirchhoff from the Vahlteich Medicinal Chemistry Core at 
University of Michigan performed statistical analysis of raw data and compound triage. Martha Larsen 




cleavage end point assay in a 384-well microplate format (details in Appendix A). 
First, we tested sensitivity of B. subtilis RNase P activity to commonly used HTS 
reagents such as DMSO and detergent. The activity of B. subtilis RNase P 
decreased upon increasing concentrations of DMSO (Figure A-4B, Appendix A). 
About 80% activity remained when the enzyme is pre-incubated with 2% DMSO. 
Therefore, no more than 2% DMSO was included in the pre-incubation of samples 
with RNase P and the final DMSO concentration was maintained at 1% in all 
reactions. The non-ionic detergent NP-40 (0.01%) was added to enhance the 
performance of liquid handling and does not affect RNase P activity at 
concentrations from 0.01 to 0.1% (v/v) (Figure A-4C, Appendix A).  
Second, the robustness of HTS assays, indicated by the Z’ factor [52], was 
optimized by examining the methods to measure positive controls (maximum 
inhibition, or 0% activity). Quenching the RNase P catalyzed cleavage reaction by 
EDTA to chelate the Mg2+ decreases the polarization value for Fl-pre-tRNA with little 
effect on the readings of the cleaved product (data not shown). This alteration in FP 
leads to a narrower dynamic range and a smaller Z’ factor (Equation 2-8). Therefore, 
the reaction was quenched by a final concentration of 80 mM CaCl2 because it both 
provides a larger dynamic range and slows the reaction dramatically, mimicking an 






Figure 2-6: High-throughput FP assay is robust for screening inhibitors of B. subtilis RNase 
P. (A) Reaction progress curves measured by quenching the reaction with calcium ions at 
specified time points in HTS buffer (50 mM Tris-HCl pH = 7.2, 10 mM MgCl2, 100 mM KCl, 
20 mM DTT, 12 mg/ml yeast tRNAMix, 10 mM spermidine, and 0.01% (v/v) NP-40) with 1% 
DMSO, 20 nM FL-pre-tR5, and 0.15 nM RNase P holoenzyme with 1.5 nM P protein at 30˚C. 
The reactions contained either no inhibitor (1% DMSO blank, ●) as negative control or 80 
mM CaCl2 (□) as positive control for inhibition. Error bars are derived from 18-32 replicates 
in one 384-well plate. (B) The Z’ factor values for the FP HTS assay across 384-well 
microplate. (C) A scatter plot of showing the percent inhibition by plate in the pilot screen of 
the 2880 compound library. Positive controls by 80 mM CaCl2 are shown by red squares. 
Negative controls with 1% DMSO are blue. Compound samples are green. The red solid line 
indicates percent inhibition at three times of standard deviation of negative controls (3SD).  
 
Using the established optimum conditions, a high-throughput screen of 2880 
compounds and 22720 natural product extracts (NPEs) was carried out in 384-well 
microplates using the endpoint FP assay. The 2880 compound library, containing 
small molecules and natural products of known structure, is a pilot set for evaluating 
assay performance. In the NPE library, each sample is often a mixture of substances 




from 0.6 to 0.8 (average Z’ factor = 0.79, (Figure 2-6), demonstrating that the assay 
is suitable for high-throughput screens [52].  
The primary screen results (n=1) were triaged (Figure 2-7) to select samples 
for further screens. First, active samples were defined by showing a percent 
inhibition that is higher than 3 standard deviations (3SD) of negative controls on 
each plate. Second, fluorescence intensity of perpendicular channel was analyzed to 
eliminate false positives that have a fluorescence intensity 3SD higher or lower than 
negative controls. Promiscuous compounds recorded in the MScreen database 




Figure 2-7: HTS screens and triage process for identification of inhibitors of B. subtilis 
RNase P.  
 
From the total of ~25600 samples from the primary screen, 1439 were selected 
for a confirmation screen (n=3). A control screen was carried out by first incubating 




Subsequently, RNase P enzyme was added to the plate for the end-point activity 
assay similar to procedures in the primary screen (30 ˚C and 35 min reaction time). 
From these two screens, 110 Samples showed repeatable inhibition (percent 
inhibition >30%) and no significant affinity to pre-tRNA (within 3SD of negative 
controls in the control screen). These 110 samples were further tested by a dose-
response assay. 57 samples inhibit B. subtilis RNase P activity in a concentration-
dependent fashion and therefore were further tested by an orthogonal radiochemical 
gel assay using the 5’ end 32P labeled pre-tRNA substrate (data not shown). Only 
one compound (iriginol hexaacetate) was considered as a hit (>30% inhibition with 
two different concentrations) from the 2880-compound set after these series of 
screens. For the NPE library, we are following up on dissecting the top-25 hits in 
collaboration with Professor David Sherman’s laboratory at the University of 
Michigan (Figure A-5, Appendix A). 
2.3.5 A Natural Product Derivative Inhibits B. subtilis RNase P in vitro  
From the 2880-compound set, iriginol hexaacetate (Ir6Ac, Figure 2-8) is the 
only compound that inhibits B. subtilis RNase P (percent inhibition > 30%) at 10 µM 
concentrations under the HTS buffer conditions (10 mM spermidine and 12 mg/mL 
yeast tRNAMix) (Figure 2-8). Ir6Ac is a derivative of irigenol, a member of the 
isoflavone natural products family. The IC50 of Ir6Ac against B. subtilis RNase P in 
HTS buffer is 1.7 ± 0.1 µM, while previous reported aminoglycoside inhibitors such 
as neomycin B has a less than 10% inhibition at 1 mM concentrations under this 
condition. In addition, Ir6Ac likely does not bind to Fl-pre-tRNA substrate under this 




into Fl-pre-tRNA substrate (data not shown). These data suggest that Ir6Ac is likely 
more specific and potent for inhibition of RNase P than previous reported inhibitors 
such as neomycin B. 
 
Figure 2-8: Iriginol hexaacetate inhibits B. subtilis RNase P catalyzed cleavage. (A) 
Chemical structure of iriginol hexaacetate (Ir6Ac). (B) Dose-response curve of inhibition by 
Ir6Ac of multiple-turnover cleavage activity catalyzed by RNase P to Ir6Ac measured by FP 
in HTS buffer (50 mM Tris-HCl pH = 7.2, 10 mM MgCl2, 100 mM KCl, 20 mM DTT, 12 mg/ml 
yeast tRNAMix, 10 mM spermidine, and 0.01% (v/v) NP-40) with 20 nM Fl-pre-tRNA and 0.1 
nM B. subtilis RNase P holoenzyme with 1 nM P protein. IC50 is 1.7 ± 0.1 µM. 
2.4 Discussion 
2.4.1 Advantage of the Fluorescence Polarization Assay 
To facilitate mechanistic studies and discovery of inhibitors of bacterial RNase 
P, we have developed a high-throughput FP assay that can measure both cleavage 
activity of RNase P in real-time and binding of small ligands to tRNA (Scheme 2-1). 
The FP assay is safer and cost-effective compared to the radioactivity-based assay 
and is ratiometric with great precision. The real-time cleavage assay by FP is 
validated by comparison with gel-based cleavage assays (Table 2-1). The FP assay 
is also suitable for high-throughput screening for inhibitors of RNase P (Figure 2-6) 




the FP assay does not require separation of substrate and product and can be used 
as a real-time assay, the time needed to measure RNase P activity is much shorter. 
The 96-well or 384-well plate high-throughput assay format greatly enhances the 
ability to measure RNase P activity under multiple conditions and to identify 
inhibitors.   
The FP assay reported here is also robust (Z’ factor >0.5) and cost-effective for 
large scale high-throughput screens. Compared to other ratio-metric assays, such as 
fluorescence resonance energy transfer (FRET), FP is easier to use because it only 
requires one fluorescent probe and does not require 100% labeling efficiency. A 
yield of 60-90% fluorescein labeled pre-tRNA is routinely obtained from the in vitro 
transcription primed by guanosine 5’-monothiophosphate (GMPS) and subsequent 
labeling by 5-Iodoacetamido-fluorescein. Moreover, unlike the short half-life of 32P in 
the radioactivity assays, Fl-pre-tRNA can be stored in ethanol at -80˚C for many 
months without significantly altering the activity or fluorescence signal. One limitation 
of using a fluorescein is the interference from fluorescent compounds [47]. 
Fluorescent dyes with a higher emission wavelength could further improve the 
performance of the FP HTS assay [47]. 
 RNA molecules have gained growing attention as drug targets [53, 54]. 
Development of RNA-friendly methods for studying RNA function and inhibitor 
screening are in great demand [55]. Fluorescence polarization/fluorescence 
anisotropy (FP/FA) methods are increasingly used in studying biomolecule-ligand 
interactions, enzyme kinetics, and high-throughput screening [56]. Recently, FP/FA 




[58], peptidyl-tRNA hydrolysis [59], RNA binding to fluorescently-labeled compounds 
[60], and RNA-Iigand affinity and specificity by competition [61]. The FP assay 
reported here provides a simple method to measure not only pre-tRNA processing 
but also pre-tRNA-ligand interactions. This new methodology will accelerate study of 
RNase P inhibition and facilitate evaluation of bacterial RNase P as an antimicrobial 
drug target [26]. 
2.4.2 NeoB and KanB Inhibit B. subtilis RNase P by Binding to Substrate 
The mechanisms for inhibition of bacterial RNase P function are multifold. For 
example, inhibitors could disrupt P RNA·P protein association, chelate structurally 
and functionally important metal ions, alter P RNA conformation, and/or interfere 
with substrate recognition [26]. Highly positively charged compounds could function 
as potent RNA binders and inhibitors but may also be nonspecific. Previous 
biochemical and computational docking studies suggested three possible 
mechanisms for inhibition of RNase P by aminoglycosides and derivatives through 
interaction with P RNA [28, 30, 62, 63]: (1) competition with the P protein and/or pre-
tRNA for binding to P RNA through P1-P4 helix junction and to J19/4 region 
(computational prediction); (2) competition with Mg2+binding with Mg2+ near the P15 
loop (based on Pb2+-induced cleavage data); and (3) competition with pre-tRNA 
binding to RNase P in P15 region (computational prediction). However, the 
hypotheses listed above have not been directly tested.  
The affinity of NeoB and KanB to Fl-pre-tRNA is only 4-fold lower than the IC50 
(Table 2-2), suggesting the binding of substrate could contribute to inhibition. It was 




fluorescence titration (Kd = 90 µM), inhibition of Pb2+-induced cleavage (IC50 = 100 
µM), UV-melt experiments [50] and X-ray crystallography [64]. NeoB also stabilizes 
tRNAPhe structure as indicated by an increase in the Tm of the native tRNAPhe when 
bound to NeoB [50]. This increase in thermal stability provides a possible 
explanation for the observation that NeoB binding leads to a striking increase in the 
FP of Fl-pre-tRNA (Figure 2-4, ΔmP > 50 mP, Kd= 90 µM). The binding of Fl-pre-
tRNA by NeoB measured by the FP assay is also consistent with a structural 
evidence of a NeoB bound yeast tRNAPhe complex [64]. In this 2.6 Å resolution co-
crystal structure, NeoB displaces a magnesium binding site in the deep groove 
below the D-loop of the yeast tRNAPhe. NeoB and KanB also bind to tRNA 
nonspecifically as demonstrated by the ability of yeast tRNAMx to compete with the 
binding (Figure 2-4). In addition, when yeast tRNAMix was used to compete with Fl-
pre-tRNA in binding NeoB and KanB, the inhibition of B. subtilis RNase P was 
weakened by more than 5-fold (Table 2-2). Based on these results, we speculate 
that the NeoB-bound pre-tRNA has an altered conformation or mobility that inhibits 
RNase P. Another possibility for the observed increase in FP is that binding of NeoB 
and KanB may cause dimerization of the Fl-pre-tRNA, which could be further 
investigated by gel mobility shift and ultracentrifugation assays.  
Spermidine is also competitive with NeoB inhibition. At high ionic strength (100 
mM KCl), spermidine (10 mM) abolished inhibition of B. subtilis RNase P by NeoB 
and KanB (Table 2-2), consistent with lack of inhibition for E. coli RNase P under 
similar conditions [28]. Spermidine is a biogenic polyamine that is polycationic and 




compete with the binding of aminoglycoside to the Fl-pre-tRNA. However, 
spermidine decreases the concentration of Mg2+ required to activate catalysis by E. 
coli P RNA [51], suggesting a stabilization effect on P RNA as well. Similarly, 
spermidine stimulates activity of B. subtilis RNase P holoenzyme (Figure A-2, 
Appendix A). Spermidine also protects certain sites in the P RNA from Pb2+-induced 
cleavage [70]. Therefore, spermidine could interfere with NeoB inhibition through 
competition with binding to Fl-pre-tRNA and/or P RNA. Since the in vivo 
concentration of spermidine is high (~5 mM) in E. coli [71], inclusion of spermidine in 
the screen for RNase P inhibitors is necessary and may lead to identification of 
RNase P-specific inhibitors. 
2.4.3 FP for Measuring Compound Binding to Pre-tRNA 
Unexpectedly, binding of low molecular weight compounds, such as NeoB and 
KanB, to Fl-pre-tRNA can be observed by FP (Figure 2-4). Calculations by Perrin 
equation [45] suggest that binding a small molecule to tRNA should not generate a 
detectable change in FP signal (Equations 2-6 and 2-7, Figure 2-5).  However, a 
more than 50 mP increase in FP was observed when NeoB binds to Fl-pre-tRNA 
(Figure 2-4). Furthermore, the experimental FP of Fl-pre-tRNA (~100 mP) deviated 
markedly from the theoretical calculation (~190 mP) (Figure 2-5). A low FP signals 
for 3’ end fluorescein labeled tRNAfmet [72], and 5’ end labeled peptidyl-tRNA have 
also been reported [59]. Two scenarios could explain the low FP values. First, the 
fluorescein substituent on the 5’ end could rotate more freely and rapidly than the 
rest of the pre-tRNA molecule. Second, pre-tRNA could be more dynamic than a 




the solution, sampling different conformations. This second hypothesis is highly 
likely as NeoB and KanB binding increased the FP of Fl-pre-tRNA markedly, which 
is in line with previous observations that these compounds interact with and stabilize 
tRNAPhe [50, 64]. Therefore, the relative low polarization state of free Fl-pre-tRNA, 
which likely reflects the highly dynamic nature of the tRNA, is an advantage because 
it is sensitive to binding of small ligands, such as aminoglycosides, at moderate 
divalent metal ion concentrations.  
To develop specific inhibitors targeting RNase P enzyme, it is important to 
distinguish compounds that function by binding to pre-tRNA. The FP assay can 
measure small ligand binding to pre-tRNA if the interactions alter the solution 
structure (Figure 2-4). Previously, small ligands binding to native tRNAPhe were 
assayed from change in the intrinsic fluorescence of a modified Y base [50]. The FP 
assay reported here using end-labeled pre-tRNA provides a more general and 
convenient way of measuring ligand binding and stabilization using in vitro 
transcribed tRNA. Additionally, this assay does not rely on binding to a given site 
[54] but can identify ligands that bind to any site that alters the conformational 
mobility of tRNA. One limitation of this approach is that if a small molecule binds to 
without affecting the RNA structure, no increase of FP signal will occur. 
Nonetheless, compounds that stabilize RNA structure might be of interest for drug 
development for many RNA targets [2]. For example, tRNA stabilizing agents will be 
a valuable tool for studying the structure, function and biology of the vast number of 




compounds that bind tRNA will potentially be useful for analyzing selectivity of other 
RNA-targeting drugs [3].  
2.4.4 FP Assay Has Robust Performance for High-throughput Screening 
To screen for specific inhibitors against RNase P cleavage activity, yeast 
tRNAMix and spermidine were added to the assay buffer to minimize nonspecific 
binding to pre-tRNA. As a result, aminoglycosides and previously reported substrate-
binding inhibitors, such as bis-benzimidazoles [31, 32], porphines and porphyrins 
[33], were not identified as inhibitors in the screens. These conditions decreased hit 
rate from 2-5% to 0.1% and increased the possibility of identifying specific inhibitors. 
Furthermore, orthogonal radioactivity cleavage assays were performed to confirm 
the hits from FP screens. Inhibitors identified in HTS also need to be further 
investigated in vivo. According to a publication from GSK [74], a compound identified 
in a HTS effort targeting RNase P failed because later investigation discovered that 
the compound has a major off-target mode of action. Therefore, the antibacterial 
activity of the inhibitors need to be validated in vivo, such as determining the 
minimum inhibitory concentration (MIC) [75] and the response of MIC to down- or 
up-regulation of the RNase P target.    
2.4.5 High-throughput Screening Identified a New Inhibitor of RNase P 
From a pilot high-throughput screen, we identified a new B. subtilis RNase P 
inhibitor Ir6Ac (Figure 2-6). Ir6Ac is a semisynthetic compound derived from irigenol, 
a member of the isoflavone natural products family produced by higher plants such 




suggested to function as phytoestrogens and antioxidants [76]. However, the 
proposed anti-cancer effects of isoflavones on mortality and recurrence rates in 
breast cancer patients are still under debate [77, 78]. To date, no pharmacological 
functions of Ir6Ac have been reported although in the PubChem website lists 14 
records marking Ir6Ac as an active hit in HTS results. Ir6Ac has a good potency 
(IC50=1.7 µM) for inhibition of RNase P and does not bind the substrate based on FP 
measurements, suggesting that it may be a more specific RNase P inhibitor than 
previously reported compounds. Ir6Ac is unlikely to function in vivo because the 
acetate groups are readily hydrolyzed in cells. Further studies on the mode of 
inhibition by Ir6Ac, such as investigation of irreversibility of inhibition and competition 
with subsrate and Mg2+ ions, will provide insights into molecular recognition of 
inhibitors by RNase P. 
The crystal structures of P RNAs [79, 80] and T. maritima RNase P 
holoenzyme with bound tRNA product demonstrate that the substrate binding 
surface in P RNA is large and shallow [81] (Figure 1-4, Chapter 1). These structural 
features suggest that the active site of RNase P might be less ideal for small 
molecule inhibitors. Therefore, natural products and compounds with novel chemical 
scaffolds might be better starting points for discovering inhibitors of bacterial RNase 
P. To search for novel RNase P inhibitors, we are collaborating with Dr. Avi Raveh, 
Pamela Schulz, and Michael Schillaci-Schofield in Professor David Sherman’s 
laboratory (University of Michigan) to further investigate the top hits from the NPE 
library. Ongoing and future works include regrowth of the microorganism for natural 




(Figure A-5, Appendix A) as well as bacterial growth assay, and structural 
characterization of active components by mass spectroscopy and NMR.  
2.4.6 Conclusion 
RNase P plays an essential role in tRNA biogenesis and is considered a novel 
antibacterial target [25]. However, RNase P assays relied mainly on radiochemical 
methods which limit the capacity for high-throughput screens to discover novel 
RNase P inhibitors. The FP assay developed in this study is the first non-radioactive 
method capable of measuring steady-state cleavage activity of bacterial RNase P in 
real-time as well as detecting small ligand binding to pre-tRNA. The FP-based HTS 
assay can be applied to screen large scale compound libraries to identify novel 
RNase P inhibitors and tRNA binders. The principle and framework in this report 
could also be adopted to develop FP assays for RNase P from other organisms, 
including the novel protein-only enzymes from human mitochondria and plants, and 
other tRNA processing enzymes. Important factors in the assay development include 
careful design of substrate constructs, assay conditions and orthogonal assays to 
confirm whether the polarization is accurately reflecting the enzymatic activity. 
Furthermore, the FP binding assay using end-labeled pre-tRNA provides a direct 
method to study binding and stabilizing of pre-tRNA by small molecules, which could 




2.5 Materials and Methods 
2.5.1 Chemicals and Reagents 
Nucleotide triphosphates, spermidine and other chemicals were obtained from 
Sigma at the highest purity unless otherwise indicated. SDS and tRNAmix from 
baker’s yeast were purchased from Fisher Scientific. Inorganic pyrophosphatase 
was purchased from Roche Applied Science. 5-Iodoacetamido-fluorescein (5-IAF) 
was obtained from Invitrogen (now Life Technologies). Iriginol hexaacetate was 
purchased from MicroSource Discovery Systems, Inc. Guanosine 5’-
monothiophosphate (GMPS) was synthesized from 2’, 3’ isopropylidene-guanosine 
and thiophosphoryl chloride as described in [82]. His6-T7 RNA polymerase was 
purified by Ni-NTA chromatography as described previously [83]. Buffer solutions 
were prepared by Milli-Q treated deionized water (Millipore Corporation) and 
autoclaved or filtered by Stericup filter units (Millipore Corporation).  
2.5.2 Assay Buffers 
The following buffers were made fresh before use in the cleavage and/or 
binding assays: Buffer A (50 mM Tris/Mes pH = 5.5, 10 mM MgCl2, 200 mM KCl, 20 
mM DTT); Buffer B (50 mM Tris-HCl pH = 7.2, 10 mM MgCl2, 100 mM KCl, 20 mM 
DTT); Buffer C (similar to buffer B except for pH = 8); HTS buffer (similar to buffer B 
with 12 mg/ml yeast tRNAMix, 10 mM spermidine, and 0.01% (v/v) NP-40).  
2.5.3 Preparation of RNA and P Protein 
P protein and P RNA were prepared as previously described [84, 85]. Fl-pre-




prepared from procedures adapted from previous reports [41, 43]. Pre-tRNAAsp with 
a 5′ monothiophosphate terminus was transcribed in the presence of 4 mM ATP, 
CTP, UTP, 4-5 mM GMPS, and 0.8-1 mM GTP, 0.1 μg/μL T7 RNA polymerase, 0.8-
1 μg/μL linearized DNA template, 1 mM spermidine, 5 mM DTT, 2 µg/mL 
pyrophosphatase, 50 mM Tris–HCl (pH 8.0) and 20-28 mM MgCl2, incubated at 37 
°C for overnight (20 mM MgCl2) or for 4-6 hours with addition of 20 µM NTPs every 
30 min (28 mM MgCl2). The transcribed 5’-GMPS-pre-tRNA was buffer exchanged 
and concentrated into a degassed labeling buffer (10 mM Tris-HCl, pH7.2 and 1 mM 
EDTA) by at least three iterations of centrifugal filtration (Amicon Ultra, 10,000 
MWCO, Millipore Corporation) at 4°C and then incubated with 20- to 40- fold excess 
of 5-IAF at 37 °C overnight to obtain Fl-pre-tRNA followed by purification using 
denaturing PAGE. The radiolabeled pre-tRNA substrate was prepared by incubating 
with calf intestinal alkaline phosphatase (NEB) followed by 5′ end-labeling using T4 
polynucleotide kinase (NEB) and [γ-32P] ATP and purified as described in [46]. All 
RNAs were purified by electrophoresis on a 6% (P RNA) or 10% (pre-tRNA) 
polyacrylamide/bis (39:1) denaturing gel containing 7 M urea. Excised RNA bands 
were soaked into a TES buffer (10 mM Tris, pH 8, 1 mM EDTA, 0.1% SDS, and 500 
mM NaCl) at 4°C overnight. Filtered solutions with eluted RNA were concentrated 
and exchanged into buffer containing 10 mM Tris, 1 mM EDTA and 500 mM NaCl by 
Amicon as described above and ethanol precipitated for storage at -80°C.  
2.5.4 Single- and Multiple-turnover Experiments 
Before use, P RNA and pre-tRNA were denatured by heating for 3 min at 95°C 




by first incubating for 10-15 min at 37°C followed by addition of according buffers 
and incubation for at least 30 min. Then P protein was added to the P RNA for a 30 
min incubation at 37°C to form the holoenzyme.  
For gel assays, time points for the cleavage reaction catalyzed by RNase P 
were taken by diluting aliquots of reaction mix into an equal volume of EDTA 
quenching solution [10 M urea, 200 mM EDTA (pH 8.0), 0.05% bromophenol blue, 
and 0.05% xylene cyanol], as described in [46]. Cleavage of pre-tRNA substrate was 
analyzed by a 10% denaturing gel and visualized by Typhoon phosphorimager using 
phosphor (32P-label) or fluorescence (fluorescein label) scan. The percentage of 
cleavage was quantified by ImageQuant 5.2 or ImageJ software.   
Real-time fluorescence polarization cleavage assays were performed in a black 
96-well microplate (Corning Incorporation, #3915 or #3686) by monitoring the 
polarization signal of fluorescein (λex = 485 nm and λem = 535 nm) using a TECAN 
plate-reader (Genois, G factor=0.95, or Infinite F500, G factor=0.94). The reactions 
were initiated by addition of the enzyme or substrate using single- or multi-channel 
pipettes. Experiments measuring single-turnover reactions were carried out using 
excess enzyme concentrations ([E] = 360 to 500 nM, [S] = 10 to 25 nM) in buffer A 
at 37 °C. The single-turnover cleavage rate constant (kobs) was calculated by fitting 
Equation 2-1 to a percentage cleaved progress curves calculated by Equation 2-2: 
 𝑌 =  𝑌∞(1 − 𝑒
−𝑘𝑜𝑏𝑠𝑡) Equation 2-1 
   
Where  
 𝑌 =
(3 − 𝑃𝐵)(𝑃 − 𝑃𝐹)
(3 − 𝑃)(𝑃𝐵 − 𝑃𝐹) + (𝑔 − 1)(3 − 𝑃𝐹)(𝑃𝐵 − 𝑃)




   
The total fluorescence change during single-turnover reaction is adjusted by 
the enhancement factor, g = FB/FF, and PB and PF are the polarization values of the 
RNase P holoenzyme-bound substrate and cleaved product, respectively [86]. 
When the Fl-pre-tRNA was measured at 37˚C, a non-linear decrease in 
polarization for the first few minutes was observed after initiating reactions by first 
moving out the plates from the temperature controlled plate-reader chamber. This 
was not detected when experiments were performed at room temperature, which 
indicates that the initial drop in FP is due to temperature difference between ambient 
and instrument during operations. Therefore, substrate-alone controls were 
presented in the experiments to adjust for this effect. The multiple-turnover 
measurements of RNase P activity were performed under excess substrate 
([S]=0.01 to 1 µM, [E]=0.15 to 1 nM) in buffer B, buffer C, or HTS buffer. The 
substrate-only controls were included on each plate and the FP trace of the 
substrate-only control was subtracted from reaction traces to adjust for temperature 
variation. The linear initial rates (mP/sec) from the time courses were obtained and 






[S] Equation 2-3 
   
ΔPc/Δt is the slope of the linear initial rate for multiple turnover reaction time 
courses. ΔPc is the polarization signal change upon complete conversion of 
substrate to product. The Michaelis-Menten equation [88] was fit to the dependence 




state kinetic parameters, kcat, KM, and kcat/KM (Figure 2-2). All data analyses were 
performed using Prism 5.03 (GraphPad Software). 
The dose-response curves of multiple-turnover activity of RNase P on inhibitors 
were measured as described in figure and table legends (Figure 2-3 and Table 2-2) 
using 96-well microplate FP assays. The enzyme and substrate concentrations were 
kept constant with varying inhibitor concentrations. For NeoB and KanB reactions 
were performed in the absence of DMSO because aminoglycosides are highly 
soluble in aqueous solution. The Ir6Ac inhibitor was dissolved freshly in DMSO and 
1% DMSO was included in the reaction for all inhibitor concentrations. The initial 
rates in the DMSO blank (MIN inhibition and 100% activity) and in the presence of 
80 mM CaCl2 or without enzyme (MAX inhibition and 0% activity) were used as 
negative and positive controls for inhibition respectively to calculate percent activity 




 Equation 2-4 
   
The concentration of an inhibitor that results in 50% loss of the enzyme activity 








𝑁 Equation 2-5 
2.5.5 Dissociation Constant Determined by Fluorescence Polarization  
The affinity of aminoglycosides (neomycin B or kanamycin B) for Fl-pre-tRNA 




tRNA at 37°C for 15 min in the plate-reader before collecting data. The titration curve 
was fit to Equation 2-6 to obtain the dissociation constant, Kd: 
 𝑌 = 𝑃𝑓 + (𝑃𝑏 − 𝑃𝑓) ×
([I] + [S] + 𝐾𝑑) − √([I] + [S] + 𝐾𝑑)
2 − 4[I][S]
2[S]
 Equation 2-6 
   
In the equation, 𝑃𝑓 is the polarization of unbound Fl-pre-tRNA and 𝑃𝑏 is signal 
from fully bound Fl-pre-tRNA·compound complex.  
2.5.6 Calculation of Fluorescence Polarization in Relation to Molecular Weight 
A theoretical dependence of polarization on the molecular weight of the 5’ end 
fluorescein-labeled RNA (Figure 2-5) was calculated according to Stoke’s (Equation 







(?̅? + ℎ) Equation 2-7 

























) Equation 2-8 
   
P0 is the limiting polarization in the absence of depolarization factors, τ is the 
fluorescence lifetime, θ is rotational correlation time, η is viscosity, M is molecular 
weight, R is gas constant =8.31 x 107 erg/K/mol. ?̅? is theoretical volume for globular 
protein, and h is the degree of hydration. The data (solid line) in Figure 2-5 was 
generated by applying P0 = 300 mP, τ = 4 ns, η = 0.0069 P, R = 8.31 x 107erg/K/mol, 




2.5.7 High-throughput Screening 
To determine the optimum conditions for the end-point HTS assay, RNase P 
cleavage reactions were carried out at 30 ˚C in a black 384-well microplate (Corning 
Corporation, Catalog # 3676) by quenched by the addition of 80 mM CaCl2 at 
various time points (Figure 2-4). The enzyme was pre-incubated with 2% DMSO for 
30 min before the reaction was initiated by addition of equal volume of substrate. 
The FP signal was measured using a PheraStar plate reader (BMG Labtech) with a 
FP filter module (λex = 485 nm and λem = 520 nm). 
The HTS library was provided by the Center for Chemical Genomics at 
University of Michigan. For the primary compound screen of ~2880 compounds 
(n=1), reactions were carried out using final concentrations of 10 µM compound, 1% 
DMSO, 0.15 nM RNase P and 20 nM Fl-pre-tRNA at 30 ˚C in HTS buffer condition. 
First, enzyme was added by a Multidrop Combi reagent dispenser with a micro-
multidrop cassette (Thermo Fisher) before each compound (in DMSO) or DMSO 
(negative controls, column 1 and 2) was pinpointed (Biomek FX Pintool, Beckman 
Coulter) into the solution. Then 80 mM CaCl2 was added to the positive control wells 
(column 23 and 24). RNase P was incubated with compounds at 30 ˚C for 30 min 
before reactions were initiated by addition of Fl-pre-tRNA substrate. The plates were 
incubated for another 35 min at 30 ˚C before addition of CaCl2 to stop the reactions. 
The microplates were read once by the PheraStar plate reader and plate-stackers 
using well H23 of each plate to adjust the gain and beam position.  
Compounds with percent inhibition values of greater than or equal to three 




samples with fluorescence intensity (perpendicular channel) of greater or less than 
3SD of negative controls were considered false positives. Promiscuous compounds 
as identified by previous HTS in the MScreen database (appears as hits in ≥21% of 
screens recorded in CCG) were also excluded from further study. 
A confirmation screen of compounds and NPEs chosen from the primary 
screen was carried out under HTS conditions with modifications. Briefly, the 
compound samples in triplicate were incubated with Fl-pre-tRNA substrate first and 
the plates were read before addition of RNase P to identify compounds that bind to 
Fl-pre-tRNA substrate. The triage criteria of the confirmation screens were to take 
samples showed repeatable 30% or more inhibition activity as actives. False 
positives were identified from florescence intensity (perpendicular channel) of 
greater or less than 3SD of negative control reads. Active compounds identified from 
the confirmation screens were picked by a Mosquito X1 robot (BMG Labtech) for 
dose-response assays using the same conditions. Samples showed concentration 
dependent inhibition activity were identified as actives. Hits selected from the dose-
response assay were further tested by 5’ end labeled 32P-pre-tRNA substrate in a 
gel assay. The 32P assay was carried out at room temperature using 100 nM 
unlabeled pre-tRNA substrate mixed with < 4 nM 32P labeled substrate with 0.5 nM 
RNase P and two different concentrations of samples. Samples that inhibit RNase P 
at both concetrations from radioactivity assay are determined as final hits.  
The robustness of the HTS assay was evaluated by calculating the Z’-factor 




positive and negative controls respectively and 𝜇𝑐+ and 𝜇𝑐− are the average values 
from positive and negative controls. 
 𝑍′ = 1 −  
(3𝜎𝑐+ + 3𝜎𝑐−)
|𝜇𝑐+ − 𝜇𝑐−|
 Equation 2-9 
   
As seen from the Equation 2-8, the Z’-factor is a screening window coefficient 
and is defined as the ratio of the separation band to the signal dynamic range of the 




2.6 Appendix A 
This appendix contains figures of supporting data for the development of the 
fluorescence polarization (FP) assay. The experiments are briefly described in the 
figure legend. No discussion is included.  
2.6.1 Cation Concentrations Affect FP of Fl-pre-tRNA 
 
Figure A-1: Fluorescence polarization of Fl-pre-tRNA in response to cation concentrations. 
(A) FP of Fl-pre-tRNA increased with increasing [Mg2+]. Measured in 50 mM Tris-HCl (pH 
7.2), varying MgCl2, 100 mM KCl, 20 mM DTT with 20 nM Fl-pre-tRNA, 0.4 nM B. subtilis 
RNase P holoenzyme with 4 nM P protein. Samples in duplicates were incubated in the 
plate (Corning #3915) for at least 15 min before reading at room temperature, G factor=0.99. 
(B) FP of Fl-pre-tRNA increased with increasing [Spermidine]. Measured in identical buffer 
conditions as A with 10 mM MgCl2. 






Figure A-2: Spermidine enhances multiple-turnover activity of B. subtilis RNase P 
holoenzyme () and P RNA (). Measured in 50 mM Tris-HCl (pH 7.2), 10 mM MgCl2, 100 
mM KCl, 12 mg/ml yeast tRNAMix, 20 mM DTT with 20 nM Fl-pre-tRNA and 0.5 nM 
holoenzyme (5 nM P protein) or P RNA at room temperature in duplicates. Relative activity 
was calculated with respect to the cleavage rate in the absence of spermidine. 
2.6.3 Mg2+ and Spermidine Are Competitive with Neomycin B Inhibition of B. 
subtilis RNase P 
  
Figure A-3: Mg2+ and spermidine are competitive with inhibition of B. subtilis RNase P by 
neomycin B. (A) [Mg2+] dependence () of relative activity of RNase P cleavage in 400 µM 
neomycin B. Relative activity is a ratio of the cleavage rate in presence of neomycin B 
compared to the rate in the absence of neomycin B at specified [Mg2+]. Measured in 50 mM 
Tris-HCl (pH 7.2), 100 mM KCl, 20 mM DTT with 50 nM Fl-pre-tRNA, 0.4 nM B. subtilis 
RNase P holoenzyme with 4 nM P protein at 37˚C in duplicates. (B) [Spermidine] 
dependence () of relative activity of RNase P cleavage in 400 µM neomycin B. Similar 






2.6.4 Optimization for High-throughput Screen: Test of Mg2+, DMSO and NP-40 
 
Figure A-4: Test of RNase P cleavage activity in response to [Mg2+], [DMSO] and [NP-40]. 
(A) Measured in 50 mM Tris-HCl (pH 7.2), varying MgCl2, 100 mM KCl, 20 mM DTT, 10 mM 
spermidine with 20 nM Fl-pre-tRNA, 0.4 nM B. subtilis RNase P holoenzyme with 10-fold 
access of P protein at room temperature and in duplicates. (B) Measured in 50 mM Tris-HCl 
(pH 7.2), 10 mM MgCl2, 100 mM KCl, 20 mM DTT and varying DMSO (v/v) with 50 nM Fl-
pre-tRNA and 4 nM RNase P holoenzyme (6 nM P protein) at room temperature. (C) Same 





2.6.5 Follow-up on the Hits from the Natural Product Library4 
 
Figure A-5: Test of inhibition of B. subtilis RNase P cleavage activity by regrowth extracts 
and extract fractions of hits from the NPE library. Graph is showing preliminary results for 7 
strains. Fraction No. 0 is the negative control (DMSO blank) while No. 11 is the positive 
control (80 mM CaCl2). Fraction No. 1 is the crude extract and No. 2-10 are fractions from a 
reverse-phase HPLC purification (from high to low hydrophilic fractions). Samples were 
dissolved in DMSO to 15 mg/ml and measured at a final concentration of 0.15 mg/ml (1%) in 
50 mM Tris-HCl (pH 7.2), 5 mM MgCl2, 100 mM KCl, 20 mM DTT, 12 mg/ml yeast tRNAMix, 
10 mM spermidine, 0.01% (v/v) NP-40 with 20 nM Fl-pre-tRNA and 0.15 nM RNase P 
holoenzyme (1.5 nM P protein) at 30˚C. Initial rate was calculated from the linear region of 
the reaction progress curve observed by FP and the percent inhibition was calculated using 
Equation 2-3. 
                                            
4 Regrowth of microbes and HPLC fractionation of extracts was carried out by Dr. Avi Raveh from 





















































2.6.6 A 96-well Plate Bacterial Growth Assay for Evaluation of Antibacterial 
Activity5 
 
Figure A-6: Test of antibacterial growth activity by two natural products extracted from NPE 
hits using a 96-well plate assay. Compound concentration is 0.15 mg/mL. Cells were grown 
in LB media at 37 ˚C.  
                                            
5 Michael Schillaci-Schofield in Professor David Sherman’s laboratory provided bacteria strains and 
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CHAPTER 3  
PROBING METAL ION BINDING SITES NEAR A CONSERVED URIDINE IN 
THE P4 HELIX OF B. SUBTILIS RNASE P BY ATOMIC MODIFICATIONS1 
 Abstract 
Ribonuclease P (RNase P) is a ribonucleoprotein enzyme that catalyzes the 
essential step of 5’ end maturation of tRNA. Bacterial RNase P is composed of one 
catalytic RNA subunit and one protein subunit important for molecular recognition. 
As in many other large ribozymes, divalent metal ions stabilize the folded structure 
and enhance substrate binding and the catalytic activity of RNase P. Identification of 
the RNA moieties involved in metal-binding and discerning the function of these 
interactions is an important remaining question in the RNA catalysis field. The 
recently solved crystal structure of bacterial RNase P proposed that a catalytic metal 
ion directly coordinates the carbonyl oxygen of the bulged uracil in the conserved 
helix P4 of the RNA subunit. To date, there is little biochemical evidence for this 
direct interaction. To examine this proposal and to further investigate the functional 
importance of the functional importance of the bulged U, I substituted this conserved 
uracil in the P4 helix of circularly permuted Bacillus subtilis RNase P with 4-
thiouridine, 4-deoxyuridine, 3-methyluridine and rSpacer (abasic modification). The 
                                            
1 Data in Chapter 3 is in preparation for a manuscript entitled “The universally conserved uridine in 
helix P4 of bacterial RNase P is an outer-sphere metal ligand for metal-dependent substrate binding, 




4-thiouridine substitution decreases substrate affinity in sub-saturating Ca2+. 
Additionally, all functional group modifications, including 4-thiouridine, 4-
deoxyuridine, and 3-methyluridine, decrease the single-turnover cleavage rate of the 
holoenzyme by 16- to 23-fold at pH 5.2 where phosphodiester bond cleavage is rate 
limiting. This effects disappears at high pH where a conformational change step is 
rate limiting. Furthermore, the activity of the 4-thiouridine modified holoenzyme is 
only marginally rescued by the addition of manganese ions, arguing against an 
inner-sphere metal interaction. In contrast, the abasic modification, which removes 
the uracil base while retaining the ribose and backbone, does not affect the cleavage 
rate at low pH but decreases the pH-independent isomerization rate by at least 6-
fold. These data suggest that this universally conserved bulge uridine is important 
for metal-dependent pre-tRNA binding and catalysis by RNase P, likely by 
coordinating at least one metal ion through an outer-sphere interaction and 
stabilization of an active conformation. 
3.2 Background 
Metal ions have important structural, catalytic, and co-catalytic roles in 
ribozyme-catalyzed reactions [1]. Most metal ions interact electrostatically with the 
negatively charged phosphate backbone to stabilize the complex three-dimensional 
structure of the RNA [2]. However, a small number of specifically bound metal ions 
can coordinate functional groups in the ribozyme to stabilize substrate binding 
and/or transition states during catalysis [3-5]. Metal ions also participate in 




the exact positions and roles of important metal ions for ribozyme catalysis has been 
a major challenge in the RNA field.  
To identify functionally important metal ion ligands in RNA, various strategies, 
including nucleotide analog-interference mapping, atomic mutagenesis, metal ion 
rescue, lanthanide cleavage, and X-ray crystallography with heavy metal soaks, 
have been developed over the past two decades (for a review of these methods see 
[8]). Important mono- and divalent metal ions and their ligands have been identified 
in several ribozymes, such as the hepatitis delta virus (HDV) enzyme [9, 10], 
hammerhead ribozyme [11, 12], and group I and II introns [5, 6, 13-15], by 
biochemical and X-ray analysis. However, crystallization of large ribozymes remains 
challenging, and discrepancies about the sites of metal ions have been observed in 
various structures and between structures and biochemical models [16]. Therefore, 
both crystallographic and biochemical data are important for identifying functional 
metal sites and their involvement in the catalytic mechanism of large ribozymes [8]. 
Ribonuclease P (RNase P) is a divalent metal ion dependent ribonucleoprotein 
endonuclease that catalyzes hydrolysis of a specific phosphodiester bond in 
precursor tRNAs (pre-tRNA) to remove the 5’ leader sequence [17-19]. RNase P in 
most organisms contain one catalytic RNA subunit (P RNA) and different numbers of 
protein subunits [20-24]. In bacterial RNase P, the single protein subunit (P protein) 
is essential in vivo and enhances substrate binding, metal affinity and cleavage rate 
at physiological salt conditions [25-28]. The bacterial P RNA subunit is a ribozyme 
that is catalytically active under high ionic strength conditions in vitro [29]. RNase P 




Measurements of isotopic effects using 18O-water suggest that a magnesium-bound 
hydroxide is the nucleophile for a RNase P catalyzed phosphodiester bond 
hydrolysis reaction [33]. RNase P is also activated by the addition of manganese 
and to a lesser extent by calcium and zinc, in vitro [34-36]. A large number of (>150) 
Mg2+ ions associate with RNase P [30-32] but only a handful of these magnesium 
ions form specific contacts with functional groups in RNase P [32, 37]. The 
interaction of these metals can be either direct coordination of functional groups 
(inner-sphere coordination), or water-mediated (outer-sphere coordination) [2]. 
Kinetic studies of magnesium activation of the RNase P•pre-tRNA (ES) complex 
suggest that at least two types of inner-sphere metal ions activate B. subtilis RNase 
P catalysis (Scheme 3-1). One class of high affinity metal ion stabilizes an active 
ES* conformation and another class of lower affinity metal ion activates cleavage 
[38]. However, the binding sites for these essential metal ions and their explicit 
contributions to RNase P structure and function are just coming into focus in 
ribozyme catalysis. 
Several metal binding sites in both the pre-tRNA substrate and RNase P RNA 
have been implicated based on biochemical and crystallographic evidence (Figure 
3-1). In pre-tRNA, potential inner-sphere metal ligands include: the pro-Rp 
nonbridging oxygen, as demonstrated by phosphorothioate substitution and metal 
rescue experiments [39-41]; the pro-Sp oxygen and the 3’ bridging oxygen, as 
indicated by enhanced miscleavage when sulfur is substituted [42]. Atomic 
mutagenesis studies also suggested that the 2’ OH of the cleavage site coordinates 





Figure 3-1: Structure of bacterial RNase P and proposed metal ion binding sites in the 
reaction mechanism. (A) A cartoon representation of the crystal structure of T. maritima 
RNase P holoenzyme in complex with tRNA and an oligonucleotide leader (4.2 Å resolution, 
PDB code: 3Q1R) [44], showing the P RNA (blue), the P4 helix (magenta) of P RNA, P 
protein (green), tRNA (orange), leader (red), and metal ions (yellow spheres). (B) An 
expanded view of the boxed region in (A), displaying the putative active site near P4 helix 
and the 5’ end of tRNA [44]. Residue numbers were adjusted to match the numbering in B. 
subtilis RNase P. Two metal ions are proposed to contact conserved nucleotides (A49-U51) 
in helix P4 and the 5’ phosphate of tRNA (gray dashed lines). One metal (M1, Eu3+ soak) is 
located within 2.1 Å of three oxygen atoms: the pro-Rp nonbridging oxygen in N+1 position 
of tRNA, the pro-Sp nonbridging oxygen in A49, and the O4 of the U51 base. The second 
metal (M2, Sm3+ soak) is clearly visible only when the leader was soaked into the crystal 
[44], and is located within 2.2 Å of the pro-Rp nonbridging oxygen of G50. (C) The RNase P 
catalyzed reaction showing possible metal ion coordinations [8, 17, 44]. The purple diagram 
is showing a part of the P4 helix (pentagons: ribose rings; solid circles: backbone 
phosphate). A proposal [44] combining the metals observed in the crystal structure (above) 
with previous biochemical studies [45-47] suggested that the M1 metal (orange sphere) 
directly coordinates ligands in the P4 helix and the scissile bond and activates a hydroxyl 
nucleophile [33], while the M2 metal (orange) could stabilize product formation. Another 
metal ion (M3, red sphere) is proposed by biochemical data probing moieties in pre-tRNA 
[39-42]. Question marks designate proposed metal ion-ligand interactions that lack either 




In the P RNA, helix P4 is the most highly conserved region and is critical for 
binding metals important to catalysis [48, 49]. Phosphorothioate substitution in both 
E. coli and B. subtilis RNase P RNA suggested that the non-bridging oxygen atoms 
in the backbone phosphate of A49 and G50 (B. subtilis numbering) are inner-sphere 
metal ligands [45-47]. X-ray absorption and NMR spectroscopic studies on a P4 
helix stem-loop model for B. subtilis RNase P suggest that an inner-sphere Mg2+ ion 
interacts with G378 and G379 [50, 51] (Figure 1-9, Chapter 1). A number of possible 
metal ion binding sites near residues A48, A49, G50, G378 and G379 (B. subtilis 
numbering) have also been identified by anomalous scattering in diffraction analysis 
of heavy metal ions soaked into B. stearothermophilus catalytic domain crystals (3.5 
Å resolution) [52] (Figure 1-5, Chapter 1). Metal soaks of a recently solved crystal 
structure of the T. maritima RNase P•tRNA ternary complex led to the proposal that 
two catalytic metal ions bind near A49, G50 and U51 in helix P4 as part of the active 
site [44] (Figure 3-1).  
In the two-metal-ion mechanism proposed using data from the recent RNase P 
crystal structure, the carbonyl oxygen-4 (O4) of the conserved bulge uridine in the 
helix P4 is proposed to directly coordinate the catalytic metal ion [44] (Figure 3-1). 
This bulged uridine is universally conserved among all RNase P RNA [49]. In E. coli 
RNase P RNA, site-directed mutations that delete or alter the position of the bulged 
uridine in the helix P4 affect the cleavage rate and pre-tRNA affinity of P RNA. 
Furthermore, these mutations decrease the cooperativity and affinity for rescue of 
the pro-Rp phosphorothioate modified pre-tRNA by Cd2+ [53]. However, when the 




+5 position in pre-tRNA, suggesting that this base is not located near the cleavage 
site under these conditions [54]. Mutation of this uridine in the T. maritima RNase P 
to cytosine decrease the catalytic efficiency (kcat/KM) of the holoenzyme by 10-fold 
and 200- to 1700-fold [55] when coupled with P protein mutants that affect substrate 
affinity [56]. These biochemical studies suggest that the P4 helix positions the 
catalytic metal ions and the pre-tRNA substrate, but do not provide direct evidence 
for an inner-sphere interaction of the bulged uridine with a catalytic metal ion.  
Therefore, I combined atomic mutagenesis and mechanistic studies to directly 
examine whether this conserved uridine coordinates a catalytic metal ion and to 
probe the biochemical role of the bulged U in the RNase P catalytic pathway. To this 
end, the conserved uridine (U51) in the P4 helix of B. subtilis RNase P was replaced 
with a series of atomic mutations, including 4-thiouridine (4SU), 4-deoxyuridine 
(4deOU), 3-methyluridine (3MU) and an abasic/rSpacer modification (abU), which 
deletes the base and keeps the ribose and backbone (Figure 3-2). Substrate affinity, 
single-turnover cleavage activity, and metal ion rescue have been measured to 
evaluate the effects of these mutations on the divalent metal ion-dependent RNase 
P activity. These data indicate that the carbonyl oxygen of the bulged uridine in the 
helix P4 of RNase P RNA is not an inner-sphere ligand for a catalytic metal. 
However, these data are most consistent with a model of which the universally 
conserved uridine coordinates a metal ion through water-mediated interactions. This 
outer-sphere metal interaction of the bulged uridine is involved in stabilizing 
substrate affinity and catalysis of pre-tRNA cleavage as well as contributing to 





Figure 3-2: Probing metal-ligand interactions in the P4 helix of B. subtilis RNase P by 
circular permutation and atomic mutagenesis. (A) Secondary structure of the circular 
permuted B. subtilis P RNA (cpPRNA) [46] highlighting one strand of the P4 helix (magenta) 
and U51 (*). The usual 5’ and 3’ termini of P RNA are joined by a six-nucleotide loop. The 
secondary structure was drawn based on the B. stearothermophilus P RNA crystal structure 
[57]. The cpPRNA used in this study contains sequences either from G46 to G45 (46P, wild-
type like) or from G56 to G45 (56P, truncated). (B) Chemical structures of the wild type 
uridine and analogs. The modified nucleotides were incorporated into P RNA by ligating the 





3.3.1 Preparation of P RNA Mutant with Modified Bulged Uridine (U51) in the 
P4 Helix 
To examine the biochemical role of the conserved U51 in metal binding and 
catalysis by B. subtilis RNase P, four different modifications of the bulged uridine 
(Figure 3-2) were incorporated into P RNA by ligation of a 10-mer 
ribooligonucleotide to a circular permuted P RNA (56P, Figure 3-2). The 10-mer 
ribooligonucleotide has a sequence identical to the 5’ strand of the P4 helix (G46-
U55) except for modifications of the uracil base of U51. The carbonyl oxygen at 
position 4 (O4), a proposed inner-sphere metal ligand, was substituted by a sulfur 
atom in 4-thiouridine (4SU) or deleted in the 4-deoxyuridine (4deOU) substitution. 
The 3-methyluridine (3MU) modification installs a bulky methyl group on the base 
and the abasic/rSpacer modification (abU) completely removes the uracil base but 
maintains the ribose sugar and the backbone. These substitutions were chosen to 
probe the metal binding sites near this bulged uridine at a single-atom level with 
minimum disruption of the base-paring geometry, in contrast to previous site-
directed mutagenesis studies [54, 55].  
Using an optimized ligation method (see Materials and Methods) [46] with T4 
DNA ligase and a DNA splint, a 10-mer ribooligonucleotide with either the 4SU or 
4deOU modification was ligated onto the 5’ end of 56P RNA with a 40-80% 
efficiency, as determined by primer extension analysis (Figure B-1, Appendix B). 
The ligation efficiency of ribooligonucleotides containing the 3MU or abU 




sequences (3MU, 10-20% and abU 20-30%). To compare the functional effects of 
these atomic modifications, an in vitro transcribed 46P RNA and a ligation control 
(10nt) prepared by ligation of a wild type 10-mer ribooligonucleotide (50-80% ligation 
efficiency) to 56P were both used to control for the effects of circular permutation 
and ligation. Both the 46P and 10nt holoenzymes have single-turnover activities 
comparable to wild type P RNA. The truncated 56P RNA is inactive and does not 
interfere with RNase P activity or substrate binding [46].  
3.3.2 4-thiouridine Substitution at U51 Affects Metal Dependent Pre-tRNA 
Affinity for RNase P2 
Divalent metal ions enhance the affinity of RNase P for pre-tRNA [37]. To 
evaluate whether the substitution of the O4 oxygen of U51 with sulfur alters the 
metal dependent pre-tRNA affinity, I measured the binding affinity of a 5’ 32P-labeled 
pre-tRNAAsp to wild type and mutant RNase P holoenzymes under sub-saturating 
(5mM) to saturating (10 mM) Ca2+ concentrations at pH 6 (Figure 3-3 and Table 3-1). 
Under these conditions, the cleavage of substrate catalyzed by RNase P is very 
slow (~10-5 s-1) [58], therefore the dissociation constant can be measured using a 
spin column assay to separate free and bound pre-tRNA [59].  
The affinity of the 4SU mutant and 46P RNase P holoenzyme is similar (within 
2 fold) to that of wild type at a saturating concentration (10 mM) of Ca2+ (Table 3-1 
and Figure 3-3). These data indicate that the circular permutation in the 5’ half of the 
P4 helix and the sulfur substitution of O4 do not significantly perturb the overall 
structure and interaction with pre-tRNA at saturating Ca2+ (10 mM).  
                                            




However, at 5 mM Ca2+, the circular permutation of P RNA decreases the 
substrate affinity by 10-fold (Table 3-1). The 4SU mutant further decreases the 
substrate affinity by 3-fold compared to the circular-permuted 46P control (Table 3-1 
and Figure 3-3). The 10-fold decrease in substrate affinity caused by circular 
permutation of this region is likely due to a modest perturbation of P RNA structure. 
The sulfur substitution of the O4 in U51 further reduced the substrate affinity, 
indicating that O4 might be involved in the metal dependent substrate binding.  
 
Table 3-1 : Circular permutation of helix P4 and 4SU modification alter metal-dependent 
substrate affinity of RNase P holoenzyme. 
 
 5 mM CaCl2










WT 2.4 ± 0.2 1 2 ± 0.5b 1 
46P 27 ± 2 10 4.7 ± 0.9 2 
4SU 72 ± 4 30 3.5 ± 0.3 2 
 
a The apparent dissociation constant, Kd,app, was measured in 50 mM Tris/Mes (pH 6), ~380 
mM KCl, and varying CaCl2 (5 to10 mM) by a spin column assay at 37˚C and calculated by 
Equation 3-1.   






Figure 3-3: The 4-thiouridine (4SU) modification affects the metal dependent substrate 
affinity. (A) Binding of 32P-pre-tRNA substrate in 5 mM CaCl2 by wild type (), 46P () and 
4SU () RNase P. Reaction conditions are described in Table 3-1. The fraction bound 
values were obtained from two to four independent experiments. The dissociation constants, 
Kd, app, were determined from the fix of a simple binding isotherm to the data (solid lines). Kd 
values are listed in Table 3-1. (B) The dissociation constants, Kd, app were measured at 
varying CaCl2 concentrations.  
 
3.3.3 Atomic Modifications 4SU, 4deOU and 3MU Decrease Cleavage Catalyzed 
by RNase P Holoenzyme at Low pH 
Therefore, to further investigate the effects of these modifications on catalysis, 
single-turnover reactions were carried out in saturating divalent metal ion conditions, 
such as 10-20 mM Ca2+ or Mg2+, where the substrate affinity of the mutant is 
comparable to the wild type. Single-turnover cleavage of a 5’ fluorescein labeled pre-
tRNAAsp (Fl-pre-tRNAAsp) catalyzed by wild-type and mutant RNase Ps were 
measured. The observed rate constants are not dependent on the RNase P 
concentrations (360 nM and 500 nM at pH 6), indicating that the enzyme is 
saturating in these experiments. These single turnover cleavage reactions are well 
described by a single exponential function (Equation 3-3, Figure 3-4).  
For wild type RNase P, the observed single-turnover rate constant (kobs) is log-
linearly dependent on pH from pH 4.5 to 6. Previous data indicate this linear pH 
dependence means that phosphodiester bond cleavage is the rate limiting step 
under these conditions [61]. At high pH, the observed cleavage rate of RNase P is 
no longer dependent on pH as indicated by a plateau in the pH profile, suggesting 
that the rate-limiting step switches to a conformational change step prior to substrate 






Scheme 3-1: A minimum kinetic mechanism for bacterial RNase P including substrate 
binding (k1), conformational change (k2), substrate cleavage (kchem) and product dissociation 
(k3) [61]. (E) RNase P holoenzyme; (S) pre-tRNA; (ES) RNase P•pre-tRNA complex; (ES*) 
RNase P•pre-tRNA complex after conformational change; (EPL) RNase P•tRNA•5’ leader 
complex; (L) 5’ leader; (P) tRNA product. The apparent dissociation constant for pre-tRNA 
binding to RNase P is: Kd, app= [E][S]/([ES]+[ES*])=K1/(1+K2). The overall observed rate 
constants under single-turnover condition is kobs=k2kchem/(kchem+k2+k-2) [59].  
 
To test if the U51 modifications affect catalysis by RNase P, single-turnover 
cleavage rates were measured at pH 5.2 (Table 3-2). Modification of the functional 
group in the base at U51, including the sulfur substitution of O4 (4SU), deletion of 
the O4 (4SU), and insertion of a methyl group at position 3 (3MU), decrease the 
single turnover cleavage rate constant by 17- to 23-fold at pH 5.2 (Table 3-2). The 
cleavage of the Fl-pre-tRNAAsp substrate by these mutants is at the correct site as 
indicated by PAGE analysis (Figure B-2, Appendix B). These data demonstrate that 
the structure of the uracil base is important for efficient cleavage. However, even 
though sulfur substitution of the O4 in the U51 decreases the cleavage activity about 
20-fold, this effect is smaller than the activity decrease (300- to 104-fold) observed 
by phosphorothioate modification of the proposed inner-sphere sites in the backbone 
phosphate of the P4 helix [45-47] and pre-tRNA substrate [39-41].  
Remarkably, removing the entire uracil base of U51 (abU) does not alter the 
single-turnover cleavage rate at this pH (Table 3-2) and no mis-cleavage is observed 
(Figure B-2, Appendix B), suggesting that the uracil base of this universally 




catalysis at this pH.  
 
Table 3-2: Single-turnover cleavage rate constants for the cleavage of Fl-pre-tRNAAsp 








 ⁄  
WT 0.035 ± 0.002 1 
46P 0.034 ± 0.001 1 
abU 0.033 ± 0.001 1 
4SU 0.00179 ± 0.00001 20 
4deOU 0.0015 ± 0.0001 23 
3MU 0.00205 ± 0.00002 17 
 
a Single-turnover cleavage was observed by a decrease in anisotropy of a fluorescein 
labeled pre-tRNA substrate (as decribed in Figure 3-4) measured in a saturating 
concentration of RNase P (360 nM), 10 nM Fl-pre-tRNAAsp substrate, 50 mM Tris/Mes, ~200 
mM KCl, 20 mM MgCl2, and 20 mM DTT.  
 
3.3.4 The Deletion of Uracil Base at U51 Decreases Cleavage Rate at High pH 
To further investigate the effects of the substitutions at U51 on the RNase P 
cleavage mechanism, the pH dependence of the observed single-turnover rate 
constant was measured for each of the U51 substitutions (Figure 3-4 and Table 3-3). 
Although the complete deletion of the uracil base (abU) does not affect the cleavage 
rate constant at low pH, the cleavage rate constant is only log-linearly dependent on 
pH within a small range (pH 4.5-5.2, Table 3-3). In contrast, the cleavage rate 
constants catalyzed by RNase P with modifications on the uracil base (4SU, 4deOU 
and 3MU) show a log-linear dependence from pH 4.5 to 7.2. The activity of RNase P 
with the deleted uracil base thus behaves differently than both wild type RNase P 






Figure 3-4: Atomic modifications of U51 alter the pH dependent activity of RNase P. (A) 
Typical time courses for the single-turnover cleavage of FI-pre-tRNA catalyzed by RNase P 
(360 nM RNase P holoenzyme and 10 nM Fl-pre-tRNAAsp) measured in 50 mM Tris/Mes, pH 
5.2 (37˚C), 200 mM KCl, 20 mM DTT with 20 mM MgCl2 by fluorescence 
polarization/anisotropy. Percent cleavage was calculated from the decrease in anisotropy of 
the Fl-pre- tRNAAsp substrate by Equation 3-2 to adjust for total fluorescence change. A 
single exponential (Equation 3-3) is fit to the data and the single-turnover cleavage rate (kobs) 
was listed in Table 3-3. (B) The pH dependence of the observed single-turnover rate 
constants for wild-type and mutant RNase P measured in the same buffer conditions as in 
(A) with KCl concentrations adjusted to maintain constant ionic strength. Each point contains 
2 to 5 independent measurements (error bars are showing standard deviations). A single 
ionization equation (Equation 3-4) was fit to these data to calculate the apparent pKa and 
pH-independent rate constants listed in Table 3-3. 
 
Table 3-3: The pH-independent rate constants (kmax) and apparent pKa values of wild type 








 ⁄  
WT 0.3 ± 0.1c 6.0 ± 0.3c 1 
46P 0.19 ± 0.01c 5.9 ± 0.1c 1.5 
abU 0.054 ± 0.003 5.0 ± 0.2 6 
4SU 0.4 ± 0.1c 7.7 ± 0.2c 0.8 
4deOU 0.21 ± 0.03c 7.4 ± 0.1c 1.5 




a Single-turnover activity of RNase P was measured in 20 mM MgCl2 (pH 4.5-8.7 at 37˚C) as 
described in Figure 3-4.  
b The kmax and pKa were calculated from fitting the data in Figure 3-3 to a single ionization 
model by Equation 3-4. 
c These values are extrapolated from fitting Equation 3-4 to the current data which best 
estimate the lowest possible values of apparent kmax and pKa for WT, 46P, 4SU, 4deOU and 
3MU RNase P. 
 
By fitting a single ionization model (Equation 3-4) to the pH profile, the 
apparent pKa and a pH-independent rate constant (kmax) can be calculated. For wild-
type RNase P, the apparent ionization in pH profile reflects a change in rate-limiting 
steps from the pH-dependent cleavage (kchem) to a pH-independent conformational 
change (k2) at pH > 7 (Scheme 3-1) [61]. The uracil base modifications, 4SU, 4deOU 
and 3MU, increase the apparent pKa value by up to 1.7 units while decrease the pH-
independent rate constant, kmax, modestly (< 1.5-fold). In contrast, the base deletion 
by the abU mutant lowers the apparent pKa by at least 1 pH unit and reduces the 
kmax by at least 6-fold. At kmax, the conformational change is the rate-limiting step 
[61]. Therefore, these data indicate that the abasic modification of the U51 affects a 
conformational change step during the RNase P-catalyzed reaction, while the 
alteration of uracil base functional groups (4SU, 4deOU, 3MU) affects the hydrolytic 
cleavage step (Scheme 3-1). A more accurate value of the conformational change 
rate constant, kmax, and pKa for wild type, 46P, and base-modified (4SU, 4deOU and 
3MU) RNase P can be calculated by measuring the cleavage rate at higher pH (> 8) 
by rapid-quench or stopped-flow methods that require significantly higher quantities 
of enzymes [62]. Nevertheless, the current pH profiles clearly demonstrate that the 
two classes of mutants, base deletion (abU) and the base modifications (4SU, 




3.3.5 U51 Modifications Alter the Cooperativity and the Apparent Affinity of 
Magnesium to P RNA 
To examine whether the modifications affect the metal dependence of P RNA 
differently than the RNase P holoenzyme, the magnesium dependence of the single-
turnover cleavage rate constant catalyzed by P RNA was measured at pH 6 where 
the cleavage step is rate-limiting (Figure 3-5). Similar to the holoenzyme, the abasic 
mutant catalyzes the single-turnover cleavage of Fl-pre-tRNAAsp at a rate constant 
that is similar to the reaction catalyzed by wild type and 46P RNA. Furthermore, the 
base modification mutants, 4SU, 4deOU and 3MU, catalyze cleavage 5 to 9 times 
slower than wild type and 46P RNA at saturating magnesium concentration (Table 
3-4 and Figure 3-5).  
 
Figure 3-5: Mg2+ dependence of wild type and U51 mutant P RNA-catalyzed single-turnover 
cleavage rate. Single-turnover cleavage of the Fl-pre-tRNAAsp (10 nM) by saturating P RNA 
(360 nM) was measured in 50 mM Tris/Mes, pH 6 (37˚C) with 6 - 200 mM MgCl2, 20 mM 
DTT and varying KCl concentrations (from 4 to 40 mM MgCl2 the KCl concentration varied 
from 112 to 5 mM; at higher Mg2+ concentration KCl was maintained at 5 mM) using a 
fluorescence polarization/anisotropy assay. A single exponetnal function (Equation 3-5) was 
fit to the decrease in anisotropy of Fl-pre-tRNAAsp to calculate the single turnover cleavage 
rate constants (kobs) by P RNA. The Mg2+ dependce of kobs was fit to Equation 3-6 to 
calculate the apparent affinity and the Hill coefficient (nH) for the Mg2+ activation (K1/2, Mg) of 









 (sec-1)b K1 2⁄ ,Mg2+
Cleavage




 ⁄  
WT 0.036 ± 0.003 25 ± 3 4 ± 1 1 
46P 0.034 ± 0.002 19 ± 2 4 ± 1 1 
abU 0.056 ± 0.008 40 ± 9 3 ± 1 0.6 
4SU 0.0042 ± 0.0004 70 ± 10 1.7 ± 0.2 9 
4deOU 0.0050 ± 0.0006 70 ± 13 1.5 ± 0.2 7 
3MU 0.008 ± 0.002 130 ± 40 1.4 ± 0.2 5 
 
a P RNA catalyzed single-turnover cleavage of Fl-pre-tRNAAsp was measured as described in 
the legend of Figure 3-5. 
b Equation 3-6 was fit to the data shown in Figure 3-4 to calculate the maximum cleavage 
rate, an apparent magnesium affinity (K1/2, Mg) and the Hill coefficient (nH). 
 
The activity of wild-type and 46P RNA are enhanced by magnesium with an 
apparent Mg2+ affinity (K1/2,Mg)  of 25 and 19 mM, respectively, and a Hill coefficient 
(nH) of 4 (Table 3-4) . The base modification mutants (4SU, 4deOU and 3MU) and 
the abasic mutant (abU) differentially affect both the Hill coefficient (nH) and the 
apparent Mg2+ affinity (K1/2, Mg) (Table 3-4). The 4SU and 4deOU modifications 
decrease the apparent Mg2+ affinity by > 3-fold and decrease the cooperativity to nH 
~ 1.4 to 1.7 (Table 3-4). The 3MU substitution has the largest effect on the apparent 
Mg2+ affinity (7-fold decrease in K1/2, Mg) although the maximum cleavage rate is 
comparable to or slightly better than the other two base modification mutants. 
Conversely, the Hill coefficient (nH = 3 ± 1) of the abU P RNA is within error of the 
wild type value and the apparent magnesium affinity is decreased marginally (2-
fold). These data indicate that alterations in uracil base affect metal binding but 




One explanation of these data is that the uracil base forms hydrogen bonds with a 
metal-water ligand and alterations of the functional groups in the base affect the 
affinity and reactivity of this metal ion. However, the deleted base is replaced with 
water molecules, which then are able to realign to adequately stabilize and position 
the active metal ion.  
3.3.6 Manganese Does Not Rescue 4SU Holoenzyme Activity  
Although the sulfur substitution of the proposed inner-sphere ligand, O4 of 
U51, decreases cleavage activity of both B. subtilis RNase P holoenzyme and P 
RNA, the effects are much smaller than previously observed deleterious effects on 
catalysis for sulfur substitution of a Mg2+ ligand in both phosphorothioate 
experiments [45-47] and model systems [63]. To further investigate the possibility 
that the O4 atom directly coordinates a magnesium ion, manganese ions were 
added to reactions catalyzed by 4SU holoenzyme to determine whether the 
cleavage activity can be rescued [8]. Increasing concentrations of Mn2+ in the 
presence of 10 and 20 mM Mg2+ decrease the single-turnover rate constant for both 
the 10nt control (ligation of a wild type ribooligonucleotide to 56P RNA) and 4SU to 
different extents (Figure 3-6). Low concentrations of Mn2+ (<10 mM, with 20 mM 
Mg2+) did not rescue the 4SU activity (data not shown). However, in higher 
concentrations of Mn2+ (50-100 mM, with 10 mM Mg2+), the 4SU RNase P activity is 
inhibited to a smaller degree leading to a modest Mn2+ rescue with krel = 
(kMn/kMg)4SU/(kMn/kMg)10nt of ≤ 2-fold (Figure 3-6) [8]. Other metal ions frequently used 
for rescue experiments, such as Zn2+ or Cd2+, were not tested because of their 




The modest rescue effect does not provide direct evidence for an inner-sphere 
coordination of the O4 site. However, direct coordination cannot be ruled out solely 
by an absence of rescue activity [8]. However, the high activity of the abasic mutant 
indicates that the uracil base is not essential for efficient cleavage of pre-tRNA 
(Table 3-1 and Figure 3-3), arguing against an inner-sphere coordination of the uracil 
base for catalysis during the transition state. 
 
Figure 3-6: Manganese ions modestly rescue 4-thiouridine holoenzyme activity. (A) The 
single turnover rate constant (kobs) for cleavage of pre-tRNA by control RNase P (ligation of 
a wild type 10-mer riboologonulcetide to 56 P RNA, 10nt in short, ) and 4SU mutant () 
with varying concentrations of MnCl2 (0-100 mM) with 200 mM KCl, 10 mM MgCl2, 50 mM 
Tris/Mes pH 6 at 37˚C, 360 nM holoenzyme and 10 nM Fl-pre-tRNAAsp) was measured by 
fluorescence polarization. (B) The differential effect of Mn2+ ions on the 10nt and 4SU 
RNase P activity is illustrated by the value of krel = (kMn/kMg)4SU/(kMn/kMg)10nt.  
 
3.3.7 4SU Does Not Affect Cleavage in Ca2+ 
In addition, the single-turnover rate constant catalyzed by the 4SU holoenzyme 
was measured in saturating concentrations of Ca2+ (10 mM) (Figure 3-7). In Ca2+, 
the cleavage rate constant is much slower and the cleavage step is rate limiting at all 
pH values [60]. Under these conditions the single-turnover rate constant of the 4SU 




3-7). These data suggest that the O4 in U51 is not important for positioning a 
catalytic Ca2+ for RNase P catalyzed cleavage reactions. This loss of O4 interaction 
could indicate that Ca2+ localizes to an alternative position, which is consistent with 
the less efficient catalysis. 
 
Figure 3-7: The 4-thiouridine modification does not alter RNase P holoenzyme-catalyzed 
single-turnover cleavage rate constant in Ca2+. Single-turnover cleavage of 10 nM Fl-pre-
tRNAAsp substrate catalyzed by 360 nM RNase P holoenzyme was measured in 50 mM 
Tris/Mes, varying pH with ~189 mM KCl to maintain ionic strength, 20 mM DTT, and 10 mM 
CaCl2 by the fluorescence polarization assay. The rate constant, kobs, was calculated from 
Equation 3-3 as described in Materials and Methods.  
3.4 Discussion 
Helix P4 contains 6 of the 13 universally conserved nucleotides in P RNA [64] 
and is proposed to be part of the active site of RNase P, as illustrated by the recently 
solved crystal structure of T. maritima RNase P ternary complex [44]. This structure 
revealed two metal ions (Eu3+ and Sm3+ soak) that bind near A49, G50 and the 5’ 
end of tRNA (Figure 3-1), leading to a proposal that a carbonyl oxygen at position 4 
(O4) of the uracil base of a conserved uridine (U51) is an inner-sphere metal ligand 




hydrolysis (Figure 3-1). To test this hypothesis, I examined the biochemical role of 
this universally conserved uridine (U51) in B. subtilis RNase P by combining atomic 
mutagenesis and detailed kinetic analysis. The functional effects of these 
modifications can be grouped into two classes. First, modifications of the base in 
U51 alter metal-dependent pre-tRNA affinity and decrease RNase P catalyzed 
cleavage rate constant and cooperativity at low pH, but affect the cleavage activity of 
RNase P modestly at high pH. Second, the deletion of the uracil base at U51 retains 
the wild-type level single-turnover cleavage rate at low pH, but substantially lowers 
the apparent pKa and decreases the conformational change rate constant. These 
data argue against an inner-sphere coordination of the O4 to a catalytic metal ion, 
but suggest that this conserved uracil base plays a role in stabilizing an active 
conformation of the RNase P•pre-tRNA (ES) complex prior to cleavage.   
3.4.1 Helix P4 Is Important for Metal Ion Stabilized Substrate Binding 
A previous study showed that circular permutation of the P4 helix and 
phosphorothioate substitutions minimally affect the substrate affinity at saturating 
divalent metal ion concentrations [46]. In this work, I also observed comparable 
affinity of the pre-tRNAAsp substrate for both circular permuted 46P RNase P and the 
4SU mutant at saturating (8 mM and 10 mM) Ca2+ (Table 3-1 and Figure 3-3). 
However, at sub-saturating Ca2+ (5 mM), the circular permutation (46P) destabilizes 
the substrate affinity by 1.5 kcal/mol3. Addition of the sulfur substitution of O4 in the 
uracil destabilizes substrate affinity by an additional 0.5 kcal/mol in comparison to 
wild type holoenzyme. Previous site-directed mutagenesis data also indicated that 
                                            







deletion of the bulge and a movement of the bulged uridine up- or down-stream in 
the helix can result in up to a 200-fold decrease in substrate affinity to P RNA (1 M 
NaCl and 25 mM MgCl2) [65], suggesting the importance of the structure of the helix 
for substrate binding. 
Under low divalent metal conditions, circular permutation and sulfur substitution 
could affect substrate affinity through either incorrect folding of P RNA and/or 
perturbation of metal coordination that enhances substrate binding. Nonetheless, 
higher divalent metal ion concentrations can compensate for the substrate affinity 
defect caused by these perturbations, demonstrating the coupling between metal ion 
binding and substrate affinity and suggesting that P4 helix contains metal binding 
sites that are associated with substrate binding. Future experiments that monitor the 
Mg2+ dependence of P RNA folding by circular dichroism could test the effects of 
these modifications on P RNA stability [66].  
3.4.2 U51 Coordinates a Co-catalytic Metal Ion through Outer-sphere 
Coordination 
In previous phosphorothioate experiments in RNase P [45-47], disruption of an 
inner-sphere contact of a catalytic metal frequently resulted in an enormous 
decrease in catalytic activity (300- to 104-fold). Some of the catalytic defects caused 
by substitution of oxygen with sulfur can be rescued by addition of thiophilic metal 
ions, such as manganese [45-47]. In this study, at low pH where cleavage is the rate 
limiting step [67], both sulfur substitution (4SU) and removal of O4 in U51 produced 
a relatively modest decrease in the single-turnover cleavage rate constant (~20-fold 




holoenzyme with these two single-atom modifications increased linearly with pH. A 
fit of a single ionization to this pH dependence suggests that the apparent pKa 
increases but the kmax is comparable to that of wild type holoenzyme. Additionally, 
manganese only marginally rescues the activity of 4SU holoenzyme (krel<2) at low 
pH. The small rescue effect cannot completely rule out an inner-sphere metal ion 
interaction because the different sizes among sulfur, oxygen, manganese and 
magnesium could disturb the active site structure, and differential solution conditions 
may also complicate the interpretation [8, 68]. In addition, differential manganese 
rescue effects have been observed with phosphorothioate substitution of the pro-Sp 
oxygen of A49 for B. subtilis holoenzyme and P RNA [46]. To examine this 
possibility, manganese rescue of the P RNA catalyzed cleavage activity of the 4SU 
mutant will be measured in the near future.  
Strikingly, the abU modification that completely deletes this conserved uracil 
base but retains the ribose and backbone moieties had no effect on the chemistry 
step (pH 4.5 - 5). These data indicate that the O4 ligand does not form an essential 
inner-sphere interaction with a metal ion to stabilize the transition state for catalysis.  
Multiple magnesium ions (≥ 3) are required for RNase P function, as 
demonstrated by the Hill coefficients (nH ~4) for the magnesium dependence of 
cleavage [30, 32]. The analysis of the magnesium dependence of the cleavage rate 
catalyzed by P RNA shows that modifications on the uracil base, including sulfur 
substitution (4SU) or deletion of O4 (4deOU) and insertion of a methyl group (3MU), 
decreases cleavage rate constant and possibly the number of metal ions from 4 to 2 




has the largest effect on the apparent Mg2+ affinity (5-fold decrease in K1/2, Mg) and 
cooperativity (nH ~1.4). In contrast, removal of the uracil base by the abasic 
modification (abU) only decreases the apparent Mg2+ affinity by < 2-fold and 
decreases the metal cooperativity by 1, indicating that the uracil base is not essential 
for directly stabilizing the chemical step, although the decrease in cooperativity could 
suggest the loss of an active site metal ion. Moreover, the reduced apparent Mg2+ 
affinity and cooperativity of the atomic modifications on the uracil base (4SU, 4deOU 
and 3MU) suggest that this site is involved in correctly positioning at least one co-
catalytic metal ion, likely through outer-sphere coordination mediated by water 
molecules. 
Outer-sphere metal ions have previously been suggested to enhance RNase P 
reactivity [34, 37]. Data presented here suggest that the carbonyl oxygen of the 
conserved uracil likely position at least one co-catalytic metal ion by a water-
mediated outer-sphere interaction (Figure 3-8). We postulate that the wild type O4 
oxygen in this conserved uridine forms a hydrogen bond with a water molecule to 
coordinate a co-catalytic metal ion in the optimal position for activity. Therefore, 
substitution of O4 with a larger sulfur atom (4SU), deletion of the O4 (4deOU) or 
insertion of a methyl group (3MU) on the base creates steric hindrance or alter 
hydrogen-bonding interactions to skew the position of the metal ion. Conversely, 
removal of the uracil base could generate space for additional water molecules at 






Figure 3-8: A cartoon diagram showing a model of U51 coordinating a co-catalytic metal ion 
through an outer-sphere interaction. The atomic modifications on the uracil base, 4-
thiouridine (4SU), 4-deoxyuridine (4deOU) and 3-methyluridine (3MU), interrupt the water-
mediated interaction with a metal ion, but the abasic modification may provide more space 
for one or more additional water molecules to stabilize the outer-sphere interaction.  
 
These experimental data suggest that the proposed direct interaction of the O4 
to M1 metal in the crystal structure of the RNase P ternary complex [44] is not 
important for stabilizing the catalytic transition state. The low resolution (4.2 Å) of the 
crystal structure combined with the larger volume of the soaked metal ions (Sm3+ 
and Eu3+) might have limited identification of an intervening water molecule. In 
addition, because the crystal structure is of a complex with products 
(E∙tRNA∙Leader) rather than with substrate (E∙pre-tRNA), it is possible that the metal 
coordination is altered in this complex. This possibility is exemplified by distinct 
conformational states observed in crystal structures of the hepatitis delta virus (HDV) 
ribozyme, which displays different arrangements of the active site including ejection 




3.4.3 U51 Enhances Conformational Kinetics 
Conformational changes also occur in RNase P during the catalytic cycle [67]. 
After formation of an initial encounter complex between RNase P (E) and pre-tRNA 
(S), the ES complex undergoes a conformational change to form an active 
conformer (ES*) prior to the chemical cleavage step [67] (Scheme 3-1). The 
apparent rate of this conformational change step is independent of pH and becomes 
rate-limiting at high pH (>7) for wild type RNase P [67]. The removal of the uracil 
base to form an abasic site (abU) substantially reduces this conformational change 
rate constant without affecting the cleavage rate constant, thereby  lowers the 
apparent pKa by at least 1-2 pH units (Figure 3-4, Table 3-3). Similar abasic 
modifications have previously been shown to dramatically reduce activity of a 
hammerhead ribozyme by up to 106-fold [72]. In some cases, the reduced activity 
caused by the abasic modifications could be partially rescued (20- to 300-fold 
activation) by addition of specific exogenous bases that restore hydrogen bonding 
and base stacking interactions [72]. The abasic modification in RNase P, however, 
does not alter the cleavage rate constant (Table 3-2 and Figure 3-4). Instead, the 
abasic modification of this conserved uridine decreases the conformational change 
rate constant by at least 6-fold. These data indicate that in RNase P the uracil base 
affects the conformational change step prior to cleavage.  
P RNA has two independent folding domains, the specificity domain (S-
domain) and the catalytic domain (C-domain) [73]. (Figure 3-2). The conformational 
change coupled to pre-tRNA binding is observed for the C-domain alone albeit with 




fluorescence resonance energy transfer (trFRET) experiments (Hsieh and Fierke, 
manuscript in preparation). Since helix P4 is the most conserved region in the C-
domain P RNA [48, 49], it is highly likely that alterations in the structure of this helix, 
possibly including the bulged U51, are involved in the conformational change for 
substrate recognition by the C-domain [54, 65]. The conformational change step is 
proposed to be a proofreading step to recognize a cognate substrate for RNase P 
[62]. The alteration in the conformational changes step caused by the abasic U51 
futher implicates the role of this region of P4 in this step (Figure 3-4).  
Furthermore, structural data suggest that the conserved uridine is able to adopt 
different conformations (Figure 3-9). In contrast to the ternary complex, a previous 
free P RNA structure shows the uridine is in a different “flipped out” conformer [57] 
(Figure 3-9). The differences between secondary structures of the A-type (T. 
maritima) and B-type P RNA (B. stearothermophilus) could be a possible reason for 
this difference. However, solution structural studies of both A-type and B-type P 
RNAs using 2'-hydroxyl acylation analyzed by primer extension (SHAPE) and small 
angle X-ray scattering (SAXS) indicate that the conserved uridine bulge in free P 
RNA is largely solvent exposed under these experimental conditions [74], which is 
consistent with the “flipped out” conformation observed the free P RNA crystal 





Figure 3-9: The universally conserved uridine in P4 helix is in different conformations 
between free P RNA and holoenzyme-substrate bound crystal structures. Two different 
views (side view in left and top view in right) are shown for an overlay of the P4 helix region 
in crystal structures of the B. stearothermophilus P RNA (PDB ID: 2A64, in cyan) [57] and 
the T. maritima RNase P ternary complex (PDB ID: 3Q1R, in dark pink) [44]. The universally 
conserved uridine (U51, B. subtilis numbering) in the RNase P∙tRNA complex [44] is in an 
inward position (orange), while the U51 in the free P RNA is bulged out (cyan) [57]. The two 
metal ions observed in the RNase P∙tRNA complex [44] are pink. The RMSD is 1.1 by 
superimposing the helix backbone using PyMOL software. 
 
Bulged nucleotides are common motifs in folded RNA molecules and have 
been shown to associate with RNA-ligand binding [76, 77]  and conformational 
transitions [78, 79]. In a highly conserved domain in the spliceosome, the U6 RNA 
internal stem-loop, a uracil base flips from a bulged position into a stacked and 
base-paired position upon deprotonation of an adjacent adenine [78, 79]. This uracil 
flipping at high pH is coupled with the disruption of the A-C wobble pair adjacent to 
the U bulge and allows binding of an important metal ion to the pro-Sp non-bridging 
oxygen of the backbone phosphate in this conserved uridine [80, 81]. The different 




conformational transitions in RNase P (Figure 3-9). The uridine bulge in the P4 helix 
of RNase P could potentially undertake a movement from a bulged position to an 
inward location after the initial substrate binding to stabilize the active ES* conformer 
prior to catalysis (Figure 3-10). Further mechanistic studies are necessary to test this 
hypothesis. 
 
Figure 3-10: A diagram showing a model in which the universally conserved uridine 
changes conformations. (A) The conserved bulge uridine (51) in P4 helix may flips from the 
solvent exposed conformation to an inward position to contact an outer-sphere metal ion 
that stabilizes the ES* conformation prior to RNase P catalyzed cleavage reaction. (B) The 
abasic modification of U51 allows positioning of the outer-sphere metal ion through 
additional water molecule but the conformational change rate constant is slower due to the 
deletion of the uracil base. 
 
In the RNase P kinetic pathway, the ES* conformer is suggested to be 
stabilized by a high affinity inner-sphere magnesium ion as indicated by the 
stabilization of this complex with Ca2+ or Mg2+ but not Co(NH3)63+ [62]. The 6-fold 
rate reduction by abasic modification is inconsistent with a specific inner-sphere 
metal interaction. However, at least one outer-sphere metal ion is associated with 




from 4 to 3 in the Mg2+ dependence of the P RNA cleavage rate (Table 3-4), 
suggesting that at least one metal ion is associated with this conformational change 
with possibily an outer-sphere interaction. Two conserved arginine residues in the P 
protein subunit have also been previously shown to stabilize the active ES* 
conformer [60]. The leader sequence in the pre-tRNA substrate is also proposed to 
rearrange to adopt an extended conformation upon binding to RNase P [82] as 
observed in the crystal structure [44]. It is expected that other residues contribute 
synergistically to stabilize the conformational transitions. However, the ligands that 
bind a proposed inner-sphere metal ion that stabilize the conformational change [62] 
have not yet been identified. 
3.4.4 Conclusions and Implications 
In this chapter, a combination of atomic mutagenesis and kinetic studies 
demonstrate that a universally conserved uridine (U51) in RNase P RNA interacts 
with and positions a metal ion, likely via interactions with a water-metal ligand 
important for substrate binding and catalysis. Notably, the uracil base of this 
conserved nucleotide is not essential for catalysis but contributes to stabilization of 
an active conformer of RNase P. These results suggest that the O4 of U51 does not 
form an inner-sphere interaction with a metal ion impoartant for stabilization of the 
transition state (Figure 3-1). However, inner-sphere coordination could occur in other 
complexes that formed during the catalytic cycles, such as E∙tRNA∙Leader product 
complex as observed in the recent crystal structure. A completely clear picture of 
coordination of metal ions that stabilizes the transition state of RNase P requires 




ions in different conformational states could provide valuable insights. Similarly, 
solution structures and metal probing studies could also provide further insights.  
Detailed mechanistic studies, such as the one described in this chapter, examining 
both cleavage and conformational change steps provide a framework to probe 
functionally important metal ion sites in the RNase P kinetic pathway. 
The conserved uridine in the P4 helix reported here is the first nucleotide 
identified in the P RNA that is important for stabilizing the active ES* conformation. 
The ability of RNA to dynamically switch between conformations is frequently crucial 
for ribozyme function [83, 84]. The global conformational change coupled to 
substrate binding in RNase P has been demonstrated by mechanistic studies [62, 
67], but the temporal, spatial and molecular details of important conformational 
change steps during the RNase P kinetic pathway are still not clear. Recently, 
advanced NMR techniques have been developed that can detect transient 
movement of single nucleotides in RNA that are potentially important for function 
[85]. It will be intriguing to investigate whether similar types of micro-movements also 
contribute to the function of RNase P.  
In addition, The abasic modification demonstrated in this study provides a 
potential strategy to probe functions of conserved bases in conformational changes 
and activity in both RNase P and other RNA systems [72], analogous to the alanine 
scanning mutagenesis strategy used to study proteins [86]. Further mechanistic and 
structural studies, such as stopped-flow fluorescence assays and FRET experiments 
[62], will provide more insights into the effects of the abasic modification on the 




3.5 Materials and Methods 
3.5.1 Materials and Reagents 
All nucleotide triphosphates and other chemicals were purchased from Sigma 
at the highest purity (RNase and DNase free grade) unless otherwise specified. 
Sodium dodecyl sulfate (SDS) was purchased from Fisher Scientific. Inorganic 
pyrophosphatase was purchased from Roche Applied Science. Ultra-pure urea was 
from MP Biomedicals. 5-Iodoacetamido-fluorescein (5-IAF) was obtained from 
Invitrogen (now Life Technologies) and dissolved in anhydrous DMSO (Sigma). 
Guanosine 5’-monothiophosphate (GMPS) was synthesized from 2’, 3’ 
isopropylidene-guanosine and thiophosphoryl chloride as described in [87]. His6-T7 
RNA polymerase was purified by Ni-NTA chromatography as described previously 
[88]. Buffer solutions were prepared by Milli-Q (Millipore Corporation) treated 
deionized water and sterilized either by autoclave (inorganic buffers such as MgCl2, 
CaCl2 and KCl) or filtration (EDTA stock solution and solutions containing Mes) using 
Stericup filter units (Millipore Corporation). Tris/Mes stock solutions at various pH 
values were made at room temperature and the pH was re-measured at 37˚C.  
All DNA oligonucleotides were purchased from Integrated DNA Technologies 
(IDT). Ribooligonuctcoties containing atomic modifications of the uridine were 
purchased from different vendors and deporotected according to manufacturing 
procedure before use. The 10-mer ribooligonucleotides containing wild type (10nt) or 
4-thiouridine (4SU) were from Dharmacon (now Thermo Scientific). The 10-mer 
ribooligonulceotides with 4-deoxyuridine (4deOU), 3-methyluridine (3MU), and 




Resource (Yale School of Medicine).  
3.5.2 Preparation of P Protein, Substrate and Unmodified P RNA 
B. subtilis RNase P protein was expressed in BL21(DE3)pLysS cells and 
purified as previously described [89, 90]. The B. subtilis Fl-pre-tRNAAsp substrate 
containing a 5-nucleotide leader sequence was prepared as described previously 
[62, 82] by 5′ monothiophosphate guanosine (5’ GMPS) primed in vitro run-off 
transcription (4 mM ATP, GMPS, CTP, UTP, and 0.8 mM GTP in 50 mM Tris-HCl pH 
8, 1 mM spermidine, 5 mM DTT and 20 mM MgCl2 for 6-12 hrs at 37˚C) using T7 
RNA polymerase from a DNA template linearized by BstNI restriction enzyme (New 
England Biolabs, NEB). The transcribed 5’-GMPS-pre-tRNA was buffer exchanged 
and concentrated into a degassed labeling buffer (10 mM Tris-HCl, pH 7.2 and 1 mM 
EDTA) for labeling by 5-IAF at 37 °C overnight. The 32P 5’ end labeled pre-tRNA 
substrate was prepared by incubating regularly transcribed (4 mM rNTPs and same 
conditions as above) pre-tRNA with calf intestinal alkaline phosphatase (NEB) 
followed by 5′ end-labeling using T4 polynucleotide kinase (NEB) and [γ-32P] ATP 
according to manufacturing instructions and purified by denaturing PAGE followed 
by phenol/chloroform extraction and ethanol precipitation [58]. The wild-type, circular 
permuted 46P and 56P RNAs were transcribed in vitro as previously reported [46] by 
T7 polymerase using DNA templates linearized by DraI, KpnI or BasI restriction 
enzymes (NEB), respectively. All RNAs were purified by electrophoresis on a 6% (P 




3.5.3 Preparation of Mutants by Ligation4 
The 10-mer ribooligonulceotide containing the same sequence as the 5’ end 
strand of the P4 helix (5’ GAA AGU* CCA U 3’) with either the wild type uridine or 
modifications (indicated by the asterisk sign, Figure 3-2) was ligated to the 5’ end of 
guanosine monophosphate (GMP) transcribed 56P RNA in the presence of a DNA 
splint that is complementary to all 10-nt of the RNA oligo and the first 23 or 41 nt of 
56P RNA (5’-GGG CAT CTC AGC ACC GTG CGA GCATGG ACT TTC A-3’ [46] or 
5’-GCT AGG CAC GAA CACTAC GGG CAT CTC AGC ACC GTG CGA GCATGG 
ACT TTC-3’) catalyzed by T4 DNA ligase. The previously reported ligation method 
[46] was used to ligate the 4-thiouridine ribooligonucleotide to GMP-56P RNA and 
the yield was 30-70%. A modified ligation protocol was developed to increase the 
ligation yield [91-93]. Specifically, 4 µM GMP-56P RNA, 28 µM 10-mer 
ribooligonucleotide and 28 µM DNA splint were annealed in 66 mM Tris-HCl (pH 
7.6), 6.6 mM MgCl2 and 10 mM DTT by denaturing at 75˚C for 5 min and cooled 
down at room temperature for 35 min before addition of a final concentration of 200 
µM ATP, 4 µM T4 DNA ligase and 0.2 unit/µL of Sperase∙InTM RNase inhibitor 
(Ambion, now Life Technology). To monitor the ligation reactions, a small amount of 
the ligation reaction mix was folded by incubation at 37 ˚C in 50 mM Tris-HCl (pH 8), 
40 mM MgCl2, 980 mM KCl and 20 mM DTT for a measurement of multiple turnover 
cleavage activity (10 nM P RNA, 50 nM Fl-pre-tRNAAsp). The ligation reactions 
progressed for 3-9 hours before being quenched by EDTA dye (10 M urea, 200 mM 
EDTA (pH 8.0), 0.05% bromophenol blue, and 0.05% xylene cyanol), and the ligated 
P RNA was purified by 6% PAGE. The ligation efficiency was determined by primer 
                                            




extension analysis using a 6FAM labeled primer that anneals to nucleotide 114 to 95 
(Figure 3-2) [46] (5’-6FAM-GCC CTA GCT TAT GAC TTC GC-3’). The 6FAM-primer 
(9 pmol) was annealed to P RNA (27 pmol) in 50 mM Tris-HCl (pH 8.3), 75 mM NaCl 
and 10 mM DTT by denaturing for 3 min at 95˚C followed by a 15 min incubation at 
37˚C. A subsequent extension step took place at 42˚C for 30 min by the addition of 
10 mM MgCl2, 0.8 mM dNTPs, and 2.5 unit/µL reverse transcriptase (Promega). 
Reactions were visualized by a 6% denaturing gel, scanned using a Typhoon 
Phosphorimager (detection limit was determined to be 5 fmol of fluorescein) and 
quantified by ImageQuant or ImageJ software (Figure B-1, Appendix B). 
3.5.4 Determination of Pre-tRNA Dissociation Constant by Spin Column  
The affinity of 32P 5’ end labeled pre-tRNAAsp with a 5-nt leader to RNase P 
holoenzyme was measured as described previously (Figure 2-4A). The recombinant 
P protein was dialyzed against binding buffers containing 50 mM Tris/Mes, pH 6, 
~380 mM KCl, and 5-10 mM CaCl2 at 4˚C. P RNA was folded by denaturation in 
water at 95˚C for 3 min followed by a 30 min incubation at 37˚C before addition of 
desired binding buffers. The P RNA were then buffer exchanged with the same 
binding buffer by Amicon centrifugation filters (MWCO 10,000, Millipore) by at least 
three iterations. RNase P holoenzyme was reconstituted by mixing P RNA and P 
protein at a 1:1 ratio. RNase P holoenzyme (0-400 nM) was incubated with 32P 5’ 
end labeled pre-tRNAAsp (<< 1 nM) for 5 min at 37˚C. The holoenzyme-
substratemixture was loaded onto a pre-packed G-75 Sephadex (GE health) spin 
column (Corning Life Sciences). The unbound substrate was separated from the 




unbound substrate was measured by scintillation counting. A single binding isotherm 
(Equation 3-1) was fit to the data to obtain the dissociation constant, Kd, app (Scheme 
3-1): 
 Fraction bound =  





 Equation 3-1 
3.5.5 Single-turnover Experiments 
Single-turnover experiments were performed at saturating concentrations of 
divalent metal ions (10 or 20 mM Mg2+ or Ca2+) and saturating RNase P (360 - 500 
nM), as indicated in the figure and table legend, to investigate the catalytic activity of 
the mutants. The RNase P holoenzyme were prepared similar to described above 
except for that the P protein and P RNA were not dialyzed or buffer exchanged 
because of the high metal ion concentrations used in the single-turnover cleavage 
experiments. Folded enzymes and substrates were kept at 37˚C until use. 
The single-turnover cleavage of FI-pre-tRNAAsp was carried out in a black 96-
well microplate with non-binding surface (Corning Incorporation, #3686) by 
monitoring the anisotropy change of fluorescein (λex = 485 nm and λem = 535 nm) 
using the fluorescence polarization function of a TECAN plate-reader (Infinite F500, 
G factor = 0.93). The substrate was pre-incubated in the plates to perform the gain 
and Z-position adjustments of the plate-reader and the reactions were initiated by 
addition of RNase P. Experiments measuring single-turnover reactions were carried 
out using excess holoenzyme or P RNA ([E] = 360 – 500 nM and [S] = 10 nM) at 37 
°C.  




fluorescence intensity decreased from the initial substrate-RNase P complex (F0) to 
cleaved product (F∞), and the extent of this decrease varies with pH. Therefore, an 
enhancement factor g, defined as described previously [94], was used to correct for 
the total fluorescence change when calculating the fraction cleaved (Y) from the 
anisotropy time trace using Equation 3-2. The enhancement factor is defined by g = 
F0/F∞. The r0 and r∞ are the anisotropy values of the RNase P holoenzyme-bound 
substrate and cleaved product, respectively, measured for each experiment.  
 𝑌 =  1 −
𝑟 − 𝑟∞
𝑟0 − 𝑟∞  +  (𝑔 − 1)(𝑟0 − 𝑟)
 Equation 3-2 
   
The single-turnover cleavage rate constant (kobs) was then calculated by fitting 
a single exponential model (Equation 3-3) to the fraction cleavage as a function of 
time. 
 𝑌 =  𝑌∞(1 − 𝑒
−𝑘obs𝑡) Equation 3-3 
   
The pKa values and pH-independent rate constants for reactions catalyzed by 
RNase P holoenzyme were calculated by fitting a single ionization model (Equation 
3-5) to the pH profile: 
 𝑝H =  
𝑘𝑚𝑎𝑥
ℎ𝑜𝑙𝑜
1 +  10(𝑝K𝑎− 𝑝H)
 Equation 3-4 
   
For the P RNA catalyzed single-turnover reactions, the total fluorescence 
intensity remains constant during the reaction and the anisotropy time course data 
are well described by a one phase exponential decay model. Therefore, Equation 3-
5 was fit to the anisotropy time course to calculate the single-turnover rate constant 





 𝑟 =  (𝑟0 − 𝑟∞)𝑒
−𝑘obs𝑡  +  𝑟∞ Equation 3-5 
   
Equation 3-6 was fit to the magnesium dependence of the P RNA catalyzed 




Cleavage ) and Hill coefficient (nH): 








 +  [Mg2+]𝑛H





3.6 Appendix B 
3.6.1 Ligation Efficiency of Different Atomic Modifications 
 
 
Figure B-1: Ligation efficiency of 10-mer ribooligonucleotides containing single atom 
modifications of U51 are determined by primer extension analysis. Experiment procedure is 
described in Materials and Methods. The primer extension reaction by 6FAM labeled primer 
was visualized by a 6% denaturing polyacrylamide gel scanned by Typhoon 
Phosphorimager. The ligation efficiency is calculated by the ratio of the intensity (I) of the 
bands corresponding to primer extension products of 46P and 56P RNA 
controls: %=Ia/(Ia+Ib). For 3MU, band a is not observed likely due to the blockage of 










Figure B-2: RNase P containing single atom modifications catalyze cleavage of pre-tRNA 
substrate at correct site. Reaction conditions are: 50 mM Tris/MES pH 6, 20 mM MgCl2, 200 
mM KCl and 20 mM DTT, with fluorescently labeled pre-tRNAAsp with 10 nM either a 7-nt 5’ 
leader (pre-tR7) or 5-nt 5’ leader (pre-tR5) and 360 nM RNase P. Reaction time is 10 min for 
holoenzyme in (A) and 2 hours for P RNA alone in (B). Products are resolved by a 22% 






1. Sigel, R.K. and A.M. Pyle, Alternative roles for metal ions in enzyme catalysis and the 
implications for ribozyme chemistry. Chem Rev, 2007. 107(1): p. 97-113. 
2. Misra, V.K. and D.E. Draper, On the role of magnesium ions in RNA stability. Biopolymers, 
1998. 48(2-3): p. 113-35. 
3. DeRose, V.J., Metal ion binding to catalytic RNA molecules. Curr Opin Struct Biol, 2003. 
13(3): p. 317-24. 
4. Hougland, J.L., et al., Functional identification of catalytic metal ion binding sites within RNA. 
PLoS Biol, 2005. 3(9): p. e277. 
5. Forconi, M., et al., Functional identification of ligands for a catalytic metal ion in group I 
introns. Biochemistry, 2008. 47(26): p. 6883-94. 
6. Shan, S.O. and D. Herschlag, Dissection of a metal-ion-mediated conformational change in 
Tetrahymena ribozyme catalysis. RNA, 2002. 8(7): p. 861-72. 
7. Woodson, S.A., Metal ions and RNA folding: a highly charged topic with a dynamic future. 
Curr Opin Chem Biol, 2005. 9(2): p. 104-9. 
8. Frederiksen, J.K. and J.A. Piccirilli, Identification of catalytic metal ion ligands in ribozymes. 
Methods, 2009. 49(2): p. 148-66. 
9. Chen, J.-H., et al., A Catalytic Metal Ion Interacts with the Cleavage Site G·U Wobble in the 
HDV Ribozyme†. Biochemistry, 2009. 48(7): p. 1498-1507. 
10. Veeraraghavan, N., et al., Metal Binding Motif in the Active Site of the HDV Ribozyme Binds 
Divalent and Monovalent Ions. Biochemistry, 2011. 50(13): p. 2672-2682. 
11. Maderia, M., L.M. Hunsicker, and V.J. DeRose, Metal−Phosphate Interactions in the 
Hammerhead Ribozyme Observed by 31P NMR and Phosphorothioate Substitutions†. 
Biochemistry, 2000. 39(40): p. 12113-12120. 
12. Osborne, E.M., et al., The Identity of the Nucleophile Substitution May Influence Metal 
Interactions with the Cleavage Site of the Minimal Hammerhead Ribozyme. Biochemistry, 
2009. 48(44): p. 10654-10664. 
13. Sigel, R.K., A. Vaidya, and A.M. Pyle, Metal ion binding sites in a group II intron core. Nat 
Struct Biol, 2000. 7(12): p. 1111-6. 
14. Marcia, M. and Anna M. Pyle, Visualizing Group II Intron Catalysis through the Stages of 
Splicing. Cell, 2012. 151(3): p. 497-507. 
15. Gordon, P.M., R. Fong, and J.A. Piccirilli, A Second Divalent Metal Ion in the Group II Intron 
Reaction Center. Chemistry & biology, 2007. 14(6): p. 607-612. 
16. Nelson, J.A. and O.C. Uhlenbeck, When to believe what you see. Mol Cell, 2006. 23(4): p. 
447-50. 
17. Kazantsev, A.V. and N.R. Pace, Bacterial RNase P: a new view of an ancient enzyme. Nat 
Rev Microbiol, 2006. 4(10): p. 729-40. 
18. Smith, J.K., J. Hsieh, and C.A. Fierke, Importance of RNA-protein interactions in bacterial 
ribonuclease P structure and catalysis. Biopolymers, 2007. 87(5-6): p. 329-38. 
19. Kirsebom, L.A., RNase P RNA mediated cleavage: substrate recognition and catalysis. 
Biochimie, 2007. 89(10): p. 1183-94. 
20. Hall, T.A. and J.W. Brown, The ribonuclease P family. Methods Enzymol, 2001. 341: p. 56-
77. 
21. Evans, D., S.M. Marquez, and N.R. Pace, RNase P: interface of the RNA and protein worlds. 
Trends Biochem Sci, 2006. 31(6): p. 333-41. 
22. Walker, S.C. and D.R. Engelke, Ribonuclease P: the evolution of an ancient RNA enzyme. 
Crit Rev Biochem Mol Biol, 2006. 41(2): p. 77-102. 
23. Hartmann, E. and R.K. Hartmann, The enigma of ribonuclease P evolution. Trends Genet, 
2003. 19(10): p. 561-9. 
24. Torres-Larios, A., et al., Structure of ribonuclease P--a universal ribozyme. Curr Opin Struct 
Biol, 2006. 16(3): p. 327-35. 
25. Crary, S., S. Niranjanakumari, and C. Fierke, The protein component of Bacillus subtilis 
ribonuclease P increases catalytic efficiency by enhancing interactions with the 5' leader 




26. Kurz, J. and C. Fierke, The affinity of magnesium binding sites in the Bacillus subtilis RNase 
P x pre-tRNA complex is enhanced by the protein subunit. Biochemistry, 2002. 41(30): p. 
9545-9558. 
27. Kurz, J., S. Niranjanakumari, and C. Fierke, Protein component of Bacillus subtilis RNase P 
specifically enhances the affinity for precursor-tRNAAsp. Biochemistry, 1998. 37(8): p. 2393-
2400. 
28. Sun, L., et al., Evidence that substrate-specific effects of C5 protein lead to uniformity in 
binding and catalysis by RNase P. The EMBO journal, 2006. 25(17): p. 3998-4007. 
29. Guerrier-Takada, C., et al., The RNA moiety of ribonuclease P is the catalytic subunit of the 
enzyme. Cell, 1983. 35(3 Pt 2): p. 849-857. 
30. Smith, D. and N.R. Pace, Multiple magnesium ions in the ribonuclease P reaction 
mechanism. Biochemistry, 1993. 32(20): p. 5273-81. 
31. Perreault, J.P. and S. Altman, Pathway of activation by magnesium ions of substrates for the 
catalytic subunit of RNase P from Escherichia coli. J Mol Biol, 1993. 230(3): p. 750-6. 
32. Beebe, J.A., J.C. Kurz, and C.A. Fierke, Magnesium ions are required by Bacillus subtilis 
ribonuclease P RNA for both binding and cleaving precursor tRNAAsp. Biochemistry, 1996. 
35(32): p. 10493-505. 
33. Cassano, A.G., V.E. Anderson, and M.E. Harris, Analysis of Solvent Nucleophile Isotope 
Effects:  Evidence for Concerted Mechanisms and Nucleophilic Activation by Metal 
Coordination in Nonenzymatic and Ribozyme-Catalyzed Phosphodiester Hydrolysis†. 
Biochemistry, 2004. 43(32): p. 10547-10559. 
34. Cuzic, S. and R.K. Hartmann, Studies on Escherichia coli RNase P RNA with Zn2+ as the 
catalytic cofactor. Nucleic Acids Res, 2005. 33(8): p. 2464-74. 
35. Brannvall, M. and L.A. Kirsebom, Manganese ions induce miscleavage in the Escherichia coli 
RNase P RNA-catalyzed reaction. J Mol Biol, 1999. 292(1): p. 53-63. 
36. Smith, D., et al., Influence of metal ions on the ribonuclease P reaction. Distinguishing 
substrate binding from catalysis. J Biol Chem, 1992. 267(4): p. 2429-36. 
37. Kurz, J.C. and C.A. Fierke, The affinity of magnesium binding sites in the Bacillus subtilis 
RNase P x pre-tRNA complex is enhanced by the protein subunit. Biochemistry, 2002. 
41(30): p. 9545-58. 
38. Hsieh, J., et al., A divalent cation stabilizes the active conformation of the B. subtilis RNase 
P•pre-tRNA complex: a role for an inner-sphere metal ion in RNase P submitted, 2010. 
39. Warnecke, J.M., et al., Ribonuclease P (RNase P) RNA is converted to a Cd(2+)-ribozyme by 
a single Rp-phosphorothioate modification in the precursor tRNA at the RNase P cleavage 
site. Proceedings of the National Academy of Sciences, 1996. 93(17): p. 8924-8928. 
40. Li, X. and P. Gegenheimer, Ribonuclease P Catalysis Requires Mg2+ Coordinated to the pro-
RP Oxygen of the Scissile Bond†. Biochemistry, 1997. 36(9): p. 2425-2438. 
41. Pfeiffer, T., et al., Effects of phosphorothioate modifications on precursor tRNA processing by 
eukaryotic RNase P enzymes. Journal of Molecular Biology, 2000. 298(4): p. 559-565. 
42. Warnecke, J.M., et al., Active site constraints in the hydrolysis reaction catalyzed by bacterial 
RNase P: analysis of precursor tRNAs with a single 3′-S-phosphorothiolate internucleotide 
linkage. Nucleic Acids Research, 2000. 28(3): p. 720-727. 
43. Persson, T., S. Cuzic, and R.K. Hartmann, Catalysis by RNase P RNA: UNIQUE FEATURES 
AND UNPRECEDENTED ACTIVE SITE PLASTICITY. Journal of Biological Chemistry, 2003. 
278(44): p. 43394-43401. 
44. Reiter, N.J., et al., Structure of a bacterial ribonuclease P holoenzyme in complex with tRNA. 
Nature, 2010. 468(7325): p. 784-9. 
45. Christian, E.L., N.M. Kaye, and M.E. Harris, Helix P4 is a divalent metal ion binding site in the 
conserved core of the ribonuclease P ribozyme. RNA, 2000. 6(4): p. 511-519. 
46. Crary, S.M., J.C. Kurz, and C.A. Fierke, Specific phosphorothioate substitutions probe the 
active site of Bacillus subtilis ribonuclease P. RNA, 2002. 8(7): p. 933-47. 
47. Christian, E.L., N.M. Kaye, and M.E. Harris, Evidence for a polynuclear metal ion binding site 
in the catalytic domain of ribonuclease P RNA. EMBO J, 2002. 21(9): p. 2253-62. 
48. Frank, D.N. and N.R. Pace, In vitro selection for altered divalent metal specificity in the 




49. Frank, D.N. and N.R. Pace, Ribonuclease P: unity and diversity in a tRNA processing 
ribozyme. Annu Rev Biochem, 1998. 67: p. 153-80. 
50. Getz, M.M., et al., Structural plasticity and Mg2+ binding properties of RNase P P4 from 
combined analysis of NMR residual dipolar couplings and motionally decoupled spin 
relaxation. RNA, 2007. 13(2): p. 251-66. 
51. Koutmou, K.S., et al., NMR and XAS reveal an inner-sphere metal binding site in the P4 helix 
of the metallo-ribozyme ribonuclease P. Proc Natl Acad Sci U S A, 2010. 107(6): p. 2479-84. 
52. Kazantsev, A.V., A.A. Krivenko, and N.R. Pace, Mapping metal-binding sites in the catalytic 
domain of bacterial RNase P RNA. RNA, 2009. 15(2): p. 266-276. 
53. Kaye, N.M., et al., Conservation of Helical Structure Contributes to Functional Metal Ion 
Interactions in the Catalytic Domain of Ribonuclease P RNA. Journal of Molecular Biology, 
2002. 324(3): p. 429-442. 
54. Christian, E.L., et al., The P4 metal binding site in RNase P RNA affects active site metal 
affinity through substrate positioning. RNA, 2006. 12(8): p. 1463-1467. 
55. Reiter, N.J., A.K. Osterman, and A. Mondragón, The bacterial ribonuclease P holoenzyme 
requires specific, conserved residues for efficient catalysis and substrate positioning. Nucleic 
Acids Research, 2012. 40(20): p. 10384-10393. 
56. Koutmou, K.S., et al., Protein–Precursor tRNA Contact Leads to Sequence-Specific 
Recognition of 5′ Leaders by Bacterial Ribonuclease P. Journal of Molecular Biology, 2010. 
396(1): p. 195-208. 
57. Kazantsev, A.V., et al., Crystal structure of a bacterial ribonuclease P RNA. Proceedings of 
the National Academy of Sciences of the United States of America, 2005. 102(38): p. 13392-
13397. 
58. Kurz, J.C., S. Niranjanakumari, and C.A. Fierke, Protein component of Bacillus subtilis 
RNase P specifically enhances the affinity for precursor-tRNAAsp. Biochemistry, 1998. 37(8): 
p. 2393-400. 
59. Koutmou, K.S., J.J. Day-Storms, and C.A. Fierke, The RNR motif of B. subtilis RNase P 
protein interacts with both PRNA and pre-tRNA to stabilize an active conformer. RNA, 2011. 
17(7): p. 1225-1235. 
60. Koutmou, K.S., J.J. Day-Storms, and C.A. Fierke, The RNR motif of B. subtilis RNase P 
protein interacts with both PRNA and pre-tRNA to stabilize an active conformer. RNA, 2011. 
17(7): p. 1225-35. 
61. Hsieh, J. and C.A. Fierke, Conformational change in the Bacillus subtilis RNase P 
holoenzyme–pre-tRNA complex enhances substrate affinity and limits cleavage rate. RNA, 
2009. 15(8): p. 1565-1577. 
62. Hsieh, J., et al., A divalent cation stabilizes the active conformation of the B. subtilis RNase P 
x pre-tRNA complex: a role for an inner-sphere metal ion in RNase P. J Mol Biol, 2010. 
400(1): p. 38-51. 
63. Pecoraro, V.L., J.D. Hermes, and W.W. Cleland, Stability constants of Mg2+ and Cd2+ 
complexes of adenine nucleotides and thionucleotides and rate constants for formation and 
dissociation of MgATP and MgADP. Biochemistry, 1984. 23(22): p. 5262-71. 
64. Frank, D.N. and N.R. Pace, RIBONUCLEASE P: Unity and Diversity in a tRNA Processing 
Ribozyme. Annual Review of Biochemistry, 1998. 67(1): p. 153-180. 
65. Kaye, N.M., et al., Conservation of helical structure contributes to functional metal ion 
interactions in the catalytic domain of ribonuclease P RNA. J Mol Biol, 2002. 324(3): p. 429-
42. 
66. Pan, T. and T.R. Sosnick, Intermediates and kinetic traps in the folding of a large ribozyme 
revealed by circular dichroism and UV absorbance spectroscopies and catalytic activity. Nat 
Struct Biol, 1997. 4(11): p. 931-8. 
67. Hsieh, J. and C.A. Fierke, Conformational change in the Bacillus subtilis RNase P 
holoenzyme--pre-tRNA complex enhances substrate affinity and limits cleavage rate. RNA, 
2009. 15(8): p. 1565-77. 
68. Frederiksen, J.K., et al., Metal-ion rescue revisited: Biochemical detection of site-bound metal 
ions important for RNA folding. RNA, 2012. 18(6): p. 1123-1141. 
69. Ferre-D'Amare, A.R., K. Zhou, and J.A. Doudna, Crystal structure of a hepatitis delta virus 




70. Harris, D.A., D. Rueda, and N.G. Walter, Local Conformational Changes in the Catalytic Core 
of the Trans-Acting Hepatitis Delta Virus Ribozyme Accompany Catalysis†. Biochemistry, 
2002. 41(40): p. 12051-12061. 
71. Ke, A., et al., A conformational switch controls hepatitis delta virus ribozyme catalysis. 
Nature, 2004. 429(6988): p. 201-5. 
72. Peracchi, A., et al., Rescue of abasic hammerhead ribozymes by exogenous addition of 
specific bases. Proc Natl Acad Sci U S A, 1996. 93(21): p. 11522-7. 
73. Loria, A. and T. Pan, Domain structure of the ribozyme from eubacterial ribonuclease P. 
RNA, 1996. 2(6): p. 551-63. 
74. Kazantsev, A.V., et al., Solution structure of RNase P RNA. RNA, 2011. 17(6): p. 1159-1171. 
75. Torres-Larios, A., et al., Crystal structure of the RNA component of bacterial ribonuclease P. 
Nature, 2005. 437(7058): p. 584-7. 
76. Wu, H.N. and O.C. Uhlenbeck, Role of a bulged A residue in a specific RNA-protein 
interaction. Biochemistry, 1987. 26(25): p. 8221-7. 
77. Ippolito, J.A. and T.A. Steitz, A 1.3-A resolution crystal structure of the HIV-1 trans-activation 
response region RNA stem reveals a metal ion-dependent bulge conformation. Proc Natl 
Acad Sci U S A, 1998. 95(17): p. 9819-24. 
78. Reiter, N.J., et al., Dynamics in the U6 RNA intramolecular stem-loop: a base flipping 
conformational change. Biochemistry, 2004. 43(43): p. 13739-47. 
79. Blad, H., et al., Dynamics and metal ion binding in the U6 RNA intramolecular stem-loop as 
analyzed by NMR. J Mol Biol, 2005. 353(3): p. 540-55. 
80. Yean, S.L., et al., Metal-ion coordination by U6 small nuclear RNA contributes to catalysis in 
the spliceosome. Nature, 2000. 408(6814): p. 881-4. 
81. Huppler, A., et al., Metal binding and base ionization in the U6 RNA intramolecular stem-loop 
structure. Nat Struct Biol, 2002. 9(6): p. 431-5. 
82. Rueda, D., et al., The 5' leader of precursor tRNAAsp bound to the Bacillus subtilis RNase P 
holoenzyme has an extended conformation. Biochemistry, 2005. 44(49): p. 16130-9. 
83. Walter, N.G., The blessing and curse of RNA dynamics: past, present, and future. Methods, 
2009. 49(2): p. 85-6. 
84. Dethoff, E.A., et al., Functional complexity and regulation through RNA dynamics. Nature, 
2012. 482(7385): p. 322-30. 
85. Dethoff, E.A., et al., Visualizing transient low-populated structures of RNA. Nature, 2012. 
491(7426): p. 724-8. 
86. Morrison, K.L. and G.A. Weiss, Combinatorial alanine-scanning. Current Opinion in Chemical 
Biology, 2001. 5(3): p. 302-307. 
87. Behrman, E.J., An improved synthesis of guanosine 5'-monothiophosphate. Journal of 
Chemical Research (Synopses), 2000. 2000(9): p. 446-447. 
88. He, B., et al., Rapid mutagenesis and purification of phage RNA polymerases. Protein Expr 
Purif, 1997. 9(1): p. 142-51. 
89. Niranjanakumari, S., et al., Protein component of the ribozyme ribonuclease P alters 
substrate recognition by directly contacting precursor tRNA. Proc Natl Acad Sci U S A, 1998. 
95(26): p. 15212-7. 
90. Niranjanakumari, S., J.C. Kurz, and C.A. Fierke, Expression, purification and characterization 
of the recombinant ribonuclease P protein component from Bacillus subtilis. Nucleic Acids 
Res, 1998. 26(13): p. 3090-6. 
91. Moore, M.J. and C.C. Query, Joining of RNAs by splinted ligation. Methods Enzymol, 2000. 
317: p. 109-23. 
92. Kurschat, W.C., et al., Optimizing splinted ligation of highly structured small RNAs. RNA, 
2005. 11(12): p. 1909-14. 
93. Ke, A. and J.A. Doudna, Crystallization of RNA and RNA-protein complexes. Methods, 2004. 
34(3): p. 408-14. 
94. Mocz, G., et al., Probing the nucleotide binding sites of axonemal dynein with the fluorescent 
nucleotide analogue 2'(3')-O-(-N-Methylanthraniloyl)-adenosine 5'-triphosphate. Biochemistry, 






CHAPTER 4  
SUBSTRATE RECOGNITION OF HUMAN MITOCHONDRIAL RNASE P: 
PROTEIN PURIFICATION AND PRE-TRNA CLONING 
 Abstract 
The essential step of removing extraneous sequences at the 5’ end of 
precursor tRNA (pre-tRNA) is catalyzed by ribonuclease P (RNase P), a 
ribonucleoprotein complex in most organisms. However, recently discovered human 
mitochondrial RNase P (mtRNase P) is composed solely of three protein subunits 
(MRPP1, MRPP1 and MRPP3). Mutations in mtRNase P subunits and mitochondrial 
transfer RNAs (mt-tRNAs) have been implicated in a number of human diseases. 
Moreover, the majority of mt-tRNAs lack consensus sequences conserved for 
secondary and tertiary structures in classic tRNA. Both human mtRNase P and mt-
tRNAs are poorly characterized. To study the catalytic mechanism and substrate 
recognition of human mtRNase P, I have optimized purification of mtRNase P and 
subcloned a series of human mitochondrial precursor tRNA (mt-pre-tRNA) genes 
that include all four types of human mt-tRNA. The reconstituted human mtRNase P 
complex as well as MRPP3 subunit alone are catalytically active under single-
turnover conditions. This work lays the foundation to investigate the catalytic 





Mitochondrial dysfunction is increasingly implicated in human aging, 
neurodegenerative diseases, cancer, diabetes and various rare diseases [1, 2]. 
Dysfuntion of mitochondria often originates from damages and mutations in the 
mitochondrial genomic DNA (mtDNA) [3-7]. Recent advances in RNA sequencing 
technology and identification of mitochondrial RNA processing and modification 
enzymes provided new ground for investigation of RNA biogenesis in human 
mitochondria [8-10]. In addition, nearly half of the disease-related mtDNA point 
mutations are mapped to mt-tRNA genes [11, 12]. Unraveling the mechanism of 
human mt-tRNA processing may provide valuable insights into understanding 
mitochondria-related diseases.  
4.2.1 RNA Processing in Human Mitochondria 
The compact human mitochondrial genome is maternally inherited with a 
circular mitochondrial DNA (mtDNA) 16,569 bp in length and encodes genes for all 
13 proteins of respiratory chain complexes, 2 rRNAs (12S and 16S), and 22 tRNAs 
[13] (Figure 4-1). Human mtDNA is transcribed into three long polycistronic 
precursor RNAs from both strands (termed “heavy” and “light”) with tRNAs 
intermingled with rRNAs and mRNAs [14]. These precursor RNAs are processed 
according to the “tRNA punctuation model” in which recognition and excision of 
tRNA genes by endonucleases are the first steps for mitochondrial mRNA 
biogenesis [15, 16]. Recently, comprehensive analysis of the mitochondrial 
transcriptome identified small RNA transcripts derived mostly from mt-tRNAs genes 




generated from 5’ end processing of light strand transcripts [17]. Biological functions 
and biogenesis pathways of these mitochondrial sRNAs and lncRNAs are unclear.  
 
Figure 4-1: Distribution of tRNA genes in human mitochondrial genome. The mt-tRNA 
genes (red) are interspersed in the genome [13]. Human mt-tRNA genes are located in both 
the heavy and light DNA strands. The black arrows indicate the transcription direction from 
two heavy-strand promoter (HSP) sites and one light-strand promoter (LSP) site [18].  
 
4.2.2 Mitochondrial tRNA Mutations and Diseases 
A growing number of mtDNA mutations are implicated in human diseases (see 
summary in MITOMAP database [19]). With approximately 500 disease-related point 




(Figure 4-2). Clinical phenotypes of these mutations are diverse, including MELAS 
(mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like symptoms), 
LHON (Leber’s hereditary optic neuropathy), opthalmoplegia, deafness, hypotension 
and diabetes [3, 7].  
Understanding how mt-tRNA mutations link to human diseases remains 
challenging due to the heterogeneity and polymorphic nature of mtDNA, complex 
combinations between genotype and phenotype, and lack of animal models [20-22]. 
Solution structure probing showed that pathogenic mutations can affect secondary 
structure of in vitro transcribed mt-tRNAs [12] by destabilizing tertiary contacts [23, 
24], causing dimerization of mt-tRNA  [24], and weakening structural elements [24, 
25]. Biochemical studies also showed that pathogenic mutations in mt-tRNA lead to 
functional defects in 5’ and 3’ processing [26-28], posttranscriptional modification 
[23, 29, 30], aminoacylation [25, 31, 32], and protein synthesis [32-34]. The 
molecular mechanism of how these pathogenic mutations affect mt-tRNA processing 






Figure 4-2: Distribution and location of disease-associated mutations in human 
mitochondrial tRNA genes. Data for this graph were generated from analysis of a summary 
on disease-associated mutations as of March 5, 2013 (see MITOMAP database: 
http://mitomap.org [19] and Mamit-tRNA database http://mamit-trna.u-strasbg.fr/ [35]). (A) A 
bar graph showing distribution of pathogenic mutations among 22 human mt-tRNA species. 
Total bar height is equal to the total number of disease-related mutations published in 
literature while red bars indicate numbers of confirmed pathogenic mutations (definition of 
“confirmed” in MITOMAP database means reported by at least two independent 
laboratories). (B) Distribution of pathogenic mutations in human mt-tRNA in the context of 
canonical tRNA secondary structure. Numbers are calculated from total reported mutations. 
The nucleotide is color-coded according to the number of mt-tRNA species affected by 
mutations at each nucleotide position. Nucleotide numbering is in accordance to consensus 




4.2.3 The “Bizarre” Human Mitochondrial tRNA 
In addition to high mutation rates, mammalian mitochondrial tRNAs are often 
referred as “bizarre tRNAs” because the majority of mt-tRNAs deviate significantly 
from the canonical tRNA with secondary cloverleaf structure and tertiary L-shaped 
structure [18, 35-38]. Although numerous X-ray and NMR structures of canonical 
tRNAs have been solved either in free form or in complex with proteins [39], only a 
few NMR studies have been reported on stem-loop elements [40] and full length [41] 
mammalian mt-tRNAs.  
 
Figure 4-3: Four types of human mitochondrial tRNA based on prediction in secondary 
structure and tertiary interactions with reference to canonical tRNA. Predicted tertiary 




Based on sequence conservation and tertiary interactions, mammalian mt-
tRNAs can be categorized into four types (Figure 4-3) [18, 37]. The first type (termed 
Type 0) preserves of the majority of nucleotides involved in canonical tertiary 
interactions between D-loop/TψC-loop and D-stem-loop/V-loop [42]. The second 
type (Type I) is comprised only of mt-tRNASer(UCN) where the D-loop/TψC-loop 
interaction is conserved (G18 and G19 in the D-loop, and U55 and C66 in the TψC-
loop), alhough D-loop is shortened [43]. In addition, mt-tRNASer(UCN) has only one 
nucleotide (N9), instead of two, linking the  acceptor- and D-stem and a 6-bp 
anticodon-stem instead of 5-bp. The majority of human mt-tRNAs are grouped to the 
third type (type II). Type II mt-tRNAs lack a strong D-loop/TψC-loop interaction but 
utilize conserved nucleotides in the D-stem and V-loop to form tertiary contacts [44]. 
The mt-tRNASer(AGY) is the sole member of type III mt-tRNA, which completely lacks 
the D-stem-loop and forms a non-L-shaped structure in solution [45, 46].  
Mitochondrial proteins and mt-tRNAs have been observed to co-evolved. For 
example, in nematode mitochondria, the elongation factor Tu that has an extended 
domain to compensate the shortened D-arm or T-armless mt-tRNAs with [47, 48]. It 
is possible that RNA processing enzymes have specifically evolved to recognize 
non-canonical mt-tRNAs in human mitochondria. 
 
4.2.4 Human Mitochondrial RNase P 
RNase P is responsible for 5’ end processing of tRNA by catalyzing hydrolysis 
of a phosphodiester bond between N(-1) and N1 nucleotides of pre-tRNA [49]. In 




RNase P proteins, MRPP1, MRPP2, and MRPP3) [50]. This is the first example of a 
protein-only RNase P. All of the previous identified isoforms of RNase P are 
ribonucleoprotein (RNP) complexes composed of one catalytic RNA subunit and 
variable numbers of protein subunits (1 in Bacteria, 4-5 in Archaea and 9-10 in 
Eukarya) [51-53] (Figure 4-4). Proteinaceous RNase P (PRORP) has also been 
identified in Arabidopsis thaliana where PRORP1 is localized in mitochondria and 
chloroplast [54], and PRORP2 and PRORP3 are localized in the nucleus [55]. A. 
thaliana PRORPs are orthologs of MRPP3 but function as a single protein for RNase 
P activity. None of the protein-only RNase P shares significant sequence homology 
with previous identified protein subunits in RNA-based RNase P. Such a dramatic 
variety in subunit composition makes RNase P one of the most diverse enzymes 







Figure 4-4: Human mitochondrial RNase P is composed of three protein subunits. (A) 
Diagram showing different composition of RNase P in human. A ribonucleoprotein RNase P 
is located in the nucleus and a protein-only RNase P that is formed by three subunits 
functions in the mitochondria. (B) Crystal structure of the methyltransferase domain (MTase 
domain, C-terminal) of TRMT10A, a MRPP1 analog (PDB ID: 4FMW [57]), showing a 
homodimer of the MT domain bound with S-adenosyl-L-homocysteine (SAH, magenta 
molecules) and a potassium ion (red sphere). (C) MRPP2 crystal structure (PDB ID: 1U7T 
[58]) as a homotetramer and in complex with nicotinamide adenine dinucleotide (NAD, 
magenta). (D) Crystal structure for PRORP1, an ortholog of MRPP3 in plant A. thaliana 
(PDB ID: 4G26 [59]), showing the metallonuclease domain (blue) with calcium ions (orange 
spheres), central domain (yellow) with a zinc ion (purple sphere) and the PPR domain (dark 
pink).  
 
All three subunits of human mtRNase are nuclear encoded and imported into 
the mitochondria [50]. The first subunit, MRPP1 (gene symbol RG9MTD1, or official 




methyltransferase [60] that belongs to the TRMT10 family [61]. MRPP1 requires 
activation by MRPP2 to catalyze the N1 methylation of both G9 and A9 (m1R9) in mt-
tRNA in vitro and in vivo [60]. MRPP1∙MRPP2 complex also methylates a nuclear 
tRNAArg efficiently [60]. In contrast, MRPP1 paralogs, TRMT10A and TRMT10B, 
function as a single protein to catalyze m1G methylation of the nuclear tRNAArg in 
vitro [60]. Interestingly, a 20-fold higher concentration of MRRP1 alone can also 
catalyze m1G methylation of the nuclear tRNAArg albeit with an at least 20-fold lower 
efficiency. However, MRPP1 alone cannot catalyze m1A of mt-tRNAIle. These data 
indicate that MRPP1 has innate methyltransferase activity but requires MRPP2 for 
efficiency and specificity toward mt-tRNA [60]. A crystal structure of the MTase 
domain (C-terminal) of TMRT10A in complex with S-adenosyl-homocysteine (SAH) 
is deposited in PDB (Figure 4-4, PDB ID: 4FMW [57]). This unpublished work shows 
the first crystal structure of the MTase domain of the TRMT10 family. The C-terminal 
MTase domain (amino acids 190 to 380) of MRPP1 likely adopts a fold similar to that 
observed in this structure according to homology structure modeling (Figure C-1, 
Appendix C). However, the structures of the N-terminal region (amino acids 40-190) 
of MRPP1 and other TRMT10 family MTase remain to be solved.   
The second human mtRNase P subunit, MRRP2 (HSD17B10, or SDR5C1), is 
a short-chain dehydrogenase/reductase that catalyzes β-oxidation of steroid and 
fatty acid substrates using NAD+ as a co-substrate [62, 63] (Figure 4-4  and Figure 
1-4, Chapter 1). Dysfunction of MRPP2 is also implicated in neurodegenerative 
diseases such as Alzheimer’s disease [64, 65]. MRPP2 has a Rossman-fold motif 




structures, MRPP2 forms a homotetramer as shown in complex with NAD+ and an 
inhibitor (PDB ID: 1U7Z [58], Figure 4-4), or has a deformed active site upon β-
amyloid (Aβ) binding (PDB ID 1SO8 [64]).  
The third subunit of human mtRNase P, MRPP3 (KIAA0391, or PRORP), is an 
ortholog of A. thaliana PRORP1 [50, 59]. The recently solved crystal structure of 
PRORP1 reveals that this new class of metallonuclease combines three functional 
domains to replace the RNA-based RNase P catalyst: a metallonuclease domain 
(NYN/PIN-domain) containing the active site, a central zinc-binding structural 
domain, and pentatricopeptide repeats (a PPR domain) important for activity and 
substrate binding [59] (Figure 4-4). PRORP1 is activated by magnesium and 
manganese ions in vitro and is proposed to use a two-metal-ion general acid/base 
catalysis mechanism [59]. In contrast to PRORP1, MRPP3 requires both MRPP1 
and MRPP2 to catalyzedcleavage of mt-pre-tRNAs [50]. But catalytic activity of 
MRPP1 and MRPP2 are not required for mtRNase P cleavage activity [60]. 
Furthermore, the MRPP1∙MRPP2 subcomplex does not tighly bind to MRPP3 [50]. 
The molecular details of exact roles of MRPP1, MRPP2 and MRPP3 in mtRNase P 
catalysis and substrate recognition remain to be elucidated.  
Knockdown of each mtRNase P subunits by siRNA in HeLa cells lead to a 
deficiency in processing of two mtRNA species [50]. Further, deep sequencing 
results showed that siRNA knockdown of either MRPP1 or MRPP3 genes leads to 
accumulation of most mitochondrial precursor RNAs and consequently impaired 
protein synthesis [8]. MRPP1 and MRPP3 knockdown also affect processing of long 




structures in the light strand transcript that mirror the sequence of tRNAs in the 
opposite (heavy) strand [17]. Interestingly, MRPP1 and 2 have been recently 
showed to co-localize and interact with a newly identified RNA-binding protein, G-
rich sequence factor 1 (GRSF1), in conjunction with nascent RNA transcripts to form 
so called “mitochondrial RNA granules” [66]. GRSF1 contains a RNA recognition 
motif (RRM) and siRNA knockdown of this protein leads to accumulations of certain 
mt-tRNA and ncRNA precursors [66] and subsequent defects in mitochondrial 
protein synthesis [67]. These findings suggest that mtRNase P may function as a 
catalytic subunit in a larger complex that processes a variety of mitochondrial RNAs. 
In recognition of pre-tRNA substrates, both commonality and specificity exist 
among protein-only and RNA-based RNase P enzymes. It is not unexpected that A. 
thaliana PRORPs (1, 2 and 3) can catalyze cleavage a bacterial substrate (T. 
thermophilus pre-tRNAGly) [68] since plant nuclear and organellar tRNAs are mostly 
canonical [39, 69]. In a structural model proposed from footprinting and small angle 
X-ray scattering (SAXS) data, PRORP2 is proposed to interact with A. thaliana mt-
tRNACys in a topology that is similar to the bacterial RNase P ternary complex [70, 
71]. In this model, the cleavage site of tRNA is recognized by the metallonuclease 
domain of PRORP2 whereas the D-TψC-loop interacts with the PPR-domain [70]. 
Human nuclear RNase P (nRNase P) does not detectably catalyize cleavage a mt-
pre-tRNATyr, but both human mtRNase P and nRNase P can catalyze cleavage of a 
mt-pre-tRNALeu(UUR) [72]. The non-canonical features of human mt-tRNAs may 
explain why human mtRNase P require two additional subunits to recognize the 




molecular interactions involved in substrate recognition and catalysis by human 
mtRNase P has yet to be carried out. 
To investigate substrate recognition of human mtRNase P, I purified all three 
human mtRNase P proteins using recombinant expression from E. coli cells. A co-
purification strategy for MRRP1 and MRPP2 was developed to produce a 
MRPP1∙MRPP2 complex with optimum purity. A series of human mitochondrial 
precursor tRNA (mt-pre-tRNA) genes covering all four types of mt-tRNA species 
have also been subcloned into high-copy number plasmids. Single-turnover 
cleavage results demonstrate that the recombinant mtRNase P is active in vitro. 
Furthermore, activity measurements demonstrate that the metallonuclease subunit, 
MRPP3, has vestigial nuclease activity that is activiated by MRPP1∙MRPP2 for 
efficient and accurate RNase P activity. 
4.3 Results 
4.3.1 Co-expression and Co-purification of the MRPP1∙MRPP2 Complex 
Protein co-overexpression facilitates expression and purification of protein 
complexes in E. coli cells [73, 74]. Among the three subunits of human mtRNase P, 
MRPP1 and MRPP2 form a stable subcomplex [50, 60]. To enhance expression and 
purification of MRPP1, the gene sequences encoding MRPP1 and MRPP2 were 
subcloned into a co-expression vector (pCDFDuet-1) for recombinant expression 
and purification of the MRPP1∙MRPP2 complex (Figure 4-5).  The  MRPP1 gene 
corresponding to amino acid 40 to 403 (Δ39MRPP1, MRPP1 in short, 42 kDa) was 




between the NcoI and BamHI restriction sites downstream of the T7 promoter-1 (see 
Materials and Methods). This construct adds as an N-terminal hexa-histidine-tag 
followed by a TEV-protease cleavage site (HisTevMRPP1, Figure 4-5). The first 39 
amino acids sequence removed from the N-terminal of MRPP1 genes are 
mitochondrial localization sequences. The DNA sequence encoding the entire 
MRPP2 was inserted between the NdeI and XhoI restriction sites downstream of T7 
promoter-2 (MRPP2, 26 kDa, Figure 4-5). Plasmids containing alternative 
combinations of MRPP1 and MRPP2 genes with different types and locations of His-
tags have also been prepared and screened for optimum co-overexpression and co-






Figure 4-5: Co-expression plasmid and protein sequences for MRPP1 and MRPP2. (A) A 
pCDFDuet-1-His6TevMRPP1+MRPP2 (pHisTevMP1+MP2) co-expression vector encoding 
HisTevMRPP1 and MRPP2 behind two independent T7 promoters. (B) Amino acid 
sequences of MRPP1 protein encoded by pCDFHisTevMP1MP2 plasmid with a His-tag 
highlighted in yellow, TEV protease cleavage sequence in cyan (cleavage site indicated) 
and MRPP1 protein sequence (amino acid 40 to 403) underlined. (C) Full length MRPP2 
protein (amino acids 1 to 261) encoded by pHisTevMP1+MP2 plasmid. 
 
To optimize recombinant overexpression and co-purification of HisTevMRPP1 
and MRPP2 in E. coli cells, a matrix of conditions varying cell lines, growth media 
and temperature, IPTG concentrations and expression time was tested, as 
described in Materials and Methods (results summarized in Table C-1, Appendix C). 
Expression of soluble MRPP1 is optimal when the co-expression plasmid containing 



















cells and expressed using auto-induction media at 25˚C overnight. MRPP2 generally 
expresses at a higher level than MRPP1 under all conditions tested. The HisTev-tag 
on MRPP1 allows for purification of the MRPP1∙MRPP2 complex. 
MRPP1 and MRPP2 co-expressed by RossttaDE3 cells and auto-induction 
was purified by two rounds of immobilized-metal affinity chromatography (IMAC) with 
chelating sepharose resins charged with NiSO4 (Figure 4-6). On the first Ni(II)-
column, HisTev-tagged MRPP1 co-eluted with native non-tagged MRPP2 at 120 mM 
imidazole after extensive washing of the loaded Ni(II)-column with 55 mM and 120 
mM imidazole sequentially to separate protein impurities followed by 1 M NaCl (15 
mM imidazole) wash to remove nucleic acids (Figure 4-6). The HisTev-tag in 
MRPP1 was removed by TEV protease digestion and the MRPP1∙MRPP2 complex 
was further purified by a second Ni(II)-column (Figure 4-5). An MRPP1∙MRPP2 
complex of high purity were obtained from the second Ni(II) column. Previously 
observed proteolysis with MRPP1 purified alone was not detected in the purified 
MRPP1∙MRPP2 complex and the proteins are stable. Although theoretical isoelectric 
points of MRPP1 (pI=9.0) and MRPP2 (pI=7.8) are different, the purified 
MRPP1∙MRPP2 complex remains intact on a cation-exchange column (SP-column) 
in which the two proteins co-elute at 400 mM NaCl (data not shown). The final yield 






Figure 4-6: Co-purification of MRPP1 and MRPP2 as a complex. (A) SDS-PAGE analysis 
(coomassie blue stain) of purification by 1st Ni(II)-chelating sepharose column. Lane 1: 200-
fold dilution of lysate from 1 L RosettaDE3 cells containing pHisTevMP1+MP2 vector 
induced using auto-induction media at 25 ºC overnight; Lane 2: 200-fold dilution of flow-
through; Lane 3: wash by 120 mM imidazole; Lane 4: wash by 1 M NaCl (15 mM imidazole); 
Lanes 5-8: elution by 120 mM imidazole. (B) SDS-PAGE analysis of 2nd Ni column 
(coomassie blue stain): Lane 1: concentrated His6TevMRPP1∙MRPP2 purified from the 1st 
Ni(II)-column as described in (A); Lane 2: overnight cleavage of HisTevMRPP1∙MRPP2 
complex by TEV protease; Lane 3: flow-through; Lanes 4-10: 50 mM imidazole wash. Purity 
of the protein samples is also indicated by the ratio of absorbance at 260 nm and 280 nm 
(A260/A280). Detailed buffer conditions are decribed in Materials and Methods. 
 
The concentrations and molar ratio of MRPP1 and MRPP2 in the purified 
protein complex were estimated by analysis of SDS-PAGE gel (Figure 4-7). Band 
intensity from a coomassie-blue stained gel image does not directly reflect the 
relative concentrations of MRPP1 and MRPP2 because dye staining is protein-




to calculate concentration of MRPP2 in the complex [75] (Figure 4-7). MRPP1 was 
difficult to purify in the absence of MRPP2. Therefore, the concentration of MRPP1 
in the MRPP1∙MRPP2 complex was calculated from the absorbance at 280 nm by 
subtracting the concentration due to MRPP2 in the complex using calculated 
extinction coefficient. The molar ratio of MRPP1:MRPP2 varies from 1:2 or 1:4 for 
fractions collected from the second Ni(II)-column (Figure 4-7). 
 
Figure 4-7: Determination of protein concentrations in the co-purified MRPP1∙MRPP2 
complex. (A) A coomassie blue stained denaturing polyacrylamide gel containing 
MRPP1∙MRPP2 complex samples and MRPP2 standards: Lanes 1-4, serial dilutions of 
known concentration of MRPP2 protein as standards. Lanes 5-7 and Lane 8-10: serial 
dilutions of complex sample 1 and sample 2 respectively; Lanes 11-12 and Lanes 13-14: 
duplicates of complex sample 3 and 4, respectively. Complex samples corresponds to 
concentrated fractions shown in Figure 4-6: 1: Lanes 3+4; 2: Lanes 5+6; 3: Lanes 7+8; 4: 
Lanes 9+10. (B) A standard curve of the protein band intensity (calculated by ImageJ 
software) that is linearly dependent on MRPP2 protein concentration. (C) Table of calculated 





4.3.2 Optimization for Purification of MRPP3 
Purification of MRPP3 followed the procedure developed by Dr. Wan Lim [77] 
with additional optimizations to increase yield and purity. The N-terminal HisTev-
tagged MRPP3, with the N-terminal 45 amino acid mitochondrial localization 
sequence deleted (HisTevΔ45MRPP3), was expressed in RosettaDE3 cells by 
induction with IPTG at 18 ˚C. HisTevΔ45MRPP3 was first purified using a Ni(II)-
column followed by TEV protease cleavage preceding a second Ni(II)-column. The 
Δ45MRPP3 fractions eluted from the second Ni(II)-column retained a considerable 
amount of nucleic acid contaminant (A260/A280>1). Further purification using either an 
anion-exchange column (DEAE-column) or a cation-exchange column (SP-column) 
can reduce the A260/A280 ratio to ~0.8 but a large fraction of Δ45MRPP3 (pI=8.7) 
does not bind to the cation-exchange column [77]. These observations indicate that 







Figure 4-8: SDS-PAGE analysis of Δ45MRPP3 purification. (A) Purification of 
HisTevΔ45MRPP3 by a 1st Ni(II)-column. Mkr: protein size marker; Lane 1: crude lysate; 
Lane 2: flow-through; Lane 3: 50 mM imidazole wash; Lane 4: 50 mM imidazole wash; 
Lanes 5-12: elution profile using a linear imidazole gradient (50 to 500 mM imidazole).  (B) 
2nd Ni(II)-column after TEV protease cleavage of HisTevΔ45MRPP3 (showing purification of 
~1/2 amount of protein from 1st Ni(II)-column). Lane Δ79: a purified Δ79MRPP3 as a size 
reference; Lane 1: before TEV protease treatment; Lane 2: after overnight digestion with 
TEV protease. Lane 3: flow-through; Lanes 4-6, 50 mM imidazole wash; Lane 7: 200 mM 
imidazole, Lanes 8-11: 300-500 mM imidazole. (C) Purification of Δ45MRPP3 (~1/2 from the 
2nd Ni(II)-column) by a Q-column. Lane 1: flow-through; Lane 3, dialyzed and concentrated 
into pH 8.6 Tris-HCl buffer; Lane 2: flow-through from the Q-column; Lane 3-6: 150 mM 
NaCl wash; Lane 7-9: 400 mM to 1 M NaCl; Lane 12: pooled fractions of Δ45MRPP3 (Lane 
2-6) concentrated and dialyzed into storage buffer (pH 7.5); (D) Purification of Δ45MRPP3 
(~1/2 from the 2nd Ni(II)-column) by a phenyl-sepharose column. Lane 1: purified 
Δ45MRPP3, flow-through sample from (B) Lane 3, dialyzed into 1.8 M (NH4)2SO4 buffer; 
Lane 2: flow-through from the phenyl-column; Lane 3-7: linear gradient from 1.8 M to 0 M 
(NH4)2SO4; Lane 8-13: elution of Δ45MRPP3 protein at 0 M (NH4)2SO4; Lane 16: pooled 
fractions of protein (Lane 8-11) concentrated and dialyzed into storage buffer (pH 7.5). 
Purify of the protein samples is also indicated by the ratio of A260/A280 ratio. Detailed buffer 
conditions are described in Materials and Methods. 
 
After two Ni(II)-IMAC columns, I applied two different strategies to optimize 




First, Δ45MRPP3 was fractionated using an anion-exchange column (Q-column) at a 
pH value (Tris-HCl, pH 9.2 at 4˚C) that is 0.5 pH units higher than the pI value of 
Δ45MRPP3 (Figure 4-8). Δ45MRPP2 elutes at low salt fractions (150 mM NaCl) 
while nucleic acids as well as protein impurities elute at higher NaCl concentration 
(Figure 4-8). Alternatively, a hydrophobic interaction column (phenyl-column) also 
efficiently removes nucleic acids from Δ45MRPP3 but the protein is less pure 
(Figure 4-8). Final A260 to A280 ratio of purified Δ45MRPP3 from these two columns is 
0.5 to 0.6 and the yield is 3-5 mg protein/L cell culture. 
4.3.3 Subcloning of Human mt-pre-tRNA Genes1  
It remains unclear whether all mt-tRNAs are processed with equal efficiency by 
mtRNase P and whether mtRNase P recognize alternative substrates. In the 
clustered mt-tRNA region, such as the mt-tRNAAla to mt-tRNAAsn loci, RNA 
sequencing identified stable conjoined tRNA transcripts, suggesting the existence of 
partially processed transcripts [9]. Mature nuclear tRNA, such as tRNAGln(UUG) [78], 
tRNALeu(UAA) and tRNALys(UUU) [9], has also been suggested to be imported into 
mitochondria. The mitochondrial counterparts of these three tRNA species are 
among the top four mt-tRNAs mapped with the most number of pathogenic 
mutations (Figure 4-2). The driving force and biological importance of the importation 
of nuclear tRNA into human mitochondria is unclear. In addition, deep sequencing 
data suggest that long non-coding RNAs generated in HeLa cell mitochondria are 
also processed by mtRNase P by recognizing tRNA-like structures that mirrors the 
                                            
1 Paul Lin and Xin Liu performed the design and cloning of the mt-pre-tRNA plasmids. Paul Lin 




mt-tRNA genes from the other strand [17]. These observations may indicate that 
mtRNase P recognizes substrates beyond tRNAs and may have altered processing 
efficiency towards different substrates.  
To study the molecular mechanism and specificity of substrate recognition by 
human mtRNase P, a library of human mitochondrial precursor tRNA (mt-pre-tRNA) 
DNA templates was prepared by subcloning mt-pre-tRNA genes into high copy 
number plasmids (Table 4-1). This mt-pre-tRNA library includes 16 constructs 
containing 14 species of the 22 mt-tRNA genes and represents all four types of mt-
tRNA species. This library includes known mtRNase P substrates, such as mt-pre-
tRNALeu(UUR) [72], mt-pre-tRNALys [60], mt-pre-tRNAIle [60], and mt-pre-tRNASer(UCN) 
[28] (Figures C-3 and C-4, Appendix C). A non-substrate of mtRNase P, mt-pre-
tRNASer(AGY) [79], is also subcloned in a mt-tRNA cluster (Figure C-4, Appendix C). 5’ 
processing of mt-pre-tRNASer(AGY) is achieved by 3’ processing of the flanking pre-
tRNAHis and is therefore independent of mtRNase P. In the 22 human mt-tRNAs, 20 












Table 4-1: Summary of plasmids containing human mitochondrial pre-tRNA genes. 
 












Type 0      
Leu(UUR) Leu(UUR)42-39 42 39 XbaI pUC18 
Leu(CUN) Leu(CUN)28-32 28 32 XbaI pUC18 
Gln Gln13-16 13 16 XbaI pUC18 
Type II      
Arg Arg19-14 19 14 XbaI pUC18 
Asp Asp19-40 19 40 XbaI pUC18 
Glu Glu12-35 12 35 XbaI pUC18 
Gly Gly26-54 26 54 XbaI pUC18 
His See Ser(AGY)     
Lys Lys10-34 10 34 XbaI pUC18 
Ile Ile42-24 42 24 XbaI pGEM-3Z 
 Ile11-5 11 5 BamHI pUC19 
Met Met10-40 10 40 XbaI pUC18 
Tyr Tyr55-39a 55 39 BamHI pGEM-1 
 Tyr55-0b 55 0 BstNI pGEM-1 
 Tyr5-0 5 0 BstNI pUC19 
Type I      
Ser(UCN) Ser(UCN)36-5 36 5 XbaI pUC18 
Type III      
Ser(AGY) His-Ser(AGY)- 
Leu(UCN)35-35 
35 35 XbaI pUC18 
 
a A gift from Dr. Walter Rossmanith (Medical University of Vienna, Austria). 
b Plasmid prepared by Dr. Wan Lim 
 
The human mitochondrial genomic DNA is extracted from human tissue culture 
cells (HEK293) and the subcloning is streamlined to a rapid process of PCR 
amplification, blunt-end ligation with pUC18 vector and blue-white selection of 
transformed cells. Using this method, various sequences of potential mitochondrial 
substrates, such as long stretches of tRNA clusters (e.g. the His-Ser(AGY)-




useful for exploring sequence and structural determinants in mt-pre-tRNA for both 5’ 
processing catalyzed by mtRNase P and specificity of m1G9 or m1A9 methylation 
catalyzed by MRPP1.  
4.3.4 Sequence Analysis of the 5’ Leader and 3’ Trailer Gene Sequences of mt-
pre-tRNA Genes 
Biochemical studies identified sequence-specific contacts between the the pre-
tRNA substrate and bacterial RNase P, including interaction of uridine at N(-1) [80, 
81] and adenosine at N(-2) [77] with RNase P RNA (P RNA), purine at N(-4) with 
conserved residues (F20 an Y34)  in  RNase P protein [82], and 3’ RCCA with a 
conserved GGU-motif in the P15-loop in P RNA [83]. These sequence-specific 
interactions correlate well with sequence preference observed in the bacterial pre-
tRNA genome [82]. Potential sequence preference at the 5’ and 3’ regions of human 
mt-pre-tRNA genes may provide clues to sequence-specific recognition by human 
mtRNase P. Therefore, I performed sequence analysis [82] for both the 5’ leader 
and the 3’ trailer region of human mt-pre-tRNA genes to evaluate potential sequence 
preferences in the regions flanking the mt-tRNA genes. 
Sequence logo plots were generated by analyzing the nucleotide content of the 
5’ leader (N(-15) through N(-1)) and 3’ trailer (N(+1) to N(+15)) of all 22 the human 
mt-tRNA genes (Figure 4-9). In these sequence logo plots, the the relative height of 
the letters correlates to nucleotide composition at this position, and the total bar 
height reflects the degree of information content enrichment with respect to 
background [82]. The background nucleotide content was calculated either from all 




N(+1) through N(+15) for 3’ trailer. Nucleotide enrichment is observed at various 
positions in both the 5’ leader and 3’ trailer sequences (Figure 4-9). 
 
Figure 4-9: Sequence preferences in the 5’ leader and 3’ trailer of human mitochondrial 
precursor-tRNAs. Nucleotide logo size is showing the nucleotide composition in the 5’ leader 
(A) and 3’ trailer (B). 
 
To determine if the observed nucleotide enrichment is statistically significant, 
chi-square analysis was performed against the background information content from 
either the 15-nt sequences or the entire human mitochondrial genome. When tested 




(26% A, 18% G, 28% C, 29% U for 5’ leader analysis and 31% A, 19% G, 22% C, 
28% U for 3’ trailer analysis), nucleotide enrichment is statistically insignificant (p > 
0.05) for most positions except for N(+7), N(+9) and N(+10) positions in 3’ trailer 
genes. However, when tested against background nucleotide content of the entire 
human mitochondrial genome (heavy strand mtDNA sequence, 31% A, 13% G, 31% 
C, 25%U), enrichments are significant (p ≤ 0.05) at N(-1), and N(-4) through N(-7) in 
the 5’ leader and N(+1), N(+3), N(+7), N(+9) and N(+10) in the 3’ trailer. The overall 
sequence enrichment in the 5’ leader is modest (bit < 0.3) but a high frequency of 
uridine is observed at N(-1). A preference for for uridine at N(-1) in the 5’ leader of 
mt-tRNA may be biological relevant since a pathogenic mutation of U to C has been 
reported at this position in mt-tRNAGln [84]. An enrichment of U at position N(-1) has 
also been observed in pre-tRNA genes from diverse bacteria, archaea and eukarya 
[85] and has been demonstrated to form a specific interaction with nucleotide A248 
in E. coli RNase P RNA [80]. In the 3’ trailer, a strong enrichment of A followed by G 
and U is indicated at position N(+1). Biological relevance of these observed 
sequence enrichment to mtRNase P activity awaits experimental investigation.  
4.3.5 Reconstitution of Human mtRNase P Activity  
The metallonuclease subunit of mtRNase P, MRPP3, is an ortholog of A. 
thaliana PRORP1 [59]. PRORP1 contains three distinct domains (Figure 4-4): a 
metallonuclease domain, a structural zinc domain and a pentatricopetide repeat 
(PPR domain) (Figure 4-4) [59]. MRPP3 contains all of the active site residues 
conserved in PRORPs [59] and has a 20% sequence identity and 29 % sequence 




MRPP3, see Figure C-2, Appendix C). It is intriguing to investigate why MRPP3 
requires two other proteins [50, 60] while PRORP1 alone functions efficiently for 
RNase P activity [54, 59, 86].  
I measured single-turnover cleavage activity catalyzed by both MRPP3 and the 
mtRNase P complex using a mt-pre-tRNAIle42-24 substrate labeled with fluoresscein 
at the 5’ end (Fl-pre-tRNAIle42-24, 20 nM, sequence see Table C-2, Appendix C). At 37 
˚C, all three proteins (MRPP1:2:3=1 µM:2 µM:500 nM)2 are required to catalyze 
cleavage of the 42-nt 5’ leader from FI-pre-tRNAIle in 4.5 mM MgCl2 and 260 mM 
NaCl (Figure 4-10). Interestingly, a 5’ end product of less than 39-nt in length is 
observed in the reactions with either MRRP3 alone or MRRP3 with one other 
subunit. This shorter length (< 39-nt) 5’ product is likely miscleavage catalyzed by 
MRRP3, considering the high purity of the protein, the broad range RNase inhibitor 
(SUPERase∙INTM) included in the reaction buffer. 
 
 
Figure 4-10: Single-turnover cleavage catalyzed by recombinant human mtRNase P 
proteins at 37 ºC. The 5’ end fluorescently labeled substrate Fl-mt-pre-tRNAIle42-24 has a 42-
nt 5’ leader and a 24-nt 3’ trailer. Reactions were performed at 37˚C in 30 mM Tris-HCl pH 8, 
4.5 mM MgCl2, 2 mM TCEP, 0.02 mM BSA, 0.1 unit/uL SUPERase∙INTM RNase inhibitor. 
The reactions were mixing enzyme with substrate and quenched by EDTA quench buffer. 
The reaction products were resolved on a 12 % denaturing PAGE and scanned by a 
Typhoon phosphorimager for fluorescence (see materials and methods). The 42-nt leader 
(correct size) product of is observed most prominently in reactions catalyzed by all three 
subunits (Lane 5). In the absence of all three subunits, the leader product is shorter (< 39-nt), 
                                            




reflecting miscleavage (Lanes 7, 9, 11, 13). Complete cleavage after 2 hour is observed in 
reactions catalyzed by both MRPP1+2+3 (500 nM MRPP3, Lane 5) and MRPP3 alone (5 
µM, Lane 13). 
 
 
Figure 4-11: Single-turnover cleavage activity of recombinant human mtRNase P proteins at 
21 ˚C. (A) Cleavage of 20 nM 5’ end fluorescently labeled Fl-mt-pre-tRNAIle42-24 (Fl-pre-
tRNAIle42-24) substrate catalyzed by recombinant human mtRNase P proteins (500 nM or 5 
µM, MRPP1+2+3 or MRPP3 alone) measured at 21 ˚C in 30 mM Tris-HCl pH 8, 4.5 mM 
MgCl2, 50 to 260 mM NaCl, 2 mM TCEP, 0.02 mM BSA and 0.1 unit/µL SUPERase∙INTM 
RNase inhibitor. Reactions were quenched by addition of EDTA quench buffer and resolved 
by 10% denaturing PAGE. The 5’ end cleavage product by RNase P is 42nt in length and a 
miscleavage product (< 39-nt) is also observed. (B) Calculation of single-turnover cleavage 
rate constant (kobs) from quantification of the percent substrate cleaved based on images 




in intensity of the substrate band. A single exponential equation (Equation 4-4) was fit to the 
time-dependence of cleavage to obtain kobs (summarized in the table). The percentage 
values in parenthesis in the table indicate the percent cleavage at the end point of each 
reaction. 
 
Similarly, when measured at 21 ˚C, a condition similar to a previous report [50], 
the mtRNase P complex combing all 3 proteins (MRPP1:2:3=1 µM:2 µM:500 nM) 
catalyzes single-turnover cleavage of Fl-mt-pre-tRNAIle42-24 substrate efficiently 
(kobs> 0.05 min-1, 90% completion), generating a 42-nt 5’ leader and a small amount 
(<10%) of miscleaved product (Figure 4-11). Both miscleaved and correct size 
product were observed for reactions containing MRPP3 alone. But different cleavage 
activity and cleavage-site selection occurred in reactions with N-terminal truncations 
(Δ45 and Δ793) and in two different concentrations (500 nM and 5 µM). With 500 nM 
MRPP3, both the correct size and miscleaved products are observed and 
Δ45MRRP3 (kobs = 0.008 ± 0.005 min-1, 77% completion) and Δ79MRPP3 (kobs = 
0.006 ± 0.002 min-1 37% completion). Although the kobs of 500 nM Δ45MRRP3 and 
Δ79MRPP3 catalyzed cleavage rate are comparable, Δ45MRRP3 is more active 
because the reaction catalyzed by Δ45MRRP3 has a higher completion at the end 
point (77% Δ45MRRP3 by vs 37% Δ79MRRP3). Interestingly, at higher 
concentration (5 µM), the miscleaved product (< 39-nt) is the main product from 
Δ45MRPP3 (kobs = 0.014 ± 0.001 min-1, 99% completion) while equal amount of the 
correct size and miscleaved products were observed from Δ79MRRP3 reaction 
albeit a 2-fold slower cleavage rate (kobs = 0.006 ± 0.002 min-1, 86% completion). 
Since activity of Δ45MRPP3 and Δ79MRPP3 are comparable when in complex with 
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MRPP1 and 2 (data not shown), the different cleavage pattern observed at 5 µM 
MRPP3 reactions could be due to a 2.5-fold difference in NaCl concentration (160 
mM NaCl for 5 µM Δ45 and 65 mM NaCl for Δ79). These data suggest that the 
MRPP1∙MRPP2 complex both activate MRPP3 and provide molecular recognition to 
cleave at the correct size. It may have mono ion dependent nuclease activity by itself 
but requires MRRP1 and 2 for precise catalysis.  
4.4 Discussions 
Newly identified protein-only RNase P in human mitochondria and plants 
sparked great interest in elucidating the mechanism of this new class of 
endonuclease to compare with that of ancient ribozyme based catalysis [59]. 
Processing of the 5’ end of mt-pre-tRNA by mtRNase P is likely the first step in mt-
tRNA processing [27] and mRNA biogenesis in mitochondria [15]. Mitochondrial 
tRNA is also a hot spot for pathogenic mutations. To investigate the mechanism of 
molecular recognition by human mtRNase P, I purified recombinant mtRNase P 
proteins (Figure 4-6 and Figure 4-8) and prepared a series of mt-pre-tRNA 
substrates (Table 4-1). In contrast to previous reports, single-turnover kinetic data 
presented here suggest that although all three mtRNase P proteins are required for 
precise catalysis, MRRP3 alone also retains metallonuclease activity in the absence 





4.4.1 Purification of Human mtRNase P Proteins 
Protein co-expression and co-purification can increase solubility and facilitate 
purification of eukaryotic protein complexes [73, 74]. MRPP1 and MRPP2 form a 
stable complex and were previously co-purified using affinity chromatography [50, 
60]. Therefore, I chose to purify MRPP1 in complex with MRPP2 by co-
overexpressing a HisTev-tagged MRPP1 with native MRPP2 (Figure 4-5). A highly 
pure MRPP1∙MRPP2 complex was obtained by two steps of Ni(II)-affinity 
chromatography with a relative low yield (0.5 mg protein/L culture). For the first 
Ni(II)-column, two extensive wash steps after initial wash (55 mM imidazole) are 
crucial for obtaining pure protiens (Figure 4-6).  Washing the column with 120 mM 
imidazole until the absorbance at 280 nm (A280) reaches a flat baseline ensures 
separation of lower affinity protein impurities and protein complex formed with 
MRPP1. A lower imidazole concentration (100 mM) wash for this step was not 
sufficient to clean up these impurities (data not shown). The second wash step with 
1 M NaCl (15 mM imidazole) successfully removes nucleic acids, a major issue for 
purifying proteins with high pI value (pI for MRPP1 is 9.0). In a recent report, a high 
purity MRPP1∙MRRP2 complex was also obtained by co-purification of non-tagged 
MRPP1 with separately purified His-tagged MRPP2 [60]. Compare to this strategy, 
my method is simpler and has a higher yield for MRPP1 because MRPP1 is tagged 
and proteins are expressed and purified in a single step. In addition, use of a 





To increase the protein yield, the purification could be further optimized. For 
example, we can optimize procedure for cell lysing, increase column size, reload 
flow-through for multiple runs of chromatography, or load the proteins with a higher 
NaCl concentration to reduce nucleic acids binding [87]. 
4.4.2 A Library of Human mt-pre-tRNA Substrates 
I cloned a library of mt-pre-tRNA DNA templates for studying the substrate 
selectivity by human mtRNase P. Earlier literature data indicated that human nuclear 
(an RNP) and mitochondrial RNase Ps have discrete but overlapping substrate 
specificity [88]. Partially purified mtRNase P did not detectably cleave a nuclear 
substrate, n-pre-tRNASer (polyU sequence at 3’ trailer) and catalyzed miscleavage of 
an E. coli pre-tRNATyrsu3+ (Figure 1-12, Chapter 1) in 4-nt upstream of cleave site 
[72]. A human mt-pre-tRNATyr (Table C-2 and Figure C-4, Appendix C) could not be 
detectably cleaved by human nRNase P [72]. However, a mt-pre-tRNALeu(UUR) (Table 
C-2 and Figure 1-12 and C-3) was  cleaved by both nRNase P and mtRNase P [72]. 
In plants, both nuclear and organellar tRNAs are mostly canonical, resembling 
eubacterial tRNAs in both primary sequence and secondary structure [69]. A. 
thaliana PRORP enzymes also catalyze cleavage of T. thermophilus pre-tRNAGly 
likely by coordination of a different non-bridging oxygen (pro-Sp) than that of 
bacterial RNase P (pro-Rp) [68] (Figure 1-8, Chapter 1). Model substrates of RNP 
RNase P enzymes include tRNA mimics with a 5’ leader, coaxially stacked acceptor-
stem and TψC-stem/loop connected by a 0-1 nt linker and containing a 3’ RCCA [89, 
90]. A minimum substrate with a 3-bp-stem, tetraloop and 3’ RCCA has also been 




pre-mRNA and unstructured RNAs [93, 94]. In human mitochondria, the need for 
recognizing non-canonical mt-tRNA substrates may explain why mtRNase P 
requires multiple subunits. However, substrate determinants for human mtRNase P 
activity remain to be investigated.  
In the mt-tRNA genes, a purine (G or A) is conserved at position 9 (R9) in all 
but two species, mt-tRNASer(UCN) and mt-tRNAMet. Several mt-tRNA are methylated at 
the R9 position in vivo [8, 18], including mt-tRNAAsp, mt-tRNAIle, mt-tRNALeu(UUR), mt-
tRNALeu(CUN), mt-tRNALys, and mt-tRNATrp. Biochemical experiments demonstrated 
that in vitro MRPP1∙MRPP2 complex catalyzes R9 methylation of mt-tRNAHis, mt-
tRNAIle, mt-tRNALeu(UUR), mt-tRNALys, mt-tRNATyr and a nuclear tRNAArg [60]. 
Unmodified primary transcripts of certain mt-tRNAs are poorly structured in solution 
[95, 96] but may be stabilized by posttranscriptional modification. For example, a 
single m1A methylation at A9 switches the mt-tRNALys transcript from an extended 
hairpin (9-nt acceptor-stem and distrupted TψC-stem) to a canonical cloverleaf 
structure (7-nt acceptor-stem) as demonstrated by solution structure probing and 
single molecule FRET experiments [97-99]. Furthermore, although mt-tRNALeu(UUR) 
preserves the majority of canonical tertiary contacts, the D-stem-loop and anticodon-
stem-loop of the in vitro transcripts are primarily unstructured in solution as indicated 
by solution structure probing [100]. Mutations that increase base paring in the D- and 
anticodon-stem stabilize mt-tRNALeu(UUR) structure and increase aminoacylation by 
its cognate synthetase [100]. It is intriguing to investigate whether mt-pre-tRNA 
methylated at position 9 could alter cleavage efficiency and/or specificity by 




The 5’ leader and 3’ sequences flanking the tRNA genes in bacteria have also 
been proposed to be co-evolved with specific regions of RNase P [77, 80-83]. In 
bacterial tRNA, the 3’ RCCA motif interacts with RNase P RNA by base pairing with 
a conserved GGU-motif in the L15 loop [83]. Biochemical studies identified a 
sequence preference of uridine at position N(-1) in 5’ leader and suggest a U(-1)-
A248 base pairing in J5/15 of E. coli RNase P RNA [81]. These interactions have 
also been observed in the recent crystal structure of bacterial RNase P ternary 
complex [71]. In addition, it has been shown that identity of base-pairing between N(-
1) and the determinant nucleotide N73 affect cleavage-site selection by E. coli and 
P. furiosus RNase P in model substrates [101]. Preference for adenine at N(-4) in B. 
subtilis results from an interaction with conserved residues in the P protein (F20 an 
Y34) that enhances binding affinity [82]. These specific sequence preferences 
correlate well with observed enrichment of these nucleotides in the genome [82].  
Sequence enrichment in positions flanking the 5’ and 3’ end of human mt-tRNA 
is also observed, as illustrated in the sequence logo plots (Figure 4-9). These 
sequence enrichments may be biological relevant. For example, a sequence 
preference of U>A>G>>C is statistically significant at the N(-1) position in the 5’ 
leader (Figure 4-9). A novel pathogenic mutation linked to a type of maternally 
inherited hypertension has been identified at this position, which affects two flanking 
mt-tRNAs in the opposite strands (U to C in mt-tRNAGln and A to G in mt-tRNAMet) 
[84]. However, these sequence enrichments may also reflect sequence conservation 




dependent substrate affinity and cleavage rates will likely reveal if these sequence 
preferences are related to mtRNase P activity. 
4.4.3 Activity of Human mtRNase P Proteins 
Protein subunits play a role in cleavage-site selection by RNA-based RNase P 
complex [101]. For example, cleavage of pATSerCGAAA and pMini3bpCG model 
substrates catalyzed by Pyrococcus furiosus (Pfu) RNase P RNA complexed with 2 
of the 4 protein subunits (RPP21∙RPP29) results in either miscleaved products or no 
product at 30 mM MgCl2 [101]. Interestingly, correct cleavage can be achieved by 
addition of all four proteins (RPP21∙RPP29 and POP5∙RPP30) or higher MgCl2 
concentration (300 mM) [101]. This study demonstrated an intricate interaction 
network between substrate and RNase P subunits.  
In human mtRNase P, the metallonuclease, MRPP3, requires two other 
subunits to function [50, 59, 60] despite predicted structural homology to the fully 
functional ortholog PRORP1 (see a homology model in Figure C-2, Appendix C). 
Consistent with previous reports [50, 60], data presented in this chapter 
demonstrated that all three subunits, MRPP1, 2 and 3, are required to accurately 
and efficiently catalyze cleavage at correct site of Fl-mt-pre-tRNAIle42-24 (Figure 4-10 
and Figure 4-11). Interestingly, MRPP3 alone catalyzes 5’ end cleavage more slowly 
and at the incorrect stie, producing significant quantities of a miscleaved product 
(Figure 4-10). Addition of either MRPP1 or MRPP2, with MRPP3 has similar activity 
to MRPP3 alone (4.5 mM MgCl2). This vestigial metallonuclease activity by MRPP3 
is consistently observed with two independently purified truncations (Δ45 and Δ79) 




shown to cleave another non-canonical mt-tRNA substrate, mt-pre-tRNATyr55-39, but 
the product identity is unclear [77]. Concentrations of monovalent ions may play an 
important role in the nuclease activity or site of cleavage of MRPP3 (Figure 4-11) 
possible by affecting mt-pre-tRNA secondary structures. The role of mono and 
divalent metal ion concentrations in enhancing cleavage activity and cleavage site-
selection should be explored in detail in the future.  
Additional experiments can be done to verify whether the observed 
miscleavage activity is catalyzed by MRRP3. For example, pre-treatment of MRRP3 
with micrococcal nuclease could rule out contaminating bacterial RNase P. MRPP3 
activity can be reduce by protease treatment or mutategensis of active site residues 
to compare with intact or wild type MRPP3 in catalyzing cleavage of mt-pre-tRNA 
substrates [59]. In addition, a 5’ monophosphate group (5’ PO4) in the tRNA body 
product and a 3’ hydroxyl (3’ OH) group in the leader product is a signature of the 
endonuclease activity of RNase P [49]. Therefore, two-dimensional thin layer 
chromatography (2D-TLC) analysis can be performed to identify the 5’ 
monophosphate group at 5’ end of the tRNA-body product using specific α-32P-NTP 
labeled pre-tRNA. In addition, the 5’ PO4 group in the tRNA body product can be 
captured by RNA ligase and then the full product sequence could be identified by a 
procedure similar to the next generation sequencing for small RNAs (small RNA-




4.4.4 Speculation on the Roles of mtRNase P Proteins in Substrate 
Recognition of mt-pre-tRNA 
It is striking that a single protein catalyst has evolved that can replace the 
function of a large ribonucleoprotein complex, as demonstrated by the ability of T. 
brucei PRORP1 to replace yeast nuclear RNase P in vivo [105]. A. thaliana 
PRORPs also catalyze cleavage of a T. thermophilus pre-tRNA substrate (pre-
tRNAGly, Figure 1-12, Chapter 1) [68]. Substrate specificity therefore seems unlikely 
to be the driving force for evolving a protein-only RNase P in plants [56]. However, 
the non-canonical features of human mt-tRNAs may explain why two additional 
subunits, a tRNA methyltransferase (MRPP1) and a dehydrogenase (MRPP2), are 
required for RNase P functionality in human mitochondria.  
MRPP1 alone is a methyltransferase that can methylate G9 of a nuclear 
tRNAArg with low efficiency but does not methylate mt-tRNAs [60]. MRPP1 is 
activated by MRPP2 for efficient catalysis to catalyze both G9 and G9 methylation in 
mt-tRNA substrates [60]. MRPP1 belongs to the TrmD methyltransferase 
superfamily [61]. TrmD methyltransferases identified to date function as homodimers 
[106]. The cystal structure of methyltransferase domain of TRMT10A, a MRPP1 
analog, also shows a homodimer , but this structure is in the absecen of the N-
terminal region of the protein (Figure 4-4 and C-1) [57].  Although MRPP1 and 
MRPP2 forms a tightly bound complex (Figure 4-6), gel shift affinity data suggest 
that MRPP1 binds tightly to tRNA (KD ~100 nM) but MRPP2 does not (KD >> 1 µM) 
[60]. In addition, neither MRPP1 nor MRPR2 tightly associates with MRPP3 [50]. 




activate MRPP3 activity [60]. Given this functional hierarchy and large non-canonical 
mt-tRNA pool, substrate recognition and catalysis by mtRNase P could involve an 
orchestra of complex events such as conformational and/or structural changes in mt-
pre-tRNA substrates and in protein subunits. 
Secondary and/or tertiary structure features of mt-tRNA may be a factor for 
observed specificities of RNA-dependent RNase P, mtRNase P, and PRORP1. For 
RNP RNase P that the a coaxially stacked acceptor-stem/TψC-stem/loop of tRNA is 
sufficient for RNase P recognition and catalysis [107]. The acceptor-stem of tRNA is 
usually a 7-nt helix but bacterial RNase P can correctly catalyze cleavage of a 9-nt 
helix (Figure 1-12, Chapter 1) while the human nuclear RNase P miscleave this 
substrate at -2 position [90]. These data suggest that protein-rich RNase P have a 
more strick “measuring mechasim” in recognizing pre-tRNA structure. However, in 
primery mt-tRNA transcripts, extended hairpins are formed with a 9-nt acceptor-stem 
are observed in mt-tRNALys and mt-tRNAAsp by solution structure probing [97, 108]. 
N1 methylation of A9 is sufficient to switch this hairpin to a cloverleaf structure by 
disrupting an A9-U64 base pairing [97-99]. In type 0 mt-tRNAs, such as mt-
tRNALeu(UUR) and mt-tRNASer(UCN), both canonical tertiary interactions between the D-
loop/TψC-loop and the canonical coaxial acceptor-stem-loop structure are preserved 
[32, 100]. But the anticodon domain and D-stem remain largely unstructured in mt-
tRNALeu(UUR), as indicated by high accessibility to modifying chemicals and 
nucleases [100]. These observations suggest that structure of primary mt-tRNA 




One possible function for the MRPP1∙MRPP2 subcomplex is to stabilize a 
productive conformation of mt-tRNA that facilitates recognition and catalysis by 
MRPP3. Structural studies have previously demonstrated a remarkable ability of 
tRNA modification enzymes to alter tRNA structure upon binding. For example, a 
tRNA ψ55 pseudouridine synthase binds a TψC-stem-loop model substrate of which 
three nucleotides, including the modification site (G55),flipped out in the crystal 
structure [109]. Furthermore, in a cocrystal structure of archaeosine tRNA–guanine 
transglycosylase (ArcTGT), the bound tRNAVal assumes a “λ-form” with a protruded 
D-stem-loop to expose the modification site (G15) [110]. In canonical L-shaped form 
of tRNA, the N9 nucleotide is buried within the folded structure of tRNA making 
tertiary contacts with N23 in D-stem (Figure 4-12) [111]. However, a detectable 
population of A9 base pairs with nucleotides in the TψC-stem was observed for mt-
tRNALys and mt-tRNAAsp by solution structure probing [97, 108]. Therefore, 
recognition of the G9 or A9 nucleotide by the MRPP1∙MRPP2 complex may require 
significant rearrangement of mt-tRNA conformation to expose the R9 nucleotide 
[112]. Consequently, binding of MRPP1∙MRPP2 to mt-tRNA may alter the mt-tRNA 
structure, defining productive mt-tRNA structure that is recognized by mt-RNase P 
(Figure 4-12). This hypothesis can be tested by biochemical studies such as solution 
structure probing of free and mtRNase P-bound mt-pre-tRNA, comparison of 
cleavage activity by various types of primary and R9 methylated mt-pre-tRNA, as 
well as mutagenesis of mtRNase P proteins and mt-pre-tRNA substrates. Structural 
studies by co-crystallization and solution NMR would be challenging but will provide 






Figure 4-12: A model illustrating a propoased interaction of human mitochondrial RNase P 
with pre-tRNA substrate. In the cartoon presentation of a pre-tRNA, the 5’ leader (red) is 
positioned close to the metallonoclease domain of MRPP3 while the nucleotides in the the 
D-TψC region (cyan), which were proposed to interact with the PPR domain by footprinting 
experiments [70], are positioned near the PPR domain. The methylation site (purine at N9) 
of tRNA recognized by MRPP1 is highlighted in green [113]. The model of one pre-tRNA per 
MRPP1 is based on proposal that two tRNA bind to one homodimer of TrmD 
methyltransferases [106]. 
 
MRPP2 does not tightly associate with meither mt-tRNA or MRPP3 [50, 60]. Its 
role in activating MRPP1 methylation and mtRNase P cleavage likely comes from 
protein-protein interactions. Consistent with this, MRPP2 has been shown to interact 
with β-amyloid (Aβ) peptides [64]. Furthermore, MRPP1∙MRPP2 co-localizes with a 
newly identified mitochondrial RNA-binding protein, GRSF1 [66]. The C-terminal 
domain of MRPP1 likely has a similar structure to the recently solved MTase domain 
of TMRT10A (Figure C-1, Appendix C) but the N-terminal region (amino acids 39 to 
190) of MRPP1 has little sequence homology to known structural motifs and has a 
predicted coiled coil region (amino acids 138 to169). The function of the N-terminal 
region of MRPP1 awaits exploration. Dissecting MRPP1-MRPP2 interactions 




advance our knowledge of the function and mechanism of this essential RNA 
processing complex.  
4.4.5 Conclusion 
This work developed materials and methods for further systematic investigation 
of substrate recognition and catalytic function of the poorly characterized protein-
only human mtRNase P complex. Single-turnover cleavage results indicate that 
MRPP3 alone can cleavages of the 5’ leader of an mt-pre-tRNAIle substrate in the 
absence of two other protein subunits, although with significant miscleavage and 
lower rate constant. Analysis of the molecular mechanism of human mtRNase P in 
processing wild-type and pathogenic mt-pre-tRNA substrates will shed light on 
understanding the role of mt-tRNA processing in mitochondria biogenesis and 
pathogenesis.    
4.5 Materials and methods 
4.5.1 Subcloning of MRPP1 and MRPP2 Subunits for Co-expression 
Genes encoding MRPP1 and MRPP2 proteins were subcloned into a 
pCDFDuet-1 (Novogen) co-expression vector by three rounds of molecular cloning 
(Figure 4-5). First, a DNA insert containing the full coding sequence of MRPP2 (261 
amino acids) and a stop codon was obtained from double digestion of an engineered 
pETM11-based vector that contain the MRPP2 encoding sequence (pMR2-TEV-
His4) [77] by NdeI and XhoI restriction enzymes (New England BioLabs, NEB) 
                                            




according to the manufacture’s specifications. This insert was then ligated (Quick 
Ligation™ Kit, NEB) into the second multiple cloning site (MCS2) of the pCDFDuet-1 
vector to generate a plasmid encoding native MRPP2 sequence (pCDFMP2).  
Second, coding sequences corresponding to amino acids 39 to 403 of MRPP1 
(deletion of the N-terminal mitochondrial localization sequence) and a stop codon 
were amplified using polymerase chain reaction (PCR) from a plasmid template 
(pJEJ449) provided by Dr. Jane Jackman (Ohio State University). The PCR reaction 
was carried out in standard PCR buffer (Strategene) with 0.04 unit/µL PfuTurbo® 
DNA polymerase (Stratagene), 0.2 mM dNTP (Invitrogen), 1 ng/µL plasmid template 
and 0.5 µM of the following primers: forward primer (FRP), ‘5-CAG TCT CAT ATG 
TCT TCC AAA ATA CCA GCT-3’; reverse primer, (RVP), 5’- GGA AGT CTC GAG 
TTA AGT CTT TGC CTT CTT TAG TC -3’ (Integrated DNA Technologies). The PCR 
cycles are: (1) denaturation at 95 ˚C for 2 min; (2) a sequence of denaturation at 95 
˚C for 2 min followed by annealing at 55 ˚C for 1 min and elongation at 72 ˚C for 2 
min that was repeated by 30 times; (3) a final elongation step at 72 ˚C for 5 min. The 
PCR product and a pETM11-based vector (kanamycin resistant, engineered HisTev 
tag) were double digested with NdeI and XhoI restriction enzymes (NEB). The 
double digested PCR insert was ligated to the pETM11 vector to produce a plasmid 
encoding an N-terminal hexa-histidine-tag followed by a cleavage sequence for TEV 
protease and the Δ39MRPP1 gene (pETM11HisTevMP1).  
Next, the MRPP1 sequence, including the N-terminal TEV-cleavage tag, was 
amplified using the same PCR amplification conditions described above and with the 




ATC ACC ATC ACC AT -3’; reverse primer, (RVP), 5’- CCA AGT GGA TCC TTA 
AGT CTT TGC CTT CTT TAG TC -3’ (Integrated DNA Technologies). The PCR 
product was double digested by NcoI-HF and BamHI-HF restriction enzymes (NEB) 
and ligated into the first multiple cloning site (MCS1) of the pCDFMP2 vector 
between NcoI and BamHI sites. This generated a plasmid encoding an N-terminal 
TEV-cleavable his-tagged Δ39MRPP1 and native MRPP2 controlled by two 
separate T7 promoters (pHisTevMP1+MP2). Plasmid constructs containing 
alternative combinations of the two proteins were also subcloned into pCDFDuet-1 
vector (Table C-1, Appendix C). Sequence are confirmed using two pairs of 
sequenceing primers as manuafarcture recommended for MCS1 and MCS2 for 
pCDFDuet-1 vector at University of Michgian DNA Sequencing Core (Novogen).  
4.5.2 Overexpression and Purification of Recombinant Human mtRNase P 
Subunits 
Optimum conditions for expression of MRPP1 and MRPP2 from the co-
expression plasmid were determined by analysis of the expression level in cell 
lysates and for Ni(II)-sepharose column affinity. The conditions tested included: E. 
coli cell strain (BL21(DE3), BL21(DE3)pLysS, Rosetta(DE3)), expression media (LB-
media, Overnight Express™ Instant TB Medium by Novogen), growth temperature 
(16 to 25 ˚C) and concentration of isopropylthio-β-D-galactopyranoside (IPTG, 0 to 1 
mM). The expression level and solubility of MRPP1 and MRPP2 in cell extracts were 
analyzed using the B-PER Protein Extraction Reagents (Thermo Scientifc) with 
procedures similar to manufacture specified protocol with addition of lysozyme and 




were analyzed by SDA-PAGE. Small scale immobilized-metal affinity 
chromatography (IMAC) column was utilized to test the nickel affinity of the His-
tagged proteins to the Ni(II)-column.  
For co-overexpression and co-purification of HisTev-tagged MRPP1 and native 
MRPP2, the pHisTevMP1+MP2 plasmid was transformed into RosettaDE3 E. coli 
cells and the proteins were expressed by growing cells in Overnight Express™ 
Instant TB Medium with 50 mg/L streptomycin and 34 mg/L chloramphenicol at 25 
˚C for 16 to 24 hours. Cells were harvested and resuspended in buffer A (20 mM 
Tris-HCl pH7.5, 10% glycerol, 150 mM NaCl, 1 mM MgCl2, 1 mM TCEP, 30 mL 
buffer/L cell culture) with 15 mM imidazole and kept frozen at -80 ˚C until 
purification. Prior to lysing the cells, one tablet of protease inhibitor (Complete EDTA 
free) and final concentrations of 30 unit/µL RNase-free DNase I (Promega or 
Qiagen) and 5 mM MgCl2 were added to the cell suspension and the mixture was 
incubated at 37 ˚C for 30 min to 1 hour. Cells were lysed by sonication on ice with 
the addition of 1 mg/mL lysozyme followed by centrifugation at 16, 000 rpm for 1 
hour at 4˚C.  
The cleared cell lysate was purified by immobilized-metal affinity 
chromatography column with NiSO4-charged chelating sepharose fast-flow resin (GE 
Healthcare) using an Econo Gradient Pump system (BioRad) at room temperature. 
Specifically, the Ni(II)-column (2 mL) was loaded with ~40 mL lysate and washed 
extensively by three steps: buffer A with 55 mM imidazole, followed by 120 mM 
imidazole and 1 M NaCl (15 mM imidazole). Each wash step was performed until the 




baseline. A protein complex of HisTev-tagged MRPP1 and native MRPP2 was then 
eluted upon addition of 120 mM imidazole in buffer A. The fractions containing the 
purified HisTevMRPP1∙MRPP2 complex were concentrated by centrifugal filtration 
(Amicon MWCO 10K, Millipore Corporation) and dialyzed overnight at 4 ˚C against 
buffer A with His-tagged TEV protease added in the dialysis cassette (MWCO, 10K). 
The TEV protease (50 unit per mg of substrate protein) is His-tagged and purified in 
our lab. The TEV-cleaved proteins were applied to a second Ni(II)-IMAC column to 
separate the HisTev-tag, His-tagged TEV protease and other impurity from the 
native MRPP1∙MRPP2 complex. The fractions containing the complex were 
concentrated to 0.1-1 mg/mL and exchanged to buffer B (Amicon MWCO10K) and 
stored in -20˚C. The final yield for purified MRPP1∙MRPP2 complex is about 0.5 mg 
protein/L cell culture. 
To estimate the protein concentration in the MRPP1∙MRPP2 complex, a 
separately purified MRPP2 protein 5  was used as the standard for quantifying 
MRPP2 concentration in a coomassie blue stained SDS-polyacrylamide gel (Figure 
4-7). Absorbance of the protein samples at 280 nm (A280) was measured using a 
NanoDrop 2000 UV-Vis spectrometer (Thermo Scientific). The theoretical extinction 
coefficient for denatured MRPP1 (ε280MRPP1 = 62,130 M-1cm-1) and MRPP2 (ε280MRPP2 
= 4,720 M-1cm-1) were calculated using the ProtParam server (Expasy Protein 
Parameter Tool [114]). Serial dilutions of known concentrations of MRPP2 (20-150 
µM, with a further 10-fold further dilution when loaded on the gel) and the 
MRPP1∙MRPP2 complex were denatured and resolved on the same SDS-
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polyacrylamide gel. The gel was stained by coomassie blue and the intensity of each 
protein band in the image was analyzed using ImageJ software. A standard curve 
was generated by fitting a linear equation to the dependence of the band intensity on 
the concentration of MRPP2. Then the concentration of MRPP2 in the complex was 
calculated from the band intensity using the standard curve. Finally, the 
concentration of MRPP1 was estimated from the measured A280 after subtraction of 
the A280 contribution by MRPP2 using the calculated extinction coefficient.  
To purify MRPP3, the plasmid encoding amino acids 46 to 583 of MRPP3 
(Δ45MRPP3) with an N-terminal HisTev-tag (pMR3-TEV-His6) [77] was transformed 
into Rosetta(DE3) E. coli cells and grown in LB-media at 37 ˚C to an OD600 ~ 0.6-0.8 
followed by induction of the protein by addition of 660 µM IPTG and incubation for 16 
hours at 18˚C. Cells were resuspended in buffer B (20 mM MOPS, pH 7.8, 10% 
glycerol, 150 mM NaCl, 1 mM MgCl2, 1 mM TCEP; ~30 mL buffer/L cell culture) with 
15 mM imidazole and were frozen in -80 ˚C. Cells expressing HisTev-MRPP3 were 
lysed by 2-3 passes through a chilled micro-fluidizer and purified by a Ni(II)-IMAC 
column (5 mL) similar to procedures described previously [77]. HisTev-MRPP3 was 
eluted using a linear gradient from 50 to 500 mM imidazole in buffer C (20 mM Tris-
HCl, pH 8.6 in 25 ˚C and pH 9.2 in 4 ˚C, 10% glycerol, 150 mM NaCl, 1 mM MgCl2, 1 
mM TCEP) and the pooled fractions (300-500 mM imidazole) were subjected to TEV 
protease (50 unit per mg of substrate protein) cleavage while dialyzing against buffer 
B at 4 ˚C overnight. The cleaved Δ45MRPP3 was further purified using a second 
Ni(II)-IMAC column (Figure 4-8) .  
                                            




Non-tagged Δ45MRPP3 was further purified by either anion-exchange 
chromatography (Q Sepharose High Performance, GE Healthcare) or hydrophobic 
interaction chromatography (Phenyl Sepharose High Performance, GE Healthcare). 
For the anion-exchange column, MRPP3 was dialyzed into buffer C (20 mM Tris-
HCl, pH 8.6 in 25 ˚C and pH 9.2 in 4 ˚C, 10% glycerol, 150 mM NaCl, 1 mM MgCl2, 1 
mM TCEP) at 4 ˚C and loaded onto a Q-column (2 mL). Pure MRPP3 are eluted at 
150 mM NaCl (Figure 4-5) and protein and nucleic acid elutes at higher salt (400 
mM to 1 M NaCl). For the hydrophobic interaction column, MRPP3 was dialyzed into 
buffer D (50 mM MOPS, pH 7.5, 10% glycerol, 1.8 M (NH4)2SO4, 1 mM MgCl2, 1 
mM TCEP) and purified on a Pheny-sepharose column (2 mL) using a linear 
gradient of decreasing concentration of (NH4)2SO4 from 1.8 M to 0 M. MRPP3 eluted 
at the fractions with 0 M (NH4)2SO4 (Figure 4-8). MRPP3 samples purified from 
either a Q-column or a Phenyl-column were collected separately and exchanged into 
buffer E (50 mM MOPS, pH 7.5, 10% glycerol, 300 mM NaCl, 1 mM TCEP) for 
storage at -20˚C until use. Final yield for Δ45MRPP3 is about 3-5 mg/L cell culture. 
Concentration of Δ45MRPP3 is calculated with a theoretical extinction coefficient of 
85, 830 M-1cm-1. 
4.5.3 Cloning of Human mt-pre-tRNA Genes 
The genomic DNA from human mitochondria was extracted from HEK293 cells 
using a mitochondrial DNA isolation kit (BioVision). The yield of mitochondrial DNA 
was 5-12 µg from ~ 5 X 107 HEK293 cells. Target human mt-pre-tRNA genes 
containing 5’ leader, tRNA body and 3’ trailer sequences were amplified by PCR with 




2 ng/µL mitochondrial genomic DNA and 0.4-0.5 µM primers (Table C-3, Appendix 
C). 
The mt-pre-tRNA genes were subcloned into high copy number plasmids to 
prepare DNA templates for transcription of mt-pre-tRNA catalyzed by T7 RNA 
polymerase [115]. The PCR primers containing T7 promoter sequences preceding 
the pre-tRNA genes are designed to start with at least one G following the TATA 
sequence and a T is avoided as the second nucleotide downstream of TATA based 
on specificity of T7 RNA polymerase [116]. Primers were also designed with an 
estimated melting temperature (Tm) in the range of 58 to 63 ˚C (accounting 50 mM 
NaCl and 2.5 mM MgCl2 by Oligo Analzyer, Integrated DNA Technologies) and GC-
content of 40-60%. Therefore the leader and trailer lengths were varied (Table 4-1). 
Typical PCR reaction cycles were: (1) denaturation at 95 ˚C for 2 min, (2) 
denaturation at 95 ˚C, annealing at 52 to 58 ˚C for 30 sec and elongation at 72 ˚C for 
1 min. (3) a final elongation step at 72 ˚C for 5 -10 min.  
Several different vectors were used for cloning mt-pre-tRNA genes. PCR 
products for mt-pre-tRNAIle42-24 (first number indicates length of 5’ leader while 
second number is the length of 3’ trailer) were ligated into a high-copy number 
plasmid vector (pGEM-3Z, Promega) by double digestion of both the PCR product 
and the vector with EcoRI and XbaI restriction enzymes (NEB) followed by ligation 
(Quick Ligation™ Kit, NEB). Sequence of mt-pre-tRNAIle42-24 was confirmed by 
sequencing results by the University of Michigan Sequencing Core using the SP6 
primer. A secondary procedure was used for cloning mt-pre-tRNA genes into pUC18 




generated by first amplifying the target gene using the mt-pre-tRNATyr (Tyr55-0)7 
plasmid as template by PfuTurbo® DNA polymerase (Stratagene), followed by a 
blunt-end ligation of the PCR product into the pUC18 vector digested with the SmaI 
restriction enzyme (NEB). The ligation reaction was transformed into XL1Blue E. coli 
cells and plated on LB-agar top dressed with IPTG (to enhance production of lacZ) 
and 5-bromo-4-chloro-indolyl-β-D-galactopyranoside (X-gal, Fisher Scientific) for 
blue-white screening [117]. White colonies were picked for extraction of plasmid 
DNA and sequencing using the M13-Reverse primer (University of Michigan DNA 
Sequencing Core). The majority of target genes of mt-pre-tRNA were amplified from 
human mitochondrial genomic DNA and ligated into SmaI digested pUC18 vector 
followed by blue white screening. Large quantities of mt-pre-tRNA plasmid (1-5 mg) 
were prepared using either a Maxi (Sigma, or Qiagen) and/or a Giga plasmid prep kit 
(Sigma) to serve as DNA templates for subsequent synthesis of mt-pre-tRNAs by in 
vitro run-off transcription by catalyzed T7 polymerase [116].  
4.5.4 Sequence Analysis of Human mt-pre-tRNA Genes 
The complete sequence of the human mitochondrial genome (NC_012920.1) 
was downloaded from GenBank. The annotated mt-tRNA genes from both the heavy 
and light strand DNA were analyzed and the first 15 nucleotides upstream [N(-15) to 
N(-1) for 5’ leader] and downstream [N(+1) to N(+15) for 3’ trailer] of each tRNA 
were identified. Background nucleotide compositions for the 5’ leader or 3’ trailer 
regions were calculated from all 22 corresponding 15-nt sequences. The information 
content indicating nucleotide frequencies and enrichment at each position (shown as 
                                            




sequence logo in Figure 4-9) were calculated relative to background information 
content from all 15-nt sequences [82, 118]  to generate a sequence logo plot [119, 
120] (Figure 4-9). The total bar height (in bits) in the sequence logo plot equals the 
information content at position N(i), RN(i), calculated by Equation 4-1: 
 𝑅𝑁(𝑖) =  𝐻𝑏𝑘𝑔𝑑 −  𝐻𝑁(𝑖) −  𝑒𝑛  Equation 4-1 
   
Where Hbkgd is the background information entropy from positions N(-1) to N(-
15) (for 5’ leader calculation) or positions N(+1) to N(+15) (for 3’ trailer calculation), 
HN(i) is the entropy of position i, and en is a correction factor by sample size (n = 22 




 Equation 4-2 
   
Hbkgd and HN(i) were calculated using Equation 4-3, in which fb is the observed 
frequency of a given nucleotide position (for  HN(i)) or in the total sequence 
combining all 15 positions in the 22 sequences for  (Hbkgd).  
 𝐻𝑏𝑘𝑔𝑑 𝑜𝑟 𝑁(𝑖) =  − ∑ 𝑓𝑏𝑙𝑜𝑔2(𝑓𝑏)
𝑏∈(𝐴,𝐺,𝐶,𝑈)
 Equation 4-3 
   
To evaluate the probability (p) that the observed nucleotide content is due to 
random fluctuations in the background nucleotide composition, chi-square analysis 
was performed by comparing the nucleotide content at each position to both the 15-
nt region proximal to tRNA genes and the overall genomic background content 





4.5.5 Single-turnover Cleavage Measurements 
Fluorescently labeled mt-pre-tRNAIle42-24 (Fl-pre-tRNAIle42-24) was prepared by 
conjugating 5-iodoacetamidofluorescein (5-IAF, Invitrogen, now Life Technologies) 
to pre-tRNAIle42-24 transcribed using T7 polymerase in vitro with a 5’ 
monothiophosphate guanosine (5’ GMPS), as described previously [121]. To 
measure cleavage activity of mtRNase P, Fl-pre-tRNAIle42-24 was denatured by 
heating for 3 min at 95°C in water and refolded by first incubating for 10-15 min at 
37°C followed by addition of the desired buffer and incubation for another 30 min at 
37 ˚C or 21 ˚C. 
Single-turnover activity of the recombinant human mtRNase P was measured 
at conditions similar to previous reports [50] with 30 mM Tris-HCl pH 8, 40-260 mM 
NaCl, 4.5 mM MgCl2, 2 mM TCEP, 0.02 mM BSA, 0.1 unit/µL RNase inhibitor 
(SUPERase∙INTM, Ambion, now Life Technologies) at 37˚C (Figure 4-10) or 21˚C 
(Figure 4-11). MRPP1 and MRPP2 proteins used in this experiment were purified 
separately8 as described in [77]. The Δ45MRPP3 was purified using two rounds of 
Ni(II)-IMAC column and one Q-column and Δ79MRPP3 was purified using two 
rounds of Ni(II)-column followed by a SP-column (GE Healthcare) and a size-
exclusion column (Sephacryl S-200 GE Healthcare)9. Single turnover kinetics were 
measured by reacting 20 nM Fl-pre-tRNAIle42-24 with either MRPP3 alone (500 nM or 
5 µM) or with addition of other subunits (MRPP1:MRPP2:MRPP3 = 1 µM:2 µM:500 
nM, MRPP1:MRPP3=1 µM:500 nM, MRPP2:MRPP3=2 µM:500 nM). Time points 
were taken by quenching the reaction with an equal volume of quenching solution 
                                            
8 Dr. Wan Lim purified the MRPP1 and MRPP2 used in this experiment. 




(10 M urea, 200 mM EDTA pH 8, 0.05% bromophenol blue, and 0.05% xylene 
cyanol). The extent of substrate cleavage was visualized by applying quenched 
solutions to a 12% or 10% denaturing polyacrylamide/bis gel containing 7 M urea 
followed by fluorescence scanning by a Typhon Phosphorimager (λex = 480 nm, λem 
= 535 nm). The scanned images were analyzed using ImageJ software and the 
percent cleavage of the substrate was determined from the disappearance of the 
substrate band (Figure 4-10). A single exponential equation (Equation 4-4) was fit to 
the percent cleavage time course to calculate the single-turnover cleavage rate 
constant (kobs). 
 𝑌 =  𝑌∞(1 − 𝑒
−𝑘𝑜𝑏𝑠𝑡) Equation 4-4 






4.6 Appendix C 
I have compiled detailed figures and tables related to Chapter 4 in this 
appendix so that future members can have easy access to this plethora of basic 
information related to human mtRNase P and mt-tRNA. The main contents of the 
following supporting figures and tables are:  
 Homology modeling and sequence alignment analysis for MRPP1 (Figure C-
1) and MRPP3 (Figure C-2) 
 Summary of molecular biology and purification of recombinant human 
mtRNase P proteins (Table C-1).  
 Molecular biology and sequence summary of mt-pre-tRNA genes presented 
in this chapter (Tables C-2 and C-3, and Figures C-3 and C-4) 
 Sequence alignment (Figure C-5) and flanking sequences (5’ leader and 3’ 






Figure C-1: Structure modeling and multiple sequence alignment of MRRP1 with TRMT10 
(TM10) family methyltransferases. (A) A superposition of TM10A MTase domain (chain A, in 
orange, PDB ID: 4FMW [57]) with a homolog structure model of C-terminal region of MRPP1 
(blue). TM10A bound SAH is shown (light blue). Homology modeling was performed on 
Phyre2 server [122] by structure based alignment of full MRPP1 sequence to possible 




adopt an identical fold to this TM10A MTase domain (confidence score: 100%). No 
significant hit for the N-terminal region of MRPP1 was identified. (B) Two-dimensional 
projection of contacting and second shell residues for SAH, generated from 4FMW pdb file 
by LigPlot+ [123]. (C) Diagram illustrating size and domain composition of human MRPP1 
and TM10A. MTS: mitochondrial localization sequence. MTase domain: methyltransferase 
domain. Structure of N-terminal domain(s) of TM10 family MTase has not been determined 
to date. (D) Multiple sequence alignment of 15 TM10 family MTase sequences (showing 6). 
Protein sequences of eukaryotic TM10, TM10A, TM10B and MRPP1 analogs were identified 
from PSI-BLAST search (http://www.ebi.ac.uk/Tools/sss/psiblast/) [124] and aligned by 
Clustal Omega [125]. Color-shading indication of sequence conservation were generated by 
ESPript 2.2 [126]. Boxed regions indicate both complete (red highlight) and partial 
conservations (red letter). Secondary structure diagram corresponds to PDBsum [127] 
annotation of TM10A chain A. Putative SAH ligands are marked by blue circles. Overall 







Figure C-2:  Homology model of MRPP3 and multiple sequence alignments of PRORP 
proteins. (A) Alignment of PRORP1 (Blue) crystal structure (PDB ID: 4G26 [59]) with a 
homology model structure of MRPP3 (yellow, amino acids 141 to 582). Calcium ion (red 
sphere) in the active site and the zinc ion (green sphere) in the central domain of PRORP1 




and the returning model has a 100% confidence score. Three regions showing 
discrepancies between the MRPP3 model and PRORP1 structure are boxed in both the 
structure cartoon and in the sequence alignment in (B). (B) Multiple sequence alignment of 
20 PRORP protein sequences showing A. thaliana PRORP1, 2, and 3 and three mammalian 
MRPP3 proteins. Secondary structure is annotated based on PRORP1 structure using 
ESPript 2.2 [126]. Sequences in dash-line boxes correspond to structure elements that differ 
between MRPP3 model and PRORP1 structure. Full sequence identity and similarity 


























































2-1 Round 1: For: 5’- CTG GTT CCA 
TGG GTA TGT CTT CCA 
AAA TAC CAG CTG -3’ 
Rev: 5’- GGA CGT CTC 
GAG AGT CTT TGC CTT 












2-2 Round 2: For: 5’- CTG GTT CCA 
TGG GTA TGT CTT CCA 
AAA TAC CAG CTG -3’ 
Rev: 5’- CGCTAA GGATCC 






















cells and affinity 
to Ni(II) column g 







See: 4.2 Results  
4 HisTevMRPP2+MRPP1 
4-1 Round 1: Same as in row 3-1 pCDFDuet-1 
(Novagen) 





4-2 Round 2: For: 5’- CGA TCA CCA 
TGG GTA TGA AAC ATC 
ACC ATC ACC AT -3’ 
Rev: 5’- GGA TTG GAT 
CCT CAA GGC TGC ATA 


















5-2 Round 2: For: 5’- GTC AGA GAG 
ATC GAA ACA TCA CCA 
TCA CCA TCA -3’ 
Rev: 5’- GTG ATT  CTC 










6 Non-tagged MRPP1 









a MRPP1 corresponds to Δ39 N-terminal truncation and MRPP2 is full length. His3C: 
hexahistidine (His6) tag followed by a cleavage sequence by 3C protease at N-terminal of 
protein sequences. HisTev: His6 tag tagged followed by TEV protease cleavage site at N-
terminal. TevHis: TEV cleavage site followed by His6 tag and stop codon. 
b Plasmid name in parenthesis corresponds to Xin Liu’s laboratory notebook recording. 
c See Materials and Methods for experimental conditions used for evaluation of expression 
and purification.  
d Cloning of pETM11HisTevMRPP2 was described in Dr. Wan Lim’s thesis [77]. 
e pJEJ494 was a gift from Dr. Jane Jackman (Ohio State University). 
f The pETM11-NcoI-XhoI-TevHis parent vector is engineered by Andrea Stoddard. A stop 
codon is engineered downstream of the C-terminal TevHis tag.  
g Expression and purification of HisTevMRPP1 from BL21DE3pLysS cells were carried out 





















Table C-2: DNA sequences of 16 plasmids for mt-pre-tRNA. T7 promoter sequence in blue, 
5’ leader and 3’ trailer sequences in lower case and sequence corresponding to transcribed 
RNA underlined. 
 























































































Table C-3: Primers for subcloning mt-pre-tRNA genes by blunt-end ligation. 
 
Sequence Name Sequence 
Arg-For TAA TAC GAC TCA CTA TAG GAT TAG ACT GAA CCG AAT TG 
Arg-Rev GGA AGT CTA GAG AGG GGC ATT TGG TAA ATA TG 
Asp-For TAA TAC GAC TCA CTA TAG CCT CCA TGA CTT TTT CAA AA 
Asp-Rev GTG AAT CTA GAG CGT CTT GTA GAC CTA CTT G 
Gly-For TAA TAC GAC TCA CTA TAG GTC TCC ATC TAT TGA TGA GGG 
Gly-Rev GGT AGT CTA GAG TAG TAA GGC TAG GAG GGT G 
His-For TAA TAC GAC TCA CTA TAG CAA CCC CGA CAT CAT TAC C 
His-Rev GTC CAT CTA GAG AGT TAG CAG TTC TTG TGA GC 
Met-For TAA TAC GAC TCA CTA TAG CCA TCC TAA AGT AAG GTC AGC 
Met-Rev GTG CTT CTA GAG TAG AGT AGA TGA CGG GTT G 
Phe-For TAA TAC GAC TCA CTA TAG CCC ACA GTT TAT GTA GCT TAC C 
Phe-Rev GCA ATT CTA GAG AAA GGC TAG GAC CAA ACC 
Trp-For TAA TAC GAC TCA CTA TAG CCA CGC TAC TCC TAC CTA TC 
Trp-Rev GCA AGT CTA GAG CAG AGT GGG GTT TTG CAG 
Thr-For TAA TAC GAC TCA CTA TAG CCA ACT ATC TCC CTA ATT G 
Thr-Rev GCT GAT CTA GAG CTA ATG GTG GAG TTA AAG 
Val-For TAA TAC GAC TCA CTA TAG ACG AAC CAG AGT GTA GC 
Val-Rev GAG GAT CTA GAG TTT AGC TCA GAG CGG TC 
Ala-For TAA TAC GAC TCA CTA TAG GTC CCA TTG GTC TAG TAA GG 
Ala-Rev GGT GAT CTA GAC TGT AAC AGC TAA GGA CTG C 
Asn-For TAA TAC GAC TCA CTA TAG CGG GAG AAG TAG ATT GAA G 
Asn-Rev GGA GTT CTA GAG CTA AGC CCT TAC TAG ACC 
Cys-For TAA TAC GAC TCA CTA TAG GCT AAA GAC AGG GGT TAG GC 
Cys-Rev GAC TCT CTA GAC AAT CTA CTT CTC CCG CC 
Glu-For TAA TAC GAC TCA CTA TAG GGG TCA TTG GTG TTC TTG 
Glu-Rev GAG ACT CTA GAC ACA CTC AAC AGA AAC AAA GC 
Gln-For TAA TAC GAC TCA CTA TAG CTG ACC TTA CTT TAG GAT GG 
Gln-Rev GTG AAT CTA GAC CCC TTA TTT CTA GGA CTA TGA G 
Pro-For TAA TAC GAC TCA CTA TAG CTT CCC CAT GAA AGA ACA G 
Pro-Rev CTG AAT CTA GAC AAG GAC AAA TCA GAG AAA AAG TC 
I-Q-M-Hvy-For TAA TAC GAC TCA CTA TAG CAT TAC AAT CTC CAG CAT TCC 
I-Q-M-Hvy-Rev GCT CAT CTA GAC CTG CAA AGA TGG TAG AGT AG 
M-Q-I-Lt-For TAA TAC GAC TCA CTA TAG CCT GCA AAG ATG GTA GAG TAG 
M-O-I-Lt-Rev GCT GAT CTA GAC ATT ACA ATC TCC AGC ATT CC 
Y-C-N-A-W-Lt-For TAA TAC GAC TCA CTA TAG AGA ATA GTC AAC GGT CGG 
Y-C-N-A-W-Lt-Rev GCT GAT CTA GAC CAC GCT ACT CCT ACC TAT C 
S-D-Hvy-For TAA TAC GAC TCA CTA TAG CAC CCT ACC ACA CAT TC 
S-D-Hvy-Rev GAC ACT TTA AAC GTC TTG TAG ACC TAC TTG C 
D-S-Lt-For TAA TAC GAC TCA CTA TAG CGT CTT GTA GAC CTA CTT GC 
D-S-Lt-Rev GAC ACT TTA AAC ACC CTA CCA CAC ATT C 
L-S-H-Hvy-For TAA TAC GAC TCA CTA TAG CTC AAC CCC GAC ATC ATT AC 
L-S-H-Hvy-Rev GAC GAT CTA GAG GTG GTT ATA GTA GTG TGC ATG 
T-P-Hvy-For TAA TAC GAC TCA CTA TAG CCA ACT ATC TCC CTA ATT G 
T-P-Hvy-Rev GAC CAT CTA GAC ATA GCG GTT GTT GAT G 
P-T-Lt-For TAA TAC GAC TCA CTA TAG CAT AGC GGT TGT TGA TG 






Figure C-3: Secondary structures of cloned human mitochondrial pre-tRNA species (part 1) 






Figure C-4: Secondary structures of cloned human mitochondrial pre-tRNA species (part 2) 








Figure C-5: Sequence alignment of all 22 human mitochondrial tRNA sequences. Primary 
sequence alignment was downloaded from mt-tRNA database [36] and the manually 
adjusted based on sequence conservation of canonical tRNA.  3’ CCA sequence is not 
encoded in the human mtDNA. The determinant nucleotide of mt-tRNATyr (A73) encoded in 
the genome is discounted in the mt-tRNAdb, which is likely due to the finding that tRNAs 
with a 3’ CCACCA sequence (CCA from N71 to N73) are targeted to a rapid tRNA 
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Ala AAGGGCU UA GCUU AA-----UUA AAGU G- GCUGA UUUGCGU UCAGU UGA-U GCAGA GUGGGG--U UUUGC  AGUCCUU A CCA 
Arg UGGUAUA UA GUUU AA-----ACA AAAC G- AAUGA UUUCGAC UCAUU AAA-U UAUGA UAA------ UCAUA  UUUACCA A CCA 
Asn UAGAUUG AA GCCA GUU-GA-UUA GGGU G- CUUAG CUGUUAA CUAAG UGUUU GUGGG UUUAAG--U CCCAU  UGGUCUA G CCA 
Asp AAGGUAU UA GAAA AAC-----CA UUUC A- UAACU UUGUCAA AGUUA AAU-U AUAGG CU-AAA--U CCUAU  AUAUCUU A CCA 
Cys AGCUCCG AG GUG- A------UUU UCAU A- UUGAA UUGCAAA UUCGA AGA-A GCAGC UUCAAA--- CCUGC  CGGGGCU U CCA 
Gln UAGGAUG GG GUGU GAUAGG--UG GCAC G- GAGAA UUUUGGA UUCUC AGG-G AUGGG UUCGAU--U CUCAU  AGUCCUA G CCA 
Glu GUUCUUG UA GUUG AAA-----UA CAAC G- AUGGU UUUUCAU AUCAU UGG-U CGUGG UUGUAG--U CCGUG  CGAGAAU A CCA 
Gly ACUCUUU UA GUAU AAA-----UA GUAC C- GUUAA CUUCCAA UUAAC UAG-U UUUGA C--AACA-U UCAAA  AAAGAGU A CCA 
His GUAAAUA UA GUUU AAC-----CA AAAC A- UCAGA UUGUGAA UCUGA CAA-C AGAGG CUUACGA-- CCCCU  UAUUUAC C CCA 
Ile AGAAAUA UG UCUG A------UAA AAGA G- UUACU UUGAUAG AGUAA AUAAU AGGAG CUUAAA--C CCCCU  UAUUUCU A CCA 
Leu(CUN) ACUUUUA AA GGAU AAC-AG--CU AUCC A- UUGGU CUUAGGC CCCAA AAA-U UUUGG UGCAAC--U CCAAA  UAAAAGU A CCA 
Leu(UUR) GUUAAGA UG GCAG AGCCCGGUAA UCGC A- UAAAA CUUAAAA CUUUA CAGUC AGAGG UUCAAU--U CCUCU  UCUUAAC A CCA 
Lys CACUGUA AA GCUA A-------CU UAGC A- UUAAC CUUUUAA GUUAA AGAUU AAGAG AACCAACAC CUCUU  UACAGUG A CCA 
Met AGUAAGG UC AGCU AAA-----UA AGCU A- UCGGG CCCAUAC CCCGA AAA-U GUUGG UUAUA---C CCUUC  CCGUACU A CCA 
Phe GUUUAUG UA GCUU ACC-UCCUCA AAGC A- AUACA CUGAAAA UGUUU AGA-C GGGCU CACA----U CACCC  CAUAAAC A CCA 
Pro CAGAGAA UA GUUU AAA----UUA GAAU C- UUAGC UUUGGGU GCUAA UGG-U GGAGU UAAA----G ACUUU  UUCUCUG A CCA 
Ser(AGY) GAGAAAG CU ---- --------CA ---- C- AAGAA CUGCUAA CUCAU GCC-C CCAUG UCUAACA-A CAUGG  CUUUCUC A CCA 
Ser(UCN) GAAAAAG U- CAUG GA--GG--C- CAUG GG GUUGG CUUGAAA CCAGC UUU-G GGGGG UUCGAU--U CCUUC  CUUUUUU G CCA 
Thr GUCCUUG UA GUAU AAA----CUA AUAC A- CCAGU CUUGUAA ACCGG AGA-U GAAAA CC------U UUUUC  CAAGGAC A CCA 
Trp AGAAAUU UA GGUU AAA-U--ACA GACC A- AGAGC CUUCAAA GCCCU CAG-U AAGUU GC-AA---- UACUU  AAUUUCU G CCA 
Tyr GGUAAAA UG GCUG AG------UG AAGC A- UUGGA CUGUAAA UCUAA AGA-C AGGGG UU-AGG--- CCUCU  UUUUACC - CCA 




Table C-4: Human mitochondrial tRNA sequences including 5’ leader, tRNA body and 3’ 
trailer genes. Yellow highlight indicates tRNA species transcribed from the light strand of 
mtDNA. 
 
 tRNA   5’ Leader    Body    3’ Trailer 
1 Ala 5’ UCC CAU 
UGG UCU 
AGU 3’ 
5’ AAG GGC UUA GCU UAA UUA AAG UGG CUG 
AUU UGC GUU CAG UUG AUG CAG AGU GGG 
GUU UUG CAG UCC UUA 3’ 
5’ GCU GUU 
ACA GAA 
AUU  3’ 
2 Arg 5’ UAG ACU 
GAA CCG 
AAU 3’ 
5’ UGG UAU AUA GUU UAA ACA AAA CGA AUG 
AUU UCG ACU CAU UAA AUU AUG AUA AUC 
AUA UUU ACC AA 3’ 
5’ AUG CCC 
CUC AUU 
UAC  3’ 
3 Asn 5’ CGG CGG 
CGG GAG 
AAG 3’ 
5’ UAG AUU GAA GCC AGU UGA UUA GGG UGC 
UUA GCU GUU AAC UAA GUG UUU GUG GGU 
UUA AGU CCC AUU GGU CUA G 3’ 
5’ UAA GGG 
CUU AGC 
UUA  3’ 
4 Asp 5’ CCA UGA 
CUU UUU 
CAA 3’ 
5’ AAG GUA UUA GAA AAA CCA UUU CAU AAC 
UUU GUC AAA GUU AAA UUA UAG GCU AAA 
UCC UAU AUA UCU UA 3’ 
5’ AUG GCA 
CAU GCA 
GCG  3’ 
5 Cys 5’ AGG CCU 
CUU UUU 
ACC 3’ 
5’ AGC UCC GAG GUG AUU UUC AUA UUG AAU 
UGC AAA UUC GAA GAA GCA GCU UCA AAC 
CUG CCG GGG CUU 3’ 
5’ CUC CCG 
CCU UUU 
UUC  3’ 
6 Gln 5’ UAG CUG 
ACC UUA 
CUU 3’ 
5’ UAG GAU GGG GUG UGA UAG GUG GCA CGG 
AGA AUU UUG GAU UCU CAG GGA UGG GUU 
CGA UUC UCA UAG UCC UAG 3’ 
5’ AAA UAA 
GGG GGU 
UUA  3’ 
7 Glu 5’ AUU GGG 
GUC AUU 
GGU 3’ 
5’ GUU CUU GUA GUU GAA AUA CAA CGA UGG 
UUU UUC AUA UCA UUG GUC GUG GUU GUA 
GUC CGU GCG AGA AUA 3’ 
5’ AUG AUG 
UAU GCU 
UUG U 3’ 
8 Gly 5’ AUU GAU 
GAG GGU 
CUU 3’ 
5’ ACU CUU UUA GUA UAA AUA GUA CCG UUA 
ACU UCC AAU UAA CUA GUU UUG ACA ACA 
UUC AAA AAA GAG UA 3’ 
5’ AUA AAC 
UUC GCC 
UUA  3’ 
9 His 5’ CCG GGU 
UUU CCU 
CUU 3’ 
5’ GUA AAU AUA GUU UAA CCA AAA CAU CAG 
AUU GUG AAU CUG ACA ACA GAG GCU UAC 
GAC CCC UUA UUU ACC 3’ 
5’ GAG AAA 
GCU CAC 
AAG  3’ 
10 Ile 5’ UCC CCC 
UCA AAC 
CUA 3’ 
5’ GAA AUA UGU CUG AUA AAA GAG UUA CUU 
UGA UAG AGU AAA UAA UAG GAG CUU AAA 
CCC CCU UAU UUC UA 3’ 
5’ GGA CUA 
UGA GAA 
UCG  3’ 
11 Leu (CUN) 5’ AAC AUG 
GCU UUC 
UCA 3’ 
5’ ACU UUU AAA GGA UAA CAG CUA UCC AUU 
GGU CUU AGG CCC CAA AAA UUU UGG UGC 
AAC UCC AAA UAA AAG UA 3’ 
5’ AAU AAC 
CAU GCA 
CAC  3’ 
12 Leu (UUR) 5’ CCA AGA 
ACA GGG 
UUU 3’ 
5’ GUU AAG AUG GCA GAG CCC GGU AAU CGC 
AUA AAA CUU AAA ACU UUA CAG UCA GAG 
GUU CAA UUC CUC UUC UUA ACA 3’ 
5’ ACA UAC 
CCA UGG 
CCA  3’ 
13 Lys 5’ ACC CCC 
UCU AGA 
GCC 3’ 
5’ CAC UGU AAA GCU AAC UUA GCA UUA ACC 
UUU UAA GUU AAA GAU UAA GAG AAC CAA 
CAC CUC UUU ACA GUG A 3’ 
5’ AAU GCC 
CCA ACU 
AAA  3’ 
14 Met 5’ CAC ACC 
CCA UCC 
UAA 3’ 
5’ AGU AAG GUC AGC UAA AUA AGC UAU CGG 
GCC CAU ACC CCG AAA AUG UUG GUU AUA 
CCC UUC CCG UAC UA 3’ 
5’ AUU AAU 
CCC CUG 
GCC  3’ 
15 Phe 5’ AAG ACA 
CCC CCC 
ACA 3’ 
5’ GUU UAU GUA GCU UAC CUC CUC AAA GCA 
AUA CAC UGA AAA UGU UUA GAC GGG CUC 
ACA UCA CCC CAU AAA CA 3’ 
5’ AAU AGG 
UUU GGU 
CCU  3’ 
16 Pro 5’ UUC CCC 
AUG 
AAAGA A 3’ 
5’ CAG AGA AUA GUU UAA AUU AGA AUC UUA 
GCU UUG GGU GCU AAU GGU GGA GUU AAA 
GAC UUU UUC UCU GA 3’ 
5’ UUU GUC 
CUU GGA 
AAA  3’ 
17 Ser (AGY) 5’ GAC CCC 
UUA UUU 
ACC 3’ 
5’ GAG AAA GCU CAC AAG AAC UGC UAA CUC 
AUG CCC CCA UGU CUA ACA ACA UGG CUU 
UCU CA 3’ 
5’ ACU UUU 
AAA GGA 
UAA  3’ 
18 Ser (UCN) 5’ UUU CUA 
AUA CCU 
UUU 3’ 
5’ GAA AAA GUC AUG GAG GCC AUG GGG UUG 
GCU UGA AAC CAG CUU UGG GGG GUU CGA 
UUC CUU CCU UUU UUG 3’ 
5’ UCU AGA 
UUU UAU 
GUA  3’ 
19 Thr 5’ UAC UCA 
AAU GGG 
CCU 3’ 
5’ GUC CUU GUA GUA UAA ACU AAU ACA CCA 
GUC UUG UAA ACC GGA GAU GAA AAC CUU 
UUU CCA AGG ACA 3’ 
5’ AAU CAG 
AGA AAA 
AGU  3’ 
20 Trp 5’ UAC UAA 
UAA UCU 
UAU 3’ 
5’ AGA AAU UUA GGU UAA AUA CAG ACC AAG 
AGC CUU CAA AGC CCU CAG UAA GUU GCA 
AUA CUU AAU UUC UG 3’ 
5’ UAA CAG 
CUA AGG 
ACU  3’ 
21 Tyr 5’ CAU CAG 
UGG GGG 
UGA 3’ 
5’ GGU AAA AUG GCU GAG UGA AGC AUU GGA 
CUG UAA AUC UAA AGA CAG GGG UUA GGC 
CUC UUU UUA CCA 3’ 
5’ GCU CCG 
AGG UGA 
UUU  3’ 
22 Val 5’ UGC ACU 
UGG ACG 
AAC 3’ 
5’ CAG AGU GUA GCU UAA CAC AAA GCA CCC 
AAC UUA CAC UUA GGA GAU UUC AAC UUA 
ACU UGA CCG CUC UGA 3’ 
5’ GCU AAA 
CCU AGC 
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CHAPTER 5  
CONCLUSIONS AND FUTURE DIRECTIONS 
 Conclusions 
The goal of this work was to advance our understanding of the molecular basis 
of how RNase P recognizes ligands and catalyzes an essential biological reaction. 
First, this work developed a fast, real-time and robust fluorescence polarization (FP) 
assay to facilitate kinetic analysis and to identify inhibitors of RNase P as chemical 
probes and potential novel anti-bacterial agents. Second, a combination of atomic 
modifications and kinetic analyses established that a universally conserved bulged 
uridine in the P4 helix of P RNA enhances conformational change kinetics and 
contacts at least one metal ion through an outer-sphere interaction. Third, this work 
provides the first evidence that MRPP3 alone is active in catalyzing cleavage of 
mitochondrial pre-tRNA and the other two subunits of mtRNase P, MRPP1 and 2, 
increase both the cleavage rate and cleavage site fidelity.  
5.1.1 A New Real-time FP Assay Facilitates Kinetic Analysis of RNase P and 
Discovery of Inhibitions 
Bacterial RNase P is an attractive novel antibacterial target, but no specific and 
potent inhibitors have been identified to date [1]. My work developed a facile non-




attached to the 5’ end of a pre-tRNA substrate (Figure 2-1, Chapter 2). This assay is 
amenable to measuring B. subtilis RNase P activity both continuously and in an end-
point format suitable for high-throughput screening using micro-plate readers. A new 
inhibitor, iriginol hexaacetate, (Ir6Ac, IC50 = 2 µM) against B. subtilis RNase P has 
been identified from high-throughput screening of a compound library. The 
fluorescence polarization/anisotropy method also reveals that aminoglycosides 
inhibit B. subtilis RNase P non-specifically by binding to the pre-tRNA substrate. This 
work provides valuable tools for identification of specific inhibitors against bacterial 
RNase P and for studying ligand recognition of this enzyme. In the future, this assay 
should be applicable to analyzing the activity and inhibitor of other forms of RNase P 
and other nucleases. Additionally, this assay can be used to measure ligand binding 
to tRNA.  
5.1.2 The Universally Conserved Bulge Uridine in Helix P4 is Important for 
Conformational Change  
Single atom modifications were incorporated into the P4 helix of a circular 
permuted RNase P RNA to examine the functional role and interaction with metal 
ions of a universally conserved bulged uridine (U51 in B. subtilis RNase P, Figure 
3-2, Chapter 3). Alteration in the substrate affinity of the 4-thiouridine mutant suggest 
that the O4 oxygen atom of U51 is important for stabilizing pre-tRNA affinity in a 
divalent metal ion-dependent fashion. The kinetic mechanism of RNase P catalyzed 
cleavage of pre-tRNA includes a conformational change step that is the rate-limiting 
step at high pH (pH≥ 8) for the wild-type enzyme [2]. Base modifications, such as 4-




cleavage rate catalyzed by RNase P holoenzyme by 20-fold and reduce 
cooperativity for Mg2+ ion-activated cleavage catalyzed by P RNA at low pH (pH < 
6). In contrast, deletion of the uracil base (abU) does not affect the single turnover 
cleavage rate constant. At higher pH, the abU modification significantly decreases 
the pH-independent conformational change rate constant, while base modifications 
have only minimal effects. These data suggest that the universally conserved bulged 
U51 enhances cleavage by positioning an Mg2+ ion through outer-sphere 
coordination and enhances the dynamics for forming an active RNase P-substrate 
conformation. These results pinpoint the first P RNA residue that is important for the 
conformational dynamics of RNase P and revise the current proposal that O4 
directly coordinates a catalytic metal ion, as proposed from recent crystallographic 
data [3].  
5.1.3 MRPP3 Is the Catalytic Component of Human mtRNase P Complex 
Unlike other RNA-dependent RNase P enzymes, the newly identified human 
mtRNase P is composed solely of three proteins (MRPP1, 2 and 3) and so far has 
been poorly characterized [4, 5]. Previous reported results suggest that in vitro 
MRPP3 is catalytically inactive without two other subunits [4, 5]. Single-turnover 
cleavage data from this work demonstrate that MRPP3 alone is the subunit that 
catalyzes cleavage of the 5’ leader of an mt-pre-tRNA substrate. Moreover, 
MRPP1∙MRPP2 subcomplex enhances the catalytic efficiency and cleavage site 




5.2 Future Directions 
RNase P is an essential yet diverse enzyme and a potential drug target.  
Bacterial and human forms of RNase P enzymes catalyze the same phosphodiester 
bond hydrolysis utilizing different substrates and subunits. Numerous fundamental 
questions remain on mechanisms used by bacterial (RNA-based) and human 
mitochondrial (protein-based) RNase P to recognize diverse ligand molecules and to 
achieve precise and efficient catalysis. Furthermore, small molecules that 
specifically target bacterial RNase P have not yet been identified. Below are my brief 
proposals on how to further investigate these mechanisms. Specifically, I will discuss 
experiments for further investigation of inhibitors, metal binding sites and the 
conformational change step of bacterial RNase P, and propose analytical, structural 
and biochemical strategies to investigate the structure, function and substrate 
specificity of human mtRNase P. 
5.2.1 RNase P Inhibitors and tRNA Ligands 
The mechanism of inhibition by the newly identified inhibitor, Iriginol 
hexaacetate (Ir6Ac) is currently unknown and should be elucidated. First, 
measurement of the time-dependence of inhibition can distinguish slow tight-binding 
irreversible inhibitors from rapid reversible inhibitors. Second, monitoring the steady-
state kinetics catalyzed by RNase P at varying substrate and inhibitor concentrations 
will allow dissection of the inhibition mechanism of this compounds (competitive, 
noncompetitive, uncompetitive or mixed [6]). If the inhibitor binds to the enzyme-
substrate (ES) complex, measurement of inhibition as a function of pH should 




interacts with. Competition between inhibitors and Mg2+ should also be tested for 
elucidating the mode of inhibition.  
In addition, interactions of P RNA with Ir6Ac could be investigated utilizing the 
fluorescent properties of this compound. Furthermore, a combination of chemical 
and enzymatic footprinting experiments using Fe (II)-EDTA, and RNases T1, U2 and 
V1 can be used to map potential interaction sites of the inhibitor in P RNA [7][8]. The 
cleavage products can be identified using 32P-labeled P RNA on a sequencing 
PAGE gel, and compared to cleavage of RNase P alone.  Footprinting pattern from 
hydroxyl and nuclease cleavage will reveal possible sites that interact with inhibitors 
on P RNA.  
 
 
Figure 5-1: Scheme for bioactivity-guided fractionation of active compounds from natural 
product library. Adapted from [9].  
 
HTS screens of small molecules have been previously carried out by 
GlaxoSmithKline [10] and Message Pharmaceuticals [11], but no high-affinity lead 
compound with good efficacy has been developed. The crystal structures of B. 
stearothermophilus P RNA [12] and T. maritima RNase P with bound tRNA show 
that the active site of P RNA is large and shallow compare to active sites in proteins 




inhibitors may suggest that the binding pocket of RNase P is less ideal for small 
molecule inhibitors. Therefore, larger natural products are likely better starting points 
for discovering inhibitors of bacterial RNase P. In collaboration with the Sherman lab 
(University of Michigan), the natural product extracts that displayed RNase P 
inhibition activity have been further fractionated to isolate and identify the natural 
products responsible for the activity (Figure A-5, Appendix A, Chapter 2). This is an 
iterative bioactivity-guided process (Figure 5-1). Mixtures of compounds can be 
extracted and fractionated by high-performance liquid chromatograph (HPLC) from 
regrowth of microorganisms. Fractions will be tested for inhibition of RNase P activity 
in vitro using the FP assay. To prioritize hits in terms of antibacterial activity, we can 
use a disk diffusion assay [13] and a 96-well plate bacterial growth assay (Appendix 
A) for various model strains including Bacillus anthracis, Staphylococcus aureus and 
Escherichia coli (Figure A-6, Appendix A, Chapter 2). Once a hit is validated from 
these assays, the active fraction can be further purified until a single active 
component that inhibits RNase P activity and bacterial growth is determined. It is 
also possible that several natural product compounds function synergistically and 
thus a decrease in activity is observed for isolated compounds. In this case, the 
synergistic effect could be tested by combining compounds isolated from active 
fractions and measuring inhibition activity. Spectroscopic methods, such as NMR, 
MS and CD, can be used to determine the chemical structure of the active 
compounds. Importantly, the metal content of these compounds should be 
determined by inductively coupled plasma mass spectrometry (ICP-MS) or atomic 




RNase P activity such as Cd2+ [14]. We can also test the antibacterial activity of the 
isolated inhibitors by determining the minimum inhibitory concentration (MIC) in E. 
coli [15]. Together, these results will broaden our knowledge of RNase P as a drug 
target and provide more candidate compounds and mechanistic information for 
developing new antibiotics targeting RNase P in the future. 
The 22 human mitochondrial tRNAs (mt-tRNAs) are often called “bizarre 
tRNAs” because several mt-tRNAs are structurally different from the classic tRNA 
cloverleaf secondary structure and the L-shaped tertiary structure [16, 17] (Figure 
4-3, Chapter 4). Nearly half of the disease-associated human tRNA point mutations 
are located in human mt-tRNAs (Figure 4-2, Chapter 4). We could optimize the FP 
assay to perform a high-throughput screen to identify small molecule and natural 
product ligands that can interact with and potentially stabilize human mt-tRNA. Then 
the effects of these molecules on processing of wild-type and pathogenic mutant mt-
pre-tRNAs by the newly discovered protein-only mtRNase P can be evaluated. 
These molecules could either function as activators (by stabilizing tRNA structure) or 
inhibitors of mtRNase P. We could also develop biophysical and computational 
methodologies, including NMR spectroscopy and in silico screening [18] (in 
collaboration with Professor Hashim Al-Hashimi at University of Michigan), to 
determine the solution structure of mt-tRNA and to directly measure ligand binding to 
tRNA. These studies would significantly enhance our understanding of the molecular 
recognition of bacterial RNase P and the structures and functions of human mt-tRNA 





5.2.2 Metal Ion Binding Site in Helix P4 
To further explore the functional role of uracil 51, additional single-atom 
modifications can be incorporated into circular permuted P RNA (Figure 5-2). For 
example, sulfur substitution of O2 can test possible metal ion coordination at this 
position. Currently, a phosphoramidite derivative of 2-thiouridine is not commercially 
available but the synthesis method is published [19]. IsoCystosine can also be used 
to probe the O2 position. However, isoC51 could potentially form a wobble base pair 
with G379 (Figure 5-2). A commercially available 2’ deoxy version of 3-
methylcytosine (3-methyl-dC) can be used in lieu of U to C mutation to avoid 
potential base paring of C51 to G379 and evaluate if a bulky methyl group and 
alteration of the O4 to an amine group have an additive effect on disrupting the 
outer-sphere coordination. These experiments might provide more details on the 
interactions between the conserved nucleotide U51, G379 and metal ions. 
 
 
Figure 5-2: Additional atomic modifications to probe function and metal ion binding of U51 





Time-resolved fluorescence energy transfer (trFRET) data have indicated that 
an inner-sphere metal ion-dependent conformational change step occurs upon 
substrate binding that leads to a ~ 40 Ǻ movement between the C- and S-domain of 
P RNA (Hsieh and Fierke, unpublished data). This conformational change step can 
be further investigated by various techniques. First, we can utilize the fluorescence 
of 4-thiouridine to monitor the conformational change step [20]. Second, small angle 
X-ray scattering (SAXS) has been applied to measure the solution structure of 
RNase P [21-23]. SAXS measurements can probe the global conformational change 
of RNase P by comparing the difference in the structure envelope under various 
conditions. Third, cryo-electron microscopy (cryo-EM) has revealed the structure of a 
folding intermediate of the S-domain of P RNA [24]. To further evaluate 
conformational transitions in RNase P, cryo-EM and single-particle image 
reconstruction can visualize structures of the wild type RNase P∙pre-tRNA complex 
at varying Ca2+ concentrations to reveal changes in the global architectural between 
the ES and ES* conformations. Additionally, new NMR methods that capture 
transient structures of RNA could be applied to study the P4 stem-loop RNA model 
to analyze the conformational change and metal ion binding in B. subtilis RNase P 
RNA at the atomic level [25]. 
5.2.3 Human Mitochondrial RNase P 
The structure of the human mtRNase P complex and the stoichiometry of the 
subunits in the active MRPP 1:2:3 complex have not been established to date. X-ray 
crystallography trials can be set up to grow crystals of MRPP1∙MRPP2 complex, 




complex by all three proteins and a tightly bound mt-pre-tRNA or model substrate. 
Purification of MRPP1 protein should be further optimized in addition to purifying 
MRPP1∙MRPP2 as a complex. This will allow variations of the stoichiometry of the 
three subunits for structure and function studies.  
In addition, preliminary data suggest that we can apply ion mobility-mass 
spectrometry (IM-MS) [26] (Figure 5-3 and Figure 5-4) to measure the stoichiometry 
and architecture of the mtRNase P complex. In collaboration with Dr. Brandon 
Ruotolo’s laboratory, we used IM-MS to observe both a heterohexamer and 
heteropentamer of the MRPP1∙MRPP2 complex (Figure 5-3) and a PRORP1∙pre-
tRNACys complex (Figure 5-4). Based on these data, a low-resolution topology of the 
protein and protein∙substrate complex can be built. Detailed protein-protein 
interaction sites could be mapped by protease footprinting and hydrogen/deuterium 
exchange (HDX) combined with mass spectrometry [27]. Furthermore, in 
collaboration with Dr. Georgios Skiniotis’s laboratory (University of Michigan) we 
have performed electron microscopy analysis of mtRNase P proteins. EM 
experiments only require a small amount of materials (~ 10 to 50 ng of protein) and 
can visualize protein structures at various fixed conditions. Negative staining images 
of MRPP3 and the MRPP1∙ MRPP2 complex show relatively good homogeneity in 
particle size (low level of observed dimerizaitona or aggregation) (Figure 5-5), which 
suggest possibility for further single particle reconstruction studies [28]. We could 
optimize the protein sample preparation of mtRNase P to use EM to visualize the 
architecture of the human mtRNase P holoenzyme, an enzyme-substrate ternary 




MRPP2 + substrate) under various subunit stoichiometries and solution conditions. 
These medium resolution studies could provide valuable insights into the solution 




Figure 5-3: Ion mobility-mass spectrometry (IM-MS) analysis of the MRPP1∙MRPP2 
complex. (A) Three populations of proteins are observed, I: homotetramer of MRPP2; II: 
heteropentamer of (MRPP1)1(MRPP2)4; III: heterohexamer of (MRPP1)2(MRPP2)4; (B) and 
(C) MS/MS analysis of protein molecular weight1.  
 
                                            
1  IM-MS analyses (Figures 5-3 and 5-4) were performed by Yueyang Zhong in Dr. Ruotolo’s 
laboratory on smaples prepared by Xin Liu (MRPP1∙MRPP2 complex) and Michael Howard 
(PRORP1, pre-tRNACys, and MRPP2). Figures 5-3 and 5-4 are adapted from figures made by 





Figure 5-4: An overlay of ion mobility-mass spectrometry (IM-MS) analysis of A. thaliana 
PRORP1 (blue), pre-tRNACys (green) and PRORP1-pre-tRNACys complex (red). PRORP1 
alone has broadened drift time which may indicate partial unfolding of the proteins. The 
PRORP1-pre-tRNACys complex has a narrower drift time, which may indicate that substrate 






Figure 5-5: Negative staining images of human mtRNase P proteins. (A) Negative staining 
image of MRPP1∙MRPP2 complex. The resolution of the current image is insufficient to 
resolve subunit composition but shows protein particles similar in size (low level of 
dimerization or aggregation). (B) MRPP3 and (C) A zoom-in view of MRPP3 showing the V-
shape of the protein2.  
 
Catalytic activity and substrate recognition of human mtRNase P can be 
elucidated using kinetics, substrate affinity and footprinting experiments. Specifically, 
we can investigate reactivity with substrates representing three types of mt-pre-tRNA 
structures as well as human nuclear pre-tRNA, including: mt-pre-tRNALeu(UUR) (type 
0, N9=G), mt-pre-tRNALys (type II, N9=A), mt-pre-tRNAIle (type II, N9=G), mt-pre-
tRNAMet (type II, N9=C),  mt-pre-tRNASer(UUR) (type 0) and n-pre-tRNASer. Substrate 
affinity could be measured by a fluorescence polarization assay in the presence of 
different combinations of human mtRNase P subunits and subunit stoichiometries. 
Catalytic activity can be investigated by measuring the cleavage activity under 
single- ([E]>>[S], kobs, K1/2) and multiple-turnover conditions ([E]<<[S], kcat, KM, 
kcat/KM) as a function of subunit stoichiometry, metal ion conditions (such as Mg2+ 
and NaCl concentrations) and co-factors (NAD+ and SAM). We can identify 
structural features of mt-pre-tRNA that are important for recognition by mtRNase P 
proteins using hydroxyl radical and enzymatic footprinting (radiochemical or 
fluorescently labeled substrate), selective 2'-hydroxyl acylation analyzed by primer 
extension (SHAPE) using fluorescent DNA-primers and automated instrumentation 
available on campus, and mutagenesis of the substrates. In addition, because mt-
pre-tRNALys (A9) and mt-pre-tRNAIle (type II, G9) have been shown to be methylated 
                                            
2  Negative-stain imaging was performed by Annie Dosey in Dr. Skiniotis’s laboratory on sample 




by MRPP1 in vitro [29], we can compare reactivity with the primary transcript and R9 
methylated form of these two substrates.  
Several pathogenic point mutations located in the D- and anticodon-domain of 
mt-tRNALeu(UUR) decrease the processing rate catalyzed by partially purified human 
mtRNase P by 2- to 5-fold [30]. The pathogenic insertion mutation (44inC in V-loop) 
of mt-tRNASer(UCN) also affects 5’ processing in cells and in vitro catalyzed by partially 
purified mtRNase P [31]. A point mutation at N(+1) (A to G) in mt-pre-tRNAIle that is 
linked to a type of maternally inherited hypertension has also been shown to reduce 
reactivity with human mtRNase P [32]. It is unclear whether these effects are due to 
global and/or local structure changes of the mt-tRNA substrate and/or loss of 
sequence specific interaction with mtRNase P. We can investigate both the 5’ 
processing activity and structural effects of pathogenic mutations both in regions of 
mt-pre-tRNA that bind to mtRNase P proteins and in sites that may disturb mt-tRNA 
structure using detailed kinetic and solution probing experiments. These studies will 
advance our understanding of mitochondria-related diseases at a molecular level. 
Deep sequencing studies revealed that knockdown of mtRNase P subunits in 
cells lead to accumulation of precursors for both tRNAs and long noncoding RNAs in 
mitochondria [4, 33]. In normally growing cells, aberrant partially processed products 
are also observed in multi-mt-tRNA junctions [34]. To investigate the pre-tRNA 
processing and other potential substrates by human mtRNase P in vivo, it might be 
possible to probe mitochondrial RNA processing by combining recently developed 
small RNA-seq [35] and living cell SHAPE [36] techniques to obtain detailed 




transcripts as a function of knockdowns of each human mtRNase P protein in HeLa 
cells. Together, the studies proposed here would address fundamental questions in 
the structure and function of human mtRNase P as well as illuminate mitochondrial 
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